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ABSTRACT 
The Delta Regional Authority (Delta Region) is a federal-state partnership aiming to 
improve socioeconomic conditions in 252 counties and parishes in the eight state Lower 
Mississippi Delta Region (LMDR). The Delta Region has a higher proportion of black residents, 
is poorer, and is more rural than the country as a whole. It also has far higher breast cancer 
mortality rates than the nation. Black women in the Region have higher breast cancer mortality 
rates than white women in the Delta Region and have higher breast cancer mortality rates than 
black women in other parts of the country. More aggressive breast cancer subtypes, more 
advanced stage at diagnosis, and less access to screening mammography may play a role in these 
high mortality rates. Studies have shown that black women have higher rates of the most 
aggressive breast cancer subtype-- triple-negative--than white women and are often diagnosed at 
a more advanced stage. Additionally, while poor and rural women tend to have lower incidence 
rates of breast cancer, they often have a higher odds of late-stage cancer and less access to 
screening services.  
 This dissertation sought to elucidate the Delta Region’s breast cancer mortality disparity 
by determining differences between the Delta and non-Delta Regions of the LMDR and by 
exploring racial differences within the Delta Region among the following areas: breast cancer 
subtype, breast cancer staging, and spatial access to mammography services. Population-based 
cancer surveillance data from the North American Association of Central Cancer Registries were 
analyzed to determine age-adjusted, subtype-specific incidence rates and rate ratios in the Delta 
and non-Delta Regions of the LMDR.  Multilevel negative binomial regression models were 
constructed to evaluate if identified disparities were attenuated after accounting for 
race/ethnicity, age, and contextual factors. These analyses were performed for all cases by 
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subtype and separately for early stage and late stage cancers by subtype. Higher rates of triple-
negative breast cancer were identified in the Delta Region compared to the non-Delta Region, 
but this was attenuated in multivariable models. However, triple-negative breast cancer rates 
were higher in the urban Delta compared to the urban non-Delta, even after accounting for 
race/ethnicity, age, and contextual factors. Black residents in the Delta Region had higher rates 
of hormone receptor-negative breast cancers and higher rates of breast cancer overall compared 
to white women in the Region. Further, there were no particularly notable differences in late-
stage breast cancers between the Delta and non-Delta Regions. However, black women in the 
Delta Region had lower rates of early-stage breast cancer, but higher rates of late-stage breast 
cancers compared to white, Delta Region women, even after accounting for age and contextual 
factors.   
To evaluate spatial access to mammography services, this study applied the enhanced 
two-step floating catchment area method to Food and Drug Administration data and census tract 
level American Community Survey data. The Food and Drug Administration data provided 
addresses of all approved mammography facilities in the LMDR and adjacent states while 
American Community Survey data were used to estimate populations of women of 
recommended screening age at the census tract level. For the most part, women in the Delta 
Region had similar spatial access to mammography services as non-Delta Region women. 
However, clusters of low spatial access within the Delta Region were identified in parts of 
Arkansas, Tennessee, and Mississippi.  
The identified higher incidence of breast cancer in black women in the Delta compared to 
white women was driven by higher rates of hormone receptor-positive cancers, but further 
research is needed to determine what individual or contextual factors may be driving the higher 
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incidence rates. Additionally, this dissertation underscores the importance of community-based, 
culturally tailored interventions to improve mammography utilization rates and subsequently 
improve early detection of hormone receptor-positive breast cancers. Furthermore, this 
dissertation signaled a need for improved state-level policy and geographically targeted regional 
resource allocation to improve screening access and utilization. Additionally, these findings 
provide the foundation for further research to explore regional breast cancer disparities at other 
points along the cancer control continuum (e.g. treatment), to examine regional disparities for 
other cancers, and to promote collaborative academic partnerships across the Delta Region. 
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This dissertation is in honor of my great grandma, Elsie Long, who died of breast cancer when 
my mom was only seven. May advances in primary prevention, detection, and treatment provide 
the opportunity for all children to grow up knowing their grandparents.  
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CHAPTER 1: INTRODUCTION AND BACKGROUND 
The Delta Regional Authority (Delta Region) is a federally designated region of 
approximately 10 million people in 252 counties and parishes in eight states along the 
Mississippi River (the Lower Mississippi Delta Region-LMDR). It is a mostly rural region with a 
high proportion of black residents and high rates of poverty. Because of its sociodemographic 
composition and limited access to care, it experiences numerous and startling health disparities, 
including both cancer and access to care inequities. Compared to the nation as a whole, residents 
in the Delta Region have higher rates of all-cause, cancer, and breast cancer mortality (1-3). 
Further, breast cancer mortality rates are not only higher among black women in the Delta 
Region compared to white women, they are also higher among black women in the Delta Region 
compared to black women in other parts of the country (1). Residents of the Delta Region have 
limited access to primary care physicians and federally qualified health centers (4,5). 
Historically, a lower proportion of women in the Delta Region regularly utilize mammography 
services (4,6). All of these factors may be indicative of less access to mammography services 
and may lead to an increased risk of late-stage breast cancer.  However, there is limited research 
on what specific cancer factors—subtype, staging, and access to mammography services—may 
exist in this region that contribute to these higher breast cancer mortality rates. Risk factors for 
the triple-negative breast cancer subtype and for more advanced cancer staging are more 
prevalent in this region, including a higher proportion of black residents, geographic location in 
the South/Midwest, rurality, and higher rates of poverty (7-9). Understanding subtype, staging, 
and access to mammography differences might help explain the mortality disparities and guide 
development of preventive interventions and regional policies.  These potential solutions are 
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especially relevant because this study assessed a federally designated region that receives annual 
appropriations to address specific healthcare infrastructure needs.  
Using data from the North American Association of Central Cancer Registries, the Food 
and Drug Administration, the American Community Survey, the United States Department of 
Agriculture, and the National Cancer Institute, this dissertation explored the breast cancer 
subtype, breast cancer staging, and access to mammography differences that exist between the 
Delta and non-Delta Regions within the LMDR states. Multilevel regression modeling methods 
were used to examine differences in breast cancer subtype and staging, and geographic 
information system methods were used to evaluate differences in spatial access to mammography 
within the LMDR states. This chapter will provide a comprehensive description of the Delta 
Region and its disparities and a brief summary of breast cancer incidence and mortality in the 
United States. Finally, this chapter will delineate the specific aims of this dissertation, provide 
corresponding conceptual frameworks, and review the relevant breast cancer epidemiology 
literature for each respective specific aim.  
The Delta Region 
Definition 
  The Delta Region, as currently defined by the Delta Regional Authority (DRA), includes 
252 counties and parishes in eight states along the Mississippi River and the Alabama Black Belt 
(Figure 1.1). These states include Alabama, Arkansas, Illinois, Kentucky, Louisiana, Mississippi, 
Missouri, and Tennessee.  
History 
 The first discussion of a Delta Region designation occurred at a meeting of the Southern 
Regional Growth Policy Board in 1971 which, of particular note, led to an agreement among 
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nine Southern and Midwestern governors to develop strategies to improve the region’s economic 
situation (10). This state-level collaboration paved the way for future federal action, and in 1988, 
Congress established the Lower Mississippi Delta Development Commission through the Rural 
Development, Agriculture, and Related Agencies Appropriations Act. This Commission was the 
vision of Senator Dale Bumpers of Arkansas and Representative Mike Espy of Mississippi. It 
sought to evaluate the needs, goals, and objectives of the residents of the Delta Region, which at 
that time, included 187 counties and parishes in Arkansas, Illinois, Kentucky, Louisiana, 
Mississippi, Missouri, and Tennessee. Senator Bumpers stated that the counties and parishes of 
the Delta Region, “share common economic, social and cultural ties, and….suffer from any 
combination of high unemployment, low net family income, agriculture and oil industry decline, 
a decrease in small business activity, or poor or inadequate transportation infrastructure, health 
care, housing, or educational opportunities” (11). This Commission studied the region and 
created a ten-year plan for economic development. In the subsequent decade, numerous federal 
agencies and entities also studied the Region’s infrastructure and economy to determine how to 
best to address the region’s challenges (12). Then, in 2000, Congress codified the Delta Region 
as one of the nation’s four chartered regional commissions—the Delta Regional Authority-- and 
extended its geographic reach into the Black Belt of Alabama (13). The regional designation was 
later expanded to its current extent of 252 counties and parishes across eight states. 
Current Delta Regional Authority Efforts  
The DRA’s current mission is to “work to improve regional economic opportunity by 
helping to create jobs, build communities, and improve the lives of the 10 million people who 
reside in the 252 counties and parishes of the eight-state Delta region” (14). In addition to broad 
socioeconomic efforts, the DRA aims to improve health outcomes, specifically, as a means to 
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maintaining a healthy workforce. In 2010, the DRA developed an action plan to improve health 
in the Region. This plan included developing regional personnel infrastructure (e.g. hiring a 
Director of Health Programs), convening stakeholders throughout the region, developing tools 
and amassing relevant health data, and initiating grant programs to fund local health initiatives 
(15).  
Additional DRA efforts include Innovative Readiness Training and the Delta Doctors 
program. Innovative Readiness Training is a partnership between the DRA and the Department 
of Defense to conduct annual medical missions and provide no-cost medical, optical, and dental 
services throughout the Region (15). The Delta Doctors Program provides J-1 visa waivers to 
foreign physicians who agree to practice within medically underserved areas in the Delta Region 
for at least three years (5). The program has located 346 physicians in practice within the Region, 
including 80 physicians in 2014 alone. Additionally, DRA investments coupled with both public 
and private monies have resulted in $101.6 million in healthcare investments between 2002 and 
2013 (16). Recent efforts supported by other federal entities include health services grant funding 
from the United States Department of Agriculture’s Rural Development program which provided 
$5.7 million of funding in 2016 and technical assistance and Affordable Care Act enrollment 
assistance provided by the Health Resource and Services Administration. 
Demographic and Socioeconomic Contextual Characteristics of the Delta Region 
The Delta Region’s population as of the 2010 census was 9,920,395 people (9). 
Demographically, the Delta Region has a higher proportion of individuals who are black 
compared to the nation as a whole (Table 1.1). Socioeconomically, the Delta Region has a higher 
proportion of residents who live in poverty and a lower proportion of adults who have a high 
school degree compared to the United States as a whole. Additionally, the Delta Region has a far 
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higher proportion of counties with persistent poverty (43.3%) than the nation as a whole 
(11.2%). Persistent poverty counties are defined as areas where 20% or more of the population 
has been in poverty for the past four census surveys. The Delta Region has a smaller population 
density than the nation as a whole, indicative of greater rurality in the Region. 
Collective Social Factors in the Delta Region 
The rural context of the Delta Region coupled with the high proportion of black residents 
indicates that this region may be particularly susceptible to health disparities (17). Additionally, 
the social and historical context of the Delta Region (e.g. racism, persistent poverty) have 
unfortunately facilitated the Region’s health disparities (18). Furthermore, a commentary by 
Hyland suggests that the pervasive, regional cultural beliefs of fatalism (i.e. focus on religious 
beliefs that leads to ultimate salvation), personalism (i.e. a trust in authority to provide for them), 
and factionalism (i.e. isolation and distrust of “others”) may be additional factors that play a role 
in the Region’s persistent poverty and poor health (10).  
Health-Related Disparities in the Delta Region 
  Studies have found that Delta Region residents indeed experience a myriad of health 
disparities—ranging from poor health behaviors, high rates of chronic disease, and elevated 
mortality rates. Multiple studies suggest that Delta Region residents have higher obesity rates 
and tobacco use compared to people nationwide (2,4). One study found that diabetes and 
hypertension were more prevalent in Delta Region residents in Arkansas, Mississippi, and 
Louisiana than they were nationally (19). After controlling for factors like age, income, and 
gender, blacks in the Region were found to be at particular risk for these chronic diseases. 
Several studies have indicated that residents of the Delta Region experience mortality rates—for 
all causes and for cancer specifically—that are persistently in excess of national rates (2-4).  
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Murray’s study of the “eight Americas” (unique demographic groups in the U.S.), although not 
explicitly evaluating the designated Delta Region, characterized two of these “eight Americas” 
as reasonably, demographically representative of the Delta Region: 1) low-income whites in 
Appalachia and the Mississippi Valley and 2) Southern low-income blacks (20). Murray 
explored the disparities in these “eight Americas” and found that the life expectancy of white 
women of Appalachia and the Mississippi Valley actually declined during the study period 
(1982-2001). Similarly, there was a notable 12.8-year life expectancy gap between women in the 
Southern/Mississippi low-income black group and the group with the longest life expectancy. 
Furthermore, Delta Region residents also experience access to care disparities. More 
Delta Region residents are uninsured (19.2%) compared to both residents in non-Delta Region 
counties in the eight Delta Region states (17.4%) and residents in the United States a whole 
(18.0%) (4). Residents also have less access to primary care providers. There are 42.14 primary 
care providers for every 100,000 residents in the Delta Region compared to 55.24 providers per 
100,000 residents nationwide (4).  Additionally, 230 counties and parishes (91%) in the Delta 
Region are considered Health Professional Shortage Areas, and 95 counties and parishes (38%) 
do not have a Federally Qualified Health Center (5). 
More germane to the current study, a limited number of studies suggest that women in the 
Delta Region experience breast cancer disparities. Trends in breast cancer mortality have varied 
over the past 30+ years in the Delta Region, but recent rates indicate significant disparities. A 
2004 study examined breast cancer mortality rates in the Delta Region compared to the rest of 
the country between 1979 and 1998 (21). At the beginning of the study period, breast cancer 
mortality rates in the Delta Region were lower than the rest of the country, but by the end of the 
study period, the rate of breast cancer mortality in the Delta Region was no different than the rest 
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of the country. In economically distressed counties, there was no difference in death rates 
compared to the rest of the country. In non-distressed counties, black women in the Delta had a 
modestly higher breast cancer mortality rate than black women elsewhere (32.8 vs. 31.0 per 
100,000, respectively). A more recent study assessing cancer mortality in the Delta Region 
between 2008 and 2012 found that breast cancer mortality rates in the Delta were statistically 
significantly higher than the rest of the country (RR=1.10; 95% CI=1.07-1.13) (1).  When 
stratified by race, there was no difference in breast cancer mortality between Delta Region and 
non-Delta Region white women. However, breast cancer mortality was higher in black women in 
the Delta (34.9 per 100,000) compared to their white Delta Region counterparts (21.3 per 
100,000) and compared to black women in the rest of the country (29.8 per 100,000). 
Additionally, the recent study found that breast cancer mortality rates overall in the Delta Region 
were 24.9 per 100,000 between 2008 and 2012, essentially the same rate reported in the 2004 
Hall study for 1994-1998 (24.5 per 100,000), which likely indicates sustained poor breast cancer 
mortality rates in the region over the last twenty years (1,21). A study by Mokdad and colleagues 
assessed cancer mortality rates throughout the country using small area estimation methods and 
found that the Delta Region contains nine of ten counties with the highest breast cancer mortality 
rates in the United States (22).  
 Additionally, studies suggest that women in the Delta Region may engage in behaviors 
that may put them at greater risk for breast cancer, broadly speaking, and at greater risk for late-
stage breast cancer, specifically. A study among women of reproductive age in the Mississippi 
Delta of Mississippi specifically as well as Louisiana, Arkansas, and Tennessee found that 
women in this area had poorer preconception health behaviors and conditions (i.e. less fruit and 
vegetable consumption and higher obesity rates) compared to women elsewhere (23). Another 
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study among women in the rural Delta Region of Mississippi found that breastfeeding rates were 
low—especially among blacks—as only 24% of study participants had initiated breastfeeding 
(24). Studies have shown that a smaller proportion of Delta Region women are up-to-date with 
mammography screening compared to women outside the region (4,6). While more recent data 
are not available on all women of recommended screening age, a 2004 study found that the age-
adjusted percentage of women in the Delta Region over the age of 40 who had a mammogram 
within the past two years was 69.3%--6.7 percentage points lower than other U.S. women (6). A 
more recent 2016 study found that, among Medicare women aged 67-69, only 56.9% had a 
mammogram in the past two years compared to 60.8% nationwide (4). 
Breast Cancer Incidence and Mortality Disparities 
Age 
Women aged 60-69 (26% of cases) comprise the highest proportion of the breast cancer 
cases, while the greatest proportion of deaths occur in women 80+ years old (25). Eighty percent 
of invasive breast cancer cases are diagnosed in women 50 years old or older, and 88% of breast 
cancer death occur among women 50+. The median age of diagnosis and death varies by race. 
The median age at diagnosis is 58 and 62 years of age for blacks and whites, respectively. The 
median age of death is also younger for black women (62 years old) than white women (69 years 
old) (26). 
Race/Ethnicity 
Historically, white women have higher breast cancer incidence rates while black women 
have higher mortality rates. However, recent studies have suggested that breast cancer incidence 
rates are converging among white and black women while mortality rates remain higher in 
blacks (27,28). The age-adjusted breast cancer incidence rate was 123.6 and 121.5 per 100,000 
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among whites and blacks, respectively, between 2009 and 2013 (27). However, breast cancer 
mortality rates differed more markedly by race. The breast cancer mortality rate in black women 
was 29.2 per 100,000 compared to 20.6 per 100,000 is white women from 2009 to 2014(27). 
While breast cancer mortality rates have decreased in both black and white women, the disparity 
in mortality has widened (28).  
Socioeconomic Status  
Breast cancer incidence rates are generally positively associated with socioeconomic 
status (SES), regardless of race/ethnicity (i.e. more affluent women have higher rates of breast 
cancer incidence) (29).  A study of California breast cancer cases found a monotonic relationship 
between a composite measure of neighborhood SES and breast cancer incidence. Compared to 
the lowest SES group, the medium-low, medium-high, and high SES groups had rate ratios of 
1.21, 1.35, and 1.59, respectively (30). A study by Robert and colleagues found that, even after 
controlling for individual risk factors, women who lived in the highest SES communities had a 
greater odds of breast cancer incidence (31). SES and breast cancer mortality tend to show a 
different relationship, as poorer women have higher mortality rates. Analysis of data from the 
California Breast Cancer Survivorship Consortium found that, except for Asian Americans, 
women of any race/ethnic group who lived in a low SES neighborhood had higher breast cancer 
mortality rates regardless of their individual educational attainment (32). 
Geographic Location 
Breast cancer incidence and mortality vary by rural-urban status and other geographic 
factors as well.  A systematic review and meta-analysis of thirty-one international studies (23 of 
which were performed in the United States) evaluated the association of residential environment, 
including rural-urban status, and breast cancer incidence (33). This meta-analysis found that, in 
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the eight studies that included rural-urban status, breast cancer incidence was modestly higher in 
urban areas than in rural areas (pooled relative risk=1.09, 95% CI=1.01-1.19). Two recent 
analyses of population-based cancer registry data representing  >90% of the United States 
population found also indicated that breast cancer incidence rates are higher in urban populations 
compared to rural (34,35). Both rural and urban populations have experienced a similar decrease 
in breast cancer incidence, with annual percentage changes of -0.52% and -0.51%, respectively 
between 1995 and 2013 (35). For the most part, breast cancer mortality rates are similar in rural 
and urban areas, although the most isolated rural counties had higher rates than those in smaller 
urban counties (34). 
In addition to rural-urban differences in breast cancer incidence and mortality, there are 
state-to-state differences. Of particular note is that in seven states --Alabama, Kentucky, 
Louisiana, Mississippi, Missouri, Oklahoma and Tennessee-- breast cancer incidence rates are 
now higher in black women than in white women (25). Among white women, age-adjusted 
breast cancer incidence rates range from 107.7 per 100,000 in Arkansas to 164.4 in the District 
of Columbia (white U.S. rate=128.1 per 100,000) (25). Among black women, age-adjusted breast 
cancer incidence rates range from 94.0 per 100,000 in Minnesota to 141.7 in Alaska (black US 
rate=124.3 per 100,000) (25). Age-adjusted breast cancer mortality rates varied from 18.7 per 
100,000 in Vermont to 25.4 in Nevada among whites (white US rate=21.9 per 100,000) (25). 
Among blacks, the breast cancer mortality rate varied from 21.7 per 100,000 in Minnesota to 
35.4 in Oklahoma (black US rate=31.0 per 100,000).  
Specific Aim #1 
Specific Aim #1: To determine differences in breast cancer risk and breast cancer risk by 
subtype between those living in Delta region and women living in non-Delta region counties in 
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the Lower Mississippi Delta Region states and between black and white women in the Delta 
region. 
 Hypothesis 1.1. Delta Region women will have a higher risk of HR- (including triple-
negative) breast cancers. 
 Hypothesis 1.2. Delta Region women will have a lower risk of HR+ breast cancers than 
non-Delta Region women. 
 Hypothesis 1.3. Delta Region black women will have a higher risk of HR- breast cancers 
(especially triple-negative breast cancer) than white Delta Region women.  
 Hypothesis 1.4. When relevant factors are controlled for, these elevated risks (Hypothesis 
1.1-1.3) will be at least partially attenuated. 
In order to achieve the aim of determining whether or not there are differences in breast 
cancer incidence overall and by subtype between the Delta Region and non-Delta Region of the 
LMDR states, three types of analyses were performed utilizing population-based cancer 
surveillance data from the North American Association of Central Cancer Registries. First, 
incidence rates were calculated to describe the breast cancer burden for all invasive breast 
cancers and for each breast cancer subtype individually in the Delta Region and non-Delta 
Regions and by race/ethnicity, rural-urban status, and SES. Second, rate ratios were calculated to 
assess the magnitude of the difference between the Delta Region and non-Delta Region and by 
stratifications noted above for all invasive breast cancers and for breast cancer subtypes 
individually. Third, multilevel models were constructed to calculate rate ratios of all invasive 
breast cancers and of each breast cancer subtype, separately, while adjusting for age, 
race/ethnicity, and contextual factors. Thus, it was determined whether or not any differences 
between the Delta Region and non-Delta Region were attenuated when relevant, confounding 
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factors are considered. These three types of analyses were also performed as part of a sub-
analysis that considers only cases diagnosed within the Delta Region with a particular focus on 
describing and determining the racial differences in breast cancer burden by subtype within the 
Region. 
Specific Aim 1 Conceptual Framework 
The conceptual framework for this aim is largely based on Warnecke’s Model for 
Analysis of Population Health and Health Disparities and Wingo’s Framework for Cancer 
Surveillance (Figure 1.2) (36,37).  Warnecke’s model is a framework that specifically focuses on 
the multilevel determinants of health (e.g. cancer) disparities (38). Wingo’s framework considers 
the continuum of cancer progression, including tumor characteristics, such as subtype, that is 
identified as part of the diagnostic process. The multilevel nature of this model is ideal for the 
multilevel modeling analytical approach that was employed in the dissertation (Chapter 2) to test 
Hypothesis 1.4, as hypothesis 1.1-1.3 were tested by calculation of breast cancer incidence rates 
and rate ratios. The multilevel nature of Warnecke’s model indicates that distal, intermediate, 
and proximal factors play a role in health disparities. Distal factors include social conditions and 
policies, which may include policy-relevant contexts like the Delta Region designation. 
Intermediate factors include measures of social and physical context which may include 
sociodemographic factors like county-level poverty or racial composition, measures of rural-
urban status, and utilization of mammography (i.e. a measure of realized accessibility). 
Additionally, this model includes proximal factors that describe the individual, like age and race. 
Such intermediate and proximal may explain differences in breast cancer subtype between the 
Delta and non-Delta Regions (i.e. a distal context) of the LMDR states. The conceptual model 
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displays the covariates that were determined a priori for consideration for inclusion in the model 
building process. Covariates in the final model are delineated in Chapter 2. 
Relevant Literature Review- Sociodemographic Disparities in Breast Cancer Subtypes 
Subtype Definition and Descriptive Epidemiology. Clinical assessment of breast cancer 
routinely includes identification of tumor marker expression that can determine the molecular 
signature of this cancer, categorizing it into one of four “intrinsic subtypes” (39).  These 
subtypes are defined using three different tumor characteristics—the presence of two hormone 
tumor receptors (estrogen and progesterone receptors, ER and PR, respectively) and the 
expression of the protein human epidermal growth factor two (HER2). The four main subtypes 
of breast cancer are:1) ER+ or PR+ or both, HER2- (also known as HR+/ HER2-); 2) ER+ or 
PR+ or both, HER2+ (also known as HR+/HER2+); 3) ER- or PR- or both, HER2+ (also known 
as HR-/ HER2+); or 4) ER- or PR- or both, HER2- (also known as HR-/ HER2- or Triple 
Negative). For the remainder of this chapter, these subtypes will be referred to by the following 
designations: HR+/HER2+, HR+/HER2-, HR-/ HER2+, and triple-negative. The inclusion of ER 
and PR statuses have been required by central cancer registries since 1990, but HER2 status has 
only been required since 2010 (39).  
The hormone receptors and the HER2 protein are often targets for drug therapies that are 
initiated in combination with chemotherapy following surgical treatment (40). For example, 
drugs like selective ER modulators (e.g. Tamoxifen) and aromatase inhibitors (e.g. Arimidex) are 
used to target HR+ cancers in all HR+ cancers and HR+ cancers in postmenopausal women, 
respectively. For cancers that overexpress HER2 (i.e. HR+/HER2+ and HR-/HER2+), Herceptin 
is often prescribed. However, for triple-negative cancers, there are no targets for such drugs, 
which limits treatment options and negatively affects prognosis.  
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Two of these types are hormone receptor-positive breast cancers: HR+/ HER2- and HR+/ 
HER2+. HR+/HER2- is the most common subtype (74% of all cases) and has the best prognosis 
(41). The distribution of this subtype varies by race ranging from 62% of breast cancers in blacks 
and 76% of cases in whites.  All race/ethnicity HR+/HER2- incidence rate in the United States is 
86.5 per 100,000, while rates for whites and blacks are 92.7 and 74.4 per 100,000, respectively 
(41). HR+/ HER2+ is far less frequent comprising only 10% of all cases. The all-race/ethnicity 
rate of 12.4 per 100,000 and the rate for whites and blacks 12.8 and 12.9 per 100,000, 
respectively (41). HR+ cancers have better survival rates than HR- subtypes (42). A study found 
that five-year disease-specific survival for HR+ cancers ranged from 85.8% to 91.6% compared 
to 76.2% to 82.4% for HR- cancers (42).   
         There are two types of hormone receptor-negative breast cancers: HR-/ HER2+ and triple-
negative. HR-/ HER2+ breast cancer is the least common cancer type (only 4% of breast cancer 
cases); the all-race/ethnicities incidence rate is 5.5 per 100,000, with rates of 5.4 and 6.7 per 
100,000 in white and black women, respectively (25,41). Triple-negative is the more common 
HR- breast cancer. Studies of large clinical databases and population-based registries estimate 
that triple-negative cases comprise 11.7-12.9% of breast cancer cases in the United States 
(7,41,43). The triple-negative breast cancer incidence rate is 15.5 per 100,000 among all women, 
and age-adjusted rates are 14.4 and 27.2 per 100,000 in white and black women, respectively. 
HR- breast cancers present at a higher grade and a more advanced stage than other breast cancers 
(43). Analysis of the Carolina Breast Study found that women with HR- cancers had poorer 
survival than those with HR+ cancers, while analysis of SEER data found a nearly twofold risk 
of cancer-specific death in women with HR- cancers compared to those with HR+ cancers 
(HR=1.91, 95% CI=1.88-1.94) (44,45).  
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Age. The odds of triple-negative breast cancer are higher in younger women. Studies have 
indicated HR- breast cancers are more likely to be diagnosed in women under 50 years old 
(46,47). A study of women with breast cancer in Atlanta showed that the odds of triple-negative 
cancer were higher among women aged 20 and 39 (OR=2.13, 95% CI=1.34-3.39) than aged 50-
54 years when controlling for other factors (47).  A study of California Cancer Registry breast 
cancer cases diagnosed from 1999 to 2003 found that triple-negative breast cancer cases were 
more likely to be diagnosed in women younger than 40 (OR=1.53, 95% CI=1.37-1.70) and aged 
40-49 (OR=1.20, 95% CI=1.02-1.22) compared to the reference group (age 60-69), controlling 
for race, stage, socioeconomic status, and tumor grade (46). Similarly, a study of SEER 18 data 
found that triple-negative breast cancer is 10-30% less likely to be diagnosed in women over the 
age of 65 compared to HR+/HER2- cancers (43).   
Race/Ethnicity. Genetic and hereditary factors play a role in the racial and ethnic disparities in 
incidence of breast cancer incidence rates by subtype (48,49). Although not population-based, 
some studies of breast cancer patients in west African countries like Ghana found that the 
proportion of triple-negative breast cancers was as high as 61% or 82% of breast cancers. 
Newman reviewed seven studies that included diverse samples of breast cancer cases in women 
of European and African descent (including women of West, Central, Southern, and east African 
descent) (49). A higher proportion of triple-negative breast cancers was found in women of 
African descent compared to cases in women of European descent. In studies that included 
women from different regions of Africa and the United States, the proportion of triple-negative 
breast cancer cases was highest among West Africans, followed by African Americans, East 
Africans, and white Americans, respectively (50).  
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Epidemiologic studies reflect this racial variation in risk of HR- cancers, broadly, and 
triple-negative cancers, specifically, in the United States.  Multiple studies have indicated that 
the odds of triple-negative breast cancer are twice as high in black women as in white women, 
even after controlling for relevant factors like age, tumor grade, and stage (41,43,51). Some 
studies have also shown a higher odds in Hispanic women. An analysis of 2010 data from SEER 
registries representing approximately 28% of the United States population found that, controlling 
for age, stage, tumor grade, and registry, black women were twice as likely to have a triple-
negative breast cancer diagnosis than white women (OR=2.0, 95 % CI=1.8-2.2) and were also 
more likely to have a HR-/HER2+ diagnosis (OR=1.4, 95% CI=1.2-1.6) (43). Similarly, 
Hispanic women had a higher odds of triple negative (OR=1.3, 95% CI=1.2-1.5) and HR-
/HER2+ (OR=1.4, 95% CI=1.2-1.6) than non-Hispanic white women. An analysis of National 
Cancer Database data, which includes ~73% of breast cancer cases diagnosed in the United 
States, found that non-Hispanic blacks (OR=1.91, 95% CI=1.80-2.03) and Hispanic women 
(1.36, 95% CI=1.20-1.55) had a higher odds of triple-negative breast cancer than white women 
after controlling for demographic, socioeconomic, and clinical characteristics(7).  A study of 629 
breast cancer cases in New Jersey found a borderline association between race and triple 
negative subtype (OR=1.9, 95% CI=1.0-3.4) when controlling for demographic and clinical 
factors (51). 
Socioeconomic Status (SES).  In addition to individual-level factors like age and race/ethnicity, 
social factors, such as SES, may play a role in the development of different breast cancer 
subtypes. Studies have shown that more affluent women have higher rates of both breast cancer 
overall and HR+ breast cancers (29-31,41).  However, the relationship between SES and 
incidence of HR- breast cancers, broadly, and triple-negative breast cancers, specifically, is 
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unclear. Some suggest that socioeconomic factors may play a role in the etiology of HR- cancers. 
In a comprehensive review, Williams and colleagues suggest that stressors across the life-course 
(i.e. allostatic load) may impact breast cancer incidence (52).  Although black race has been 
identified as an independent predictor of triple-negative breast cancer, Dietze and colleagues 
suggest that the intersection of socioeconomic disparities and African ancestry may play a role in 
more aggressive tumor biology (53). Similarly, Vona-Davis posits that poverty may be a factor, 
independent of race/ethnicity, which facilitates angiogenesis and increases leptin subsequently 
stimulating the growth of breast cancer cells in triple-negative cancers (54).  
  A study utilizing a population-based cancer registry in Scotland indicated a higher 
proportion of estrogen receptor-negative cancers in those who lived in areas with less affluence 
(55). Similarly, an association of borderline significance was seen between social deprivation 
and estrogen receptor negative cancers in England (56). A study by Gordon of breast cancer 
clinical trial participants found that women who lived in impoverished (OR=1.77, 95% CI=1.28-
2.44) or less educated (OR=1.98, 95% CI=1.43-2.73) areas had a higher odds of estrogen 
receptor-negative cancers (57). However, a recent study of high quality, population-based 
registries in the United States found no clear association between census tract level poverty and 
estrogen receptor negative subtypes’ incidence rates—at least at an ecological level (41). 
The relationship of socioeconomic status on triple-negative breast cancer risk, 
specifically, is unclear. Bauer and colleagues used California Cancer Registry data and found 
that breast cancer cases in the lowest two quintiles of socioeconomic status are 12-22% more 
likely to be diagnosed with triple-negative breast cancer than the most affluent quintile, even 
after controlling for race, age, stage, and tumor grade (46). Similarly, in a study using National 
Cancer Database data, Sineshaw and colleagues found that those in the lowest socioeconomic 
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group were 14% more likely to be diagnosed with triple-negative breast cancer than more 
affluent women (7). However, a recent population-based study of SEER 18 registry data found 
no association between lower socioeconomic status and greater odds of triple negative breast 
cancer (58). No associations between socioeconomic status and odds of triple negative breast 
cancer were found when stratified by race in that same study. 
Studies have suggested a positive relationship between HR+ breast cancer and 
socioeconomic status.  The 2015 Annual Report to the Nation on Cancer found that HR+/HER2- 
incidence rates decreased with increasing census tract poverty levels (i.e. hormone receptor-
positive rates are higher among the most affluent) (41). Similarly, a study by Krieger and 
colleagues utilizing SEER 13 data found that breast cancer cases in counties with large income 
inequities had higher rates of estrogen receptor-positive breast cancers (59). A study by 
Akinyenmiju found that, in whites, there was a higher incidence rate of HR+/HER2- cancers in 
the higher income compared to lower income areas (IRR=1.32, 95%CI=1.27-1.39) (58).  A 
similar association was seen with HR+/HER2+ cases as well (IRR=1.45, 95% CI=1.27-1.68) 
(58). The relationship between affluence and elevated incidence of HR+/HER2- cancers was also 
seen for Hispanics, but not for blacks.  
Another social factor, residential segregation, includes neighborhood conditions that 
facilitate poor health outcomes in blacks. These conditions include lower income and education 
levels, less home ownership, residential instability, and less access to parks and sources of 
healthy foods. Williams and colleagues suggest that such conditions may facilitate breast cancer 
risk (52). As such, residential segregation is a common contextual factor that has been 
considered in breast cancer disparity studies (60-62).  Studies evaluating the relationship 
between residential segregation and breast cancer subtype, specifically, are limited and have 
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shown mixed results. Although Krieger and colleagues found an association between income 
inequality and ER+ breast cancer, they found no association between and higher residential 
segregation levels of ER+ breast cancer (59). A study by Linnenbringer found that, among black 
women, living in a neighborhood with higher concentrations of black residents actually reduced 
the odds of HR- breast cancers (63).  
Geographic Location. There are few studies that have explored geographic differences in breast 
cancer by subtype in the United States, and none of these have explored rural-urban differences. 
A descriptive study showed that the highest quartile of triple-negative breast cancer rates is 
concentrated in southern states with a few Midwestern states (Illinois, Missouri, and Indiana) 
also ranking in this top quartile (41). State level proportion of the black population was strongly 
positively correlated with triple-negative breast cancer incidence (r=0.80, p<0.001) (41). Another 
study utilizing National Cancer Database data indicated that compared to the Northeast, the odds 
of triple-negative breast cancer were statistically significantly higher in the Midwest (OR=1.13, 
95%=1.08-1.17) and the South (OR=1.18, 95% CI=1.14-1.23), even after controlling for factors 
like age, race/ethnicity, and socioeconomic factors (7). An analysis of SEER 18 registries 
showed that the percentage of breast cancer cases that had a triple negative status ranged from 
9.3% in the Seattle/Puget Sound registry to 15.7% in the Louisiana and Detroit metropolitan 
registries (43). Kohler and colleagues found that the highest quartile of HR+/HER2- cancers 
were clustered in the Northeast (41).  One study evaluated differences in breast cancer subtypes 
between two states—Ohio and South Carolina—and found an elevated incidence of estrogen 
receptor-positive cancers in black women in Ohio compared to their South Carolinians (64). This 
suggests that geographic factors and/or related socioeconomic, behavioral, or other factors may 
play a role in subtype differences, even among black women. 
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Specific Aim #2 
To evaluate differences in breast cancer staging by subtype between women in the Delta region 
and women in non-Delta Region counties within the LMDR states and between black and white 
women in the Delta region. 
 Hypothesis 2.1. Delta Region women will have a higher risk of advanced stage breast 
cancers across all subtypes. 
 Hypothesis 2.2.Delta Region black women will have a higher risk of advanced stage 
cancer than white Delta Region women. 
 Hypothesis 2.3. When relevant factors are controlled for, these risks will be at least 
partially attenuated. 
In order to determine whether or not there are differences in breast cancer staging between 
the Delta Region and non-Delta region of the LMDR states, three types of analyses were 
performed using population-based cancer surveillance data from the North American Association 
of Central Cancer Registries. First, incidence rates were calculated to describe the breast cancer 
burden by stage (early and late) for all invasive breast cancers and for all breast cancer subtypes 
individually in the Delta Region and non-Delta Region and by race/ethnicity, rural-urban status, 
and other relevant stratifications. Second, rate ratios were calculated to assess the stage by 
subtype differences between the Delta Region and non-Delta Region and by stratifications noted 
above. Third, multilevel models were constructed to assess the odds of early-stage and late-stage 
diagnoses, respectively, for all invasive breast cancers and for each breast cancer subtype, 
separately, while adjusting for the effect of individual level and neighborhood level factors. 
Thus, any stage differences between the Delta Region and non-Delta Region were determined 
after accounting for individual and contextual factors. These three types of analyses were also 
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performed by considering only cases diagnosed within the Delta Region with a particular focus 
on describing and determining the racial differences in breast cancer staging by subtype within 
the region. 
Specific Aim #2 Conceptual Framework 
The conceptual framework applied to specific aim #1 was also applied to specific aim #2 
with the outcome of interest being breast cancer stage by subtype. To test Hypotheses 2.1-2.2, 
incidence rates and rate ratios were calculated, while multilevel regression models were 
employed to test Hypothesis 2.3 (Chapter 3).  As described for Specific Aim #1, the conceptual 
framework in Figure 2 displays all covariates (individual characteristics and measures of social 
and physical context) that were a priori considered for inclusion in the model building process. 
The final model is described and depicted in Chapter 3. 
Relevant Literature Review-Sociodemographic Disparities in Breast Cancer Staging 
Breast cancer staging characterizes how far cancer has spread from its origin (i.e. spread 
to nearby lymph nodes and/or metastasized to other parts of the body). Staging helps healthcare 
providers and patients understand the progression and prognosis of the disease and guides what 
treatment options may be most appropriate. There are multiple ways to characterize staging. The 
TNM staging system considers the tumor size (T), number of regional lymph nodes involved 
(N), and whether or not cancer has metastasized (M) (65). The American Joint Commission on 
Cancer also has a staging scheme that uses the TNM designations to generate a stage designation 
of 0, I, II, III, or IV with 0 indicating abnormal cells that have not spread and IV indicating the 
most progressive spread of disease (66).  There are two main types of staging: 1) clinical, which 
is based upon physical examination, imaging, and biopsy; and 2) pathological, which uses 
information from the clinical staging plus information from surgery to make a determination. 
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The Surveillance Epidemiology and End Results (SEER) staging system categorizes cancers 
using both clinical and pathological documentation of disease spread for characterization in 
cancer registries (67). This staging system often categorizes cancers as in situ, localized, 
regional, or distant, indicating more advanced spread of the disease. In situ indicates that 
abnormal cells have not penetrated the membrane of the tissues. Localized staging means that the 
cancerous cells are confined only to the organ of origin. Regional staging indicates cancer has 
spread beyond the organ of origin, such as to nearby lymph nodes. Distant staging is defined as 
cancer that has spread beyond the organ of origin, has traveled to other parts of the body, and has 
started to grow in a new location. Additionally, staging can be characterized as 
“unknown/unstaged” if there is not sufficient information to stage, if a patient refuses diagnostic 
procedures or treatment, if there is a contraindication for diagnostic procedures or treatment, or if 
a patient dies before stage can be determined. 
In the United States between 2007 and 2013, 62% of breast cancer cases were localized, 
31% were regional, 6% were distant stage, and 2% were of unknown stage (68). More advanced 
staging has been associated with reduced 5-year relative survival. Breast cancer cases diagnosed 
at a localized stage have very good 5-year disease-specific survival (98.9%) (68). With more 
advanced staging, 5-year survival decreases, as regional and distant stage cancers have 85.2% 
and 26.9% 5-year survival rates, respectively. 
Race/Ethnicity. The distribution and rates of staging, and subsequently survival, vary by race 
and ethnicity. Descriptively, 64% of white female breast cancer cases are diagnosed at a 
localized stage, compared to 53% in blacks, 56% in Hispanics, 63% in Asian and Pacific 
Islanders, and 57% in American Indian/Alaska Natives (25). A third of white cases are diagnosed 
at a regional or distant stage, while 43% of blacks, 40% of Hispanics, 35% of Asians and Pacific 
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Islanders, and 38% of American Indian/Alaska Natives are diagnosed at these more advanced 
stages. Five-year disease-specific survival rates for localized cancers are similar for all 
race/ethnic groups, ranging from 93-98% (25). However, greater survival disparities occur for 
more advanced stages. This is most starkly seen in distant stage survival where 5-year survival is 
34% for whites and 24% for blacks, with other race/ethnic groups ranging from 38-39%.  
Additional studies have shown associations between race/ethnicity and staging 
independent of confounding factors. A study by Lantz and colleagues found that blacks and 
Hispanics have a lower odds of being diagnosed at an earlier stage, even after controlling for age 
and SES (69). Similarly, both Hispanic and non-Hispanic black women were at a greater odds of 
being diagnosed with Stage II-IV compared to whites and Stage IV cancers in two SEER-based 
studies, respectively (70,71).  
Rural Status and Socioeconomic Status. In addition to race and ethnicity, there are other 
socioeconomic and demographic factors, such as rurality, poverty, and insurance status that are 
associated with more advanced staging at diagnosis. A meta-analysis of 21 studies indicated that 
rural women had a higher odds of being diagnosed at a more advanced stage than their urban 
counterparts (OR=1.19, 95% CI =1.12-1.27) (8). However, a recent population-based descriptive 
analysis in the United States found that the most rural counties had a lower incidence of late-
stage breast cancer compared to the most urban counties (34). Late stage breast cancers 
decreased at similar rates in both rural and urban populations between 2004 and 2013 (34).  
Additionally, regardless of race or ethnicity, lower SES was associated with more 
advanced staging in multiple studies (72-74). A population-based study of cancers diagnosed in 
16 states in the United States and in Los Angeles found a higher risk of advanced stage breast 
cancer in women who live in census tracts with greater than 20% of the population living poverty 
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compared to census tracts with less than 5% living in poverty (72).  Another study utilizing 
Texas Cancer Registry data found a higher odds of distant stage breast cancer in low SES census 
tracts compared to more affluent census tracts (OR=1.35, 95% CI=1.31-1.39) (73).  Similarly, 
women without private insurance (i.e. uninsured, Medicaid, or Medicare) had a greater odds of 
being diagnosed at a more advanced stage of breast cancer (75,76). As previously noted, 
residential segregation is a commonly considered covariate in breast cancer disparity studies 
(59,61,62).  Studies evaluating the association between racial segregation and breast cancer stage 
at diagnosis have yielded mixed results. Dai found that women living in areas of higher racial 
segregation in Detroit had a higher risk for late-stage breast cancer (77).  However, studies using 
data from the California Cancer Registry and from SEER found no association between 
segregation and late-stage breast cancer diagnosis (61,78). 
Breast Cancer Stage and Subtype. Breast cancer stage varies by subtype, with HR- subtypes 
generally being diagnosed at a later stage. A study utilizing National Cancer Database data found 
that compared to HR+/HER2-, all other subtypes had an increased odds of Stage II or later, with 
triple-negative cancers showing the greater magnitude of an increased odds (7). An analysis of 
breast cancer cases in the 2010 SEER 18 registries indicated that HR- cases were more likely to 
be diagnosed at a late stage (OR=1.29, 95% CI=1.27-1.31), even after controlling for other 
factors (45). However, another study of very similar data (SEER 17-the Alaskan registry was 
excluded) found that HR+/HER2- and triple-negative breast cancers had similar stage 
distributions, but HR+/HER2+ and HR-/HER2+ had a higher odds of being diagnosed at Stage 
III or IV (43). 
Age-adjusted breast cancer subtype incidence rates vary by stage and race/ethnicity. 
HR+/HER2- localized incidence is highest among white women (63.51 per 100,000) compared 
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to blacks (44.43 per 100,000), Asian/Pacific Islanders (43.16 per 100,000), and Hispanics (40.94 
per 100,000) (41). Distant stage HR+/HER2- incidence rates were higher in black women than 
white women (5.79 vs. 4.32 per 100,000, respectively). For triple-negative breast cancer, black 
women had the highest rates across all stages.  
Several analyses of SEER data suggest that black women are diagnosed at more 
advanced stages of breast cancer either stratified by subtype or controlling for subtype. A study 
from Chen and colleagues found that, compared to white breast cancer cases, black women with 
breast cancer had a higher odds of being diagnosed at a later stage of cancer across all four 
subtypes (79). Similarly, three studies found that black women have a greater odds of late-stage 
breast cancer or a lower odds of early-stage breast cancer compared to white women, 
respectively, even after controlling for estrogen receptor/hormone receptor status and other 
factors (45,80,81). 
Specific Aim #3 
To compare spatial accessibility to mammography services for women living in the Delta region 
compared to those living in the non-Delta region of the LMDR states and between black and 
white women in the Delta region. 
• Hypothesis 3.1.Delta Region women will have less spatial access to mammography 
services than non-Delta women. 
• Hypothesis 3.2. Black women will have less spatial access to mammography services 
than white women. 
• Hypothesis 3.3. Rural women will have less spatial access to mammography services 
than their urban counterparts. 
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 In order to achieve this aim, the enhanced two-step floating catchment area method was 
used to calculate a spatial accessibility score for each census tract in the LMDR states. Data from 
the Food and Drug Administration on mammography facility locations and population estimates 
from the American Community Survey were utilized. To determine whether or not there were 
differences between the Delta and non-Delta Regions and between rural and urban populations 
(Hypotheses 3.1 and 3.3), summary statistics were calculated and compared. To assess 
differences in access by race within the Delta Region (Hypothesis 3.2), bivariate statistical and 
spatial analyses were performed. Spatial statistics were also calculated to identify clusters of low 
spatial access in the Delta Region.  
Specific Aim #3 Conceptual Framework 
This aim utilized a conceptual framework based on Khan’s Typology of Access to Health 
Care (82) (Figure 1.3). In particular, this aim characterized the potential accessibility to 
mammography services in the Lower Mississippi Delta Region as a measure of spatial access. 
Potential accessibility is defined as the availability of services (i.e. mammography) relative to the 
population in need. Spatial access was considered in relation to aspatial access measures like 
racial composition and rurality, a construct that transcends both spatial and aspatial measures.  
Relevant Literature Review-Disparities in Spatial Access to Mammography Services 
Mammography Screening Recommendations. Regular mammograms are recommended to 
detect breast cancer at an earlier stage, thus improving survival and reducing mortality. Different 
entities, such as the United States Preventive Services Task Force (USPSTF), the American 
Cancer Society (ACS), and the National Comprehensive Cancer Network (NCCN), have 
different recommendations for age for initiation of screening and frequency of screening.   The 
USPSTF’s most recent guideline releases (2009 and 2016) recommend biennial screening for 
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women aged 50-74 (83,84).  Screening for average-risk women between the ages 40 and 49 is 
recommended on an individual basis only in accordance with patient preference and provider 
recommendation, while women 75 and older are not explicitly recommended to get screened. 
The 2003 ACS recommendation indicated that average-risk women should receive an annual 
mammogram beginning at age 40. However, the most recent (2015) ACS guidelines recommend 
that women with average risk aged 45-54 receive annual screening, and women aged 55 and 
older should receive biennial screening as long as they are of good health with a life expectancy 
of 10 years or more (85). Additionally, the ACS recommends magnetic resonance imaging 
(MRI) screening for women whose lifetime risk of breast cancer exceeds 20% (86). The NCCN 
recommends that women of average risk be screened annual starting at the age of 40 (87). 
Screening Options. The most common screening option is a film mammography, which is a 
scan of the breast to detect breast cancer in women with no signs or symptoms (88).  Other, less 
common options are digital mammography and 3D mammography. Digital mammography 
allows for easier, electronic transfer between healthcare providers and clearer distinction 
between normal and abnormal tissue. 3D mammography is similar to a film mammography, but 
it records multiple images rather than solely one to create a three-dimensional image of the 
breast. Other radiographic methods are being tested for sensitivity and specificity including MRI, 
positron emission tomography (PET), and diffuse optical tomography. MRI is generally only 
recommended for women at high risk for breast cancer, such as the recommendation of the ACS. 
Screening and breast cancer subtype. While adherence to mammography screening is 
recommended to help ensure that breast cancer is detected at an early stage, X-ray 
mammography may not always be sufficient to detect HR- breast cancers. Triple-negative breast 
cancer lacks the shape, margin, and calcification characteristics of other breast cancer subtypes 
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that are detectable on X-Ray mammography (89). Thus, other screening modalities, such as 
ultrasound or MRI may be preferable in women with high risk for triple-negative breast cancer.  
A study has also shown that, while digital and film mammography were comparable overall, 
digital mammography is more accurate than X-Ray mammography to detect breast cancer among 
women under 50 who are premenopausal or perimenopausal, factors often associated with triple-
negative cancers (90). Similarly, another study showed that digital mammography was more 
sensitive to detect HR- cancers compared to film mammography, and digital mammography had 
borderline better sensitivity than film mammography in women between the age of 40 and 49, 
were premenopausal/perimenopausal, and who had dense breasts (91). 
Screening’s effect on cancer staging and mortality. Implementation of regular mammography 
screening has had a strong effect on trends in stage at diagnosis, but only a modest effect on 
reduction of breast cancer mortality rates. A study of more than thirty years of SEER data found 
that the proportion of breast cancers diagnosed at an early stage doubled between 1976 and 2008, 
while advanced stage cancers decreased by just 8% (92).  A pooled analysis of numerous 
domestic and international studies suggests that mammography screening was associated with an 
approximate 20% reduction in breast cancer mortality, but the benefits for screening women 
under the age of 50 was unclear (93). Another study showed that 15% of the reduction in breast 
cancer mortality between 1975 and 2000 was due to mammography—a modest absolute 
reduction of 0.29% (94). A study by Bleyer, Baines, and Miller suggested that mammography 
utilization and penetrance (i.e. expansion of mammography services) was not associated with 
breast cancer mortality reduction (95). Instead, much of the reduction in mortality is due to 
improved chemotherapy and radiation treatment (96). Indeed, there is a growing body of 
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evidence suggesting that women are more likely to be “overdiagnosed” with breast cancer than 
they were to be detected early with a tumor that would later become large (96-97).  
Screening adherence by demographic groups. Results from studies assessing mammography 
guidelines adherence across different demographic groups—race/ethnicity, insurance status, and 
rural-urban-status—have yielded mixed results. Findings from the Health Information and 
National Trends Survey found that black women were more likely than white women to have 
had a mammogram in the past three years (Adjusted prevalence ratio=1.48, 95% CI=1.06-2.07) 
even after adjusting for age, insurance status, income, education, and other factors (98).  A 2016 
study found that black women on Medicaid had a lower odds of mammography use than white 
women (OR=0.87, 95% CI=0.87-0.88) while Hispanic women had a higher odds (OR=1.06, 95% 
CI=1.05-1.07) (99). A systematic review and meta-analysis of 28 international studies (16 of 
which were from the United States) found that rural women were less likely than urban women 
to have ever had a mammogram (OR=0.74, 95% CI=0.62-0.89) (100). However, a study utilizing 
data from the Utah Behavioral Risk Factor Surveillance System found that geographic factors 
(i.e. rurality) were not associated with nonadherence to mammography guidelines, but not having 
a regular physician, not having health insurance, low income, and other factors were associated 
with nonadherence (101). 
Geographic variability in mammography access in the United States. Access to health care is 
often defined across five dimensions: availability, accessibility, accommodation, affordability, 
and acceptability (102). Two of these dimensions are constructs of spatial access--availability 
and accessibility. Availability of care defines service supply related to need for services. 
Availability is often assessed using area measures, which are generally defined as the ratios of 
health care providers or service locations to the population in need within a specific geographic 
 30 
 
context, such as an administratively defined area (e.g. number of physicians per 100,000 
population in a county). Accessibility characterizes the geographic relationship between health 
services and a population or individual (e.g. distance or travel time to services). Access to 
mammography facilities, specifically, can be quantitatively characterized by availability and 
accessibility. Availability can be considered as geographic capacity and mammography facility 
density (i.e. the number of facilities per population) (103). Accessibility to mammography may 
be characterized by distance or travel time to a mammography facility or by utilizing 
methodologies that take both distance and travel time into account (103).  
There is geographic and socioeconomic variability in mammographic availability in the 
United States. A study by Elkin and colleagues found that mammography capacity per 10,000 
women 40 years of age and older dropped 20% during between 2000 and 2010, but capacity 
increased in rural areas (104). Additionally, they found that counties with high population 
density and poorer socioeconomic status had lower mammography capacity, and one in five 
counties had no mammographic capacity. A study by Peipins and colleagues assessed 
characteristics of counties with no mammographic capacity and found that low population 
density was associated with no mammographic capacity, even after controlling for other factors 
(OR=11.0, 95% CI=7.7-15.9) (105). Another study looked at mammography supply and demand 
in 14 southern states between 2002 and 2008 (106). The authors found that during the study 
period, the proportion of women who lived in an area with low mammography capacity 
increased 10%. Capacity decreased in ten states: Arkansas, Louisiana, Mississippi, Alabama 
Oklahoma, Kentucky, Georgia, Florida, South Carolina, and Texas, with Mississippi showing the 
largest decrease in capacity.  
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Geographic access to mammography services and cancer outcomes. Studies that have 
explored the relationship between geographic access to mammography facilities and cancer 
outcomes have yielded conflicting results. Several studies utilizing city, state, and multi-state 
data found associations between limited access to mammography and later stage of cancer at 
diagnosis (77,107-110). A study in Detroit, Michigan found that poorer mammography access 
was associated with later stage at diagnosis (77). One study utilizing data from 8 SEER registries 
found that low density of mammography facilities was associated with later stage of breast 
cancer at diagnosis (107). A study of a Wisconsin healthcare system suggested increased travel 
time to the nearest mammography facility was associated with later stage at diagnosis (108). A 
study of Kentucky cancer registry cases showed that cases residing more than 15 minutes from a 
mammography facility had greater odds of being diagnosed at more advanced stage than those 
who lived closer (111).   Similarly, a study of women in Los Angeles showed that further 
distance from mammography facilities was associated with later stage of breast cancer diagnosis 
(110). However, two population-level studies of cancer registry data from 10 states showed that, 
after controlling for other factors, travel time to mammography facilities was not associated with 
later stage at diagnosis (76,101). The first study evaluated the association between travel time to 
mammography and stage at diagnosis and found no association when controlling for race, age, 
poverty level and other factors (101). The second study looked at the association between spatial 
access to mammography and breast cancer stage at diagnosis and found no relationship when 
controlling for census tract level poverty (76). 
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Tables and Figures 
Table 1.1: Sociodemographic Characteristics of the Delta Region and the United States  
 
Figure 1.1: Map of Counties within the Delta Regional Authority Designation 
 
 
 
 
 
 Delta Region United States 
%  African American 32.5% 13.2% 
% of Adults 25+ Years of Age with a High School Degree 82.7% 86.3% 
% of Population Living below Poverty Level 21.3% 15.6% 
% of Counties in Persistent Poverty 43.3% 11.2% 
Median Household Income $40,833 $53,482 
Unemployment Rate 7.2% 6.2% 
Population per square mile 65.0 90.3 
Source: Delta Regional Authority. Today’s Delta A Research Tool for the Region 3rd Edition. 
Available at  http://dra.gov/images/uploads/content_files/DRA_Todays_Delta_2016.pdf 
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 Figure 1.2: Conceptual Model for Elucidating Breast Cancer Disparities in the Delta Region 
 
 
Figure 1.3: Conceptual Model for Assessing Spatial Access to Mammography in the Delta 
Region 
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CHAPTER 2: DISPARITIES IN BREAST CANCER SUBTYPES AMONG WOMEN IN 
THE LOWER MISSISSIPPI DELTA REGION STATES 
Introduction 
The Delta Regional Authority (Delta Region) is a federally designated region that 
includes 252 counties and parishes in the eight Lower Mississippi Delta Region (LMDR) of 
Alabama, Arkansas, Illinois, Kentucky, Louisiana, Mississippi, Missouri, and Tennessee. More 
than a third of residents in the Delta Region are black, and more than 20% of the population live 
in poverty(1). Additionally, this region is largely rural and has limited access to healthcare 
services (2,3). All of these factors make the Region vulnerable to a myriad of health disparities, 
including breast cancer disparities. Women in the Delta Region have higher rates of breast 
cancer mortality than women in the rest of the country, including the similarly impoverished 
Appalachian Region (4). Further, black women in the Delta Region have a higher breast cancer 
mortality rate than white women in the Region as well as a higher rate than black women in other 
parts of the country (4). Nine of the ten counties with the nation’s highest breast cancer mortality 
rates are in the Delta Region (5).  Recent state-level studies have yielded some breast cancer 
incidence findings that require additional exploration.  One study found that in six LMDR states, 
black women had higher breast cancer incidence rates than white women (6). Another study 
found that the LMDR states of Illinois, Kentucky, Louisiana, Mississippi, Missouri, and 
Tennessee (Alabama and Arkansas did not have sufficient data for analysis) are in the top 
quartile in the nation for triple-negative breast cancer incidence, the breast cancer subtype with 
the worst prognosis (7).   There is limited research on what factors contribute to these mortality 
disparities and how breast cancer incidence is distributed within the Delta and non-Delta Regions 
of the LMDR states and by race within the Delta Region. 
 43 
 
Breast cancer can be classified into four molecular subtypes based upon the presence or 
absence of two broad tumor characteristics—hormone (i.e. estrogen and progesterone) receptor 
(HR) and human epidermal growth factor 2 (HER2) status: 1)HR+/HER2-; 2) HR+/HER2+;3) 
HR-/HER+; 4) HR-/HER2- (“triple-negative”) (8). The subtype of a breast cancer tumor plays a 
role in its aggressiveness and informs the use of targeted drug treatments. HR+ cancers tend to 
have a better prognosis and more comprehensive treatment options than HR- cancers (9-11). 
Triple-negative breast cancer is the most aggressive and has limited treatment options (11).  
While central cancer registries have been required to collect information on HR status since 
1990, they have only been required to collect information on HER2 status since 2010 (8). 
Therefore, population-based assessment of the distribution of breast cancer by subtype is 
burgeoning but still limited.  
Risk of breast cancer by subtype varies by race/ethnicity, age, socioeconomic status, and 
geography. Multiple studies indicate that black women have greater than twice the rate or risk of 
triple-negative breast cancers compared to white women, even after controlling for other factors 
(12,13). Similarly, black women have a higher odds of both HR- breast cancer subtypes (12). 
Meanwhile, white women have higher rates of the HR+/HER2- cancers than other racial/ethnic 
groups (7). Women under the age of 50 are at greater risk for HR- breast cancers (14,15). 
Although the relationship between HR- cancers and socioeconomic status is unclear in current 
studies (16,17), some have suggested that the poverty may be an upstream social factor 
facilitating angiogenesis and other biological processes related to cancer growth, especially 
amongst black women (18-20). Other studies have shown that incidence of each breast cancer 
subtype varies by geographic region with HR+/HER2- cancers clustered in the Northeast and 
triple-negative cancers clustered in the South and Midwest (7,16). 
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The sociodemographic composition of the Delta Region suggests the Region may have 
higher incidence rates of triple-negative cancers that may contribute to its high breast cancer 
mortality rate. The objective of this present study was to three-fold. First, it aimed to describe the 
subtype-specific incidence rates of breast cancer in the Delta Region compared to those in the 
non-Delta Region of the LMDR states. Second, it aimed to determine how subtype specific 
incidence rates differ between white and black women within the Delta Region. Thirdly, it 
sought to determine how the differences in these subtype rates may be explained by contributing 
individual level and contextual factors, like age and county-level poverty rates, respectively.  
Methods 
Conceptual Model 
 A conceptual model, drawing from Warnecke’s Model for Analysis of Population Health 
and Health Disparities, was developed to identify individual and area-level factors that may be 
associated with breast cancer incidence by subtype within the Delta Region (21) (Figure 2.1).  
The Delta Region is a conceptualized as a supramacro, policy-relevant context that may affect 
the distribution of the incidence of breast cancer by subtype. Specifically included are individual-
level factors—age and race/ethnicity-- that have been shown in previous studies to affect one’s 
risk for any breast cancer or one’s risk for developing specific subtypes of breast cancer (7,12). 
Also included are measures of social and physical context that have been identified to affect 
breast cancer incidence rates overall or by specific subtype, including socioeconomic factors, 
racial composition, rural-urban status, mammography utilization, and provider density (16,17,22-
24). 
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Data 
Data from the North American Association of Central Cancer Registries (NAACCR) 
Cancer in North America (CINA) Deluxe File were used (25). This file provided individual-level 
data on all breast cancer cases diagnosed between 2012 and 2014 in the LMDR States. To be 
included in this dataset, data from central cancer registries must have 90+% case ascertainment, 
passing edits of 97% or better, and other quality indicators. These data are based on the 
NAACCR December 2016 data submission. Support for cancer registries is provided by the 
state, province or territory in which the registry is located. In the U.S., registries also participate 
in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program 
or the Centers for Disease Control and Prevention's National Program of Cancer Registries 
(NPCR) or both. In Canada, all registries submit data to the Canadian Cancer Registry 
maintained by Statistics Canada. Seven of the eight LMDR states provided active consent for 
their data to be included in this analysis (Alabama, Arkansas, Illinois, Kentucky, Louisiana, 
Mississippi, and Tennessee). Missouri’s data were not included in this study as this registry did 
not provide the necessary consent for their data to be used.  
 Inclusion/exclusion criteria were based on Kohler’s study and were employed to 
optimize the accuracy of rate calculations and data quality for breast cancer subtype analyses (7). 
Cases included all invasive female breast cancers (International Classification of Disease for 
Oncology 3rd Edition (ICD-O-3) of C500-C509). Cases with histology codes of 9050-9055 
(mesothelioma), 9140 (Kaposi’s sarcoma), 9590-9992 (leukemia and lymphoma) were excluded 
as were cases who were diagnosed who were missing on race/ethnicity and county of residence 
and cases who were 85 years of age or older. Cases that were reported to their respective central 
 46 
 
cancer registry by way of a death certificate, autopsy report, or by nursing home or hospice were 
also excluded.   
Relevant to this study, the NAACCR CiNA Deluxe data file included individual-level 
data on age (19 groups), race/ethnicity, county of residence at diagnosis, and collaborative 
staging site-specific factors, 1,2, and 15, which corresponded to estrogen receptor (ER), 
progesterone receptor (PR), and HER2 statuses, respectively. County of residence at diagnosis 
was used to determine if a patient lived in the Delta or non-Delta Regions of these states. ER and 
PR statuses were considered jointly and described as hormone receptor (HR) status. HR+ cases 
included those that were ER+ or PR+ or borderline. HR- included those cases that were both ER- 
and PR-. Cases with unknown HR status were considered unknown. For HER2 status, HER2+ 
and HER2- were categorized accordingly, while cases with borderline or unknown status were 
considered to be of unknown status. Based upon these site-specific factors, molecular subtypes 
of breast cancer cases were approximated: 1) HR+/HER2-; 2) HR+/HER2+; 3)HR-/HER2+; 4) 
HR-/HER2- (triple-negative); 5) unknown (12).  
Because data in cancer registries are not missing at random, especially with HR and 
HER2 statuses, subtype-specific analyses are subject to bias. Previous studies have shown that 
racial minorities and those from impoverished areas have a greater risk for missing/unknown 
status data in cancer registries (26). Failing to account for missing/unknown data may produce 
inaccurate estimates of disparities (27). While missing subtype information may be addressed 
through imputation (28,29), it is also important to understand and elucidate what individual level 
and area level factors are associated with unknown subtype status, especially as HER2 status 
information has only been required to be collected since 2010. There is an opportunity to 
intervene to improve clinical ascertainment to better inform targeted treatment and ensure quality 
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care (30) and to enhance the quality of cancer surveillance to improve cancer control efforts and 
better estimate biases (31). Thus, this analysis also aimed to evaluate differences in unknown 
status by Delta Region designation.  
Age-adjusted Incidence Rates and Rate Ratio Calculations 
 Age-adjusted incidence rates (IR) and rate ratios (RR) with 95% confidence intervals for 
all invasive breast cancer combined and individually by molecular subtype and unknown subtype 
status by Delta and non-Delta Region status. These IRs and RRs were also calculated stratified 
by race/ethnicity, rural-urban status, and percent of a county living in poverty. Additional IR and 
RR calculations were performed to evaluate racial, rural-urban, and poverty level differences 
within the Delta Region specifically.  Rates were expressed per 100,000 population and were 
age-adjusted using the 2000 US standard population.  Tiwari modifications were used in all 
analyses which were performed using SEER*Stat 8.4.3.  
Multilevel Regression Models 
Proc GLIMMIX in SAS 9.4 was used to construct multilevel regression models to 
calculate RRs for all breast cancers, each subtype individually, and breast cancers of unknown 
subtype as a means of comparing the Delta Region to the non-Delta Region overall and stratified 
by race/ethnicity, rural-urban status, and poverty level. Similar analyses were performed 
examining solely Delta Region cases to assess race/ethnic, rural-urban, and poverty level 
differences within the Region. 
  Because counts were overdispersed for all cancers combined, each individual subtype, 
and for cancers of unknown subtype, multilevel negative binomial regression models were 
constructed.  For these models, analyses cells were constructed containing the number of cases in 
each county within each analysis cell, which were divided by age (<50 years of age and 50+ 
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years of age) and race/ethnicity (Non-Hispanic White, Non-Hispanic Black, Hispanic/Non-
Hispanic Other). Analysis groups were divided at age 50 as it is the age at which estrogen 
receptor negative cancer rates peak, making 50 a good demarcation for risk, and because 50 
years of age is the recommended starting age for mammography for women of average risk 
(32,33) (Figure 2.2).  A three-level model in which analysis cells were nested within counties 
and counties were nested by the state was initially tested, but models did not converge for 
analyses of the less common breast cancer subtypes. Therefore, for consistency, a two-level 
model in which analysis cells were nested by county was used for all analyses. County was 
included in the model as both a random and a fixed effect and analysis cells were considered in 
the model as fixed effects. Age and race/ethnicity-specific rates were calculated for the entire 
geographic area of our study to estimate the expected counts for each analysis cell. The natural 
log of these expected counts was included in each model as an offset variable.  
       Contextual factors that may affect breast cancer incidence and had been explored in previous 
research, as shown in Figure 2.1, were considered in the regression model building process. 
These factors may explain any differences in incidence between the Delta and non-Delta Regions 
within the seven LMDR states.  Contextual factors were county-level variables extracted from 
the American Community Survey (ACS), National Cancer Institute, United States Department of 
Agriculture (USDA), and the Area Health Resource File to describe the physical and social 
context of the county of residence of each cancer case (34-36). The ACS is an ongoing national 
survey performed by the U.S. Census Bureau that collects information on a variety of factors, 
including county-level sociodemographic characteristics (34). 2010-2014 ACS county-level 
factors on % living in poverty, median household income, % with at least a high school 
education, and % of the population that identify as black were extracted. Counties were 
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considered rural or urban based upon the USDA’s Rural-Urban Continuum Codes, which 
consider a county’s population size and adjacency to a metropolitan area (36). A code of 1-3 was 
considered urban; a code of 4-9 was considered rural. The National Cancer Institute’s State 
Cancer Profile includes county-level modeled estimates of the percentage of women aged 40+ 
who had a mammogram in the past two years (35). Data on the number of primary care physician 
per county was extracted from the Area Health Resource File for the years 2011 to 2014 to 
determine the average number of primary care physicians per 100,000 (i.e. provider density) for 
each county(37). Because sociodemographic variables may cause multicollinearity, correlations 
among these variables were assessed and were indeed found to be highly correlated. Therefore, 
only one sociodemographic variable was considered in the model—poverty level—as that 
variable has been considered the most robust socioeconomic variable for measuring inequalities 
in cancer incidence (38). All other variables were considered in the analysis: rural-urban status, 
provider density, and mammography utilization. Provider density proved to non-significantly 
contribute to all models and caused poorer goodness of fit as measured by the Akaike 
Information Criterion, and therefore was excluded from inclusion in final models. Because of the 
important, but understudied, consideration of the interaction between race and rural context, 
particularly in the South (39), the interaction between rural-urban status and race were 
considered in all models and was retained if the interaction was statistically significant.  
Exponentials of coefficients estimated RRs. 95% confidence intervals were used to determine 
whether there were statistically significant differences in cancer incidence between the Delta 
Region and non-Delta Region after accounting for the aforementioned potential confounders. 
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Results 
 A total of 82,223 invasive breast cancer cases were diagnosed in these seven LMDR states 
between 2012 and 2014. Among these cases, 19,334 (23.5%) occurred in the Delta Region, and 
62,889 (76.5%) occurred in the non-Delta Region. Table 2.1 summarizes the distribution of 
subtypes by sociodemographic characteristics.  
     Age-adjusted IRs and RRs by Delta Region designation are displayed overall and stratified by 
age, race/ethnicity, rural-urban status, and poverty level for all breast cancer cases and HR+ 
cases are displayed in Table 2.2. For all breast cancer cases, the age-adjusted incidence rate was 
higher in the non-Delta Region (120.8 per 100,000) than the Delta Region (116.2), with a 
corresponding rate ratio of 0.96 (95% CI=0.95-0.98; non-Delta Region as the reference group). 
The rates of all breast cancers combined and stratified by age (<50 or 50+ years of age) were 
higher in the non-Delta Region for both stratifications. When rates were stratified by 
race/ethnicity, non-Hispanic white women in the Delta Region (IR=114.5 per 100,000) had a 
lower rate of breast cancer than women in the non-Delta Region (IR=123.9). There was no 
statistically significant difference in the overall breast cancer rate among and Delta Region 
(IR=122.9) and non-Delta Region (IR=123.9) for non-Hispanic black women or Hispanic 
women (IR=89.1 and 84.8 in the Delta and non-Delta Regions, respectively). Urban women in 
the Delta Region had a slightly lower overall rate of breast cancer than their non-Delta 
counterparts (RR=0.97, 95% CI=0.95-0.99), but there was no statistically significant rural 
difference between the regions.  
 For the most part, the Delta/non-Delta Regions differences for HR+ cancers were similar 
to the differences seen in overall breast cancers with a few exceptions. For the overall breast 
cancer rates, the Delta Region had lower rates of both HR+/HER2+ (RR=0.93; 95% CI=0.88-
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0.98) and HR+/HER2- (RR=0.88; 95% CI=0.86-0.90) cancers. Non-Hispanic black Delta 
women (RR=0.93; 95% CI=0.88-0.97) had lower rates of HR+/HER2- cancers than those in the 
non-Delta Region, as did non-Hispanic white women (RR=0.88; 95% CI=0.86-0.90). Both rural 
and urban women in the Delta had lower rates of HR+/HER2- cancers than non-Delta women. 
           Age-adjusted IRs and RRs by Delta Region designation are displayed overall and 
stratified by age, race/ethnicity, rural-urban status, and poverty level for HR- cases and cases of 
unknown subtype are displayed in Table 2.3. Women in the Delta Region (IR=17.0) had higher 
rates of triple-negative breast cancer than non-Delta Region women (IR=14.4) (RR=1.18; 95% 
CI=1.13-1.24). In stratified analysis, Delta Region women had higher rates of triple-negative 
breast cancer than women in the non-Delta Region for the following sociodemographic 
stratifications: under 50 years old, 50+ years old, non-Hispanic black, urban, <20% living in 
poverty, and 20+% living in poverty. The greatest rate difference was among Delta women under 
50 years of age (IR=8.4) who had higher rates of triple-negative breast cancer than their non-
Delta counterparts (IR=6.6) (RR=1.29; 95% CI=1.18-1.40). Also of note, non-Hispanic black 
women in the Delta Region (IR=26.8) had higher rates of triple-negative breast cancer than their 
non-Delta counterparts (IR=24.6) (RR=1.09; 95 CI=1.01-1.17). Urban women in the Delta 
Region had higher triple-negative breast cancer than urban women in the non-Delta Region 
(RR=1.26; 95% CI=1.19-1.33). Among women in counties with 20% or greater of the population 
living in poverty, Delta Region women had notably higher rates of triple-negative breast cancer 
(RR=1.21; 95 CI=1.12-1.31). Rates of unknown breast cancer subtype were higher in the Delta 
Region among all stratifications, except among Hispanics and those living in counties with 
20%+ of the population living in poverty. Rates of unknown subtype were higher in the Delta 
Region than the non-Delta Region (RR=1.30; 95% CI=1.23-1.37). The magnitude of Delta/non-
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Delta Region differences in unknown subtype rates had the highest magnitude among rural 
populations (RR=1.37; 95% CI=1.29-1.49) and among those living in counties with less than 
20% living below the poverty level (RR=1.39; 95% CI=1.29-1.49).  
  The age-adjusted IRs and RRs for racial/ethnic, rural-urban, and poverty level 
stratifications for all invasive breast cancers and HR+ breast cancers within the Delta Region 
alone are displayed in Table 2.4. For all breast cancer cases, non-Hispanic black women had 
higher rates than non-Hispanic white women (RR=1.07; 95% CI=1.04-1.11). For HR+/HER2- 
breast cancers, non-Hispanic black (IR=63.3) and Hispanic women (IR=59.4) had lower rates 
than white Delta Region women (IR=72.9). Both overall rates of breast cancer and HR+/HER2- 
breast cancers were lower in the rural and more impoverished Delta Region compared to the 
urban and less impoverished areas of the Delta Region. 
         Age-adjusted IRs and RRs for HR- breast cancers and for cancers of unknown subtype 
stratified by race/ethnicity, rural-urban status, and poverty for Delta Region cases only are 
displayed in Table 2.5. Rates of HR-/HER2+ are higher in non-Hispanic blacks than whites 
(IR=6.9 and 4.6, respectively). Triple-negative breast cancer rates are more than twice as high 
among Delta Region non-Hispanic blacks (IR=26.8) compared to non-Hispanic whites (IR=12.8) 
(RR=2.10; 95% CI=1.94-2.27). Rates of both HR- subtypes are lower in rural populations in the 
Delta Region. Rates of triple-negative breast cancers are higher among more impoverished 
counties than counties with less than 20% of the population in poverty (RR=1.10; 95% CI=1.01-
1.19).  Rates of cancers of unknown subtype are higher in non-Hispanic black women compared 
to non-Hispanic white women (RR=1.15; 95% CI=1.35-1.61) as well as rural compared to urban 
women in the Delta Region (RR=1.48; 95% CI=1.35-1.41).  
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          Table 2.6 displays the results of multivariable, multilevel negative binomial regression 
modeling for all breast cancer cases, individual subtypes, and cases of unknown subtype for all 
cases and stratification by age, race/ethnicity, rural-urban status, and poverty level which 
assesses the difference in rates in the Delta and non-Delta Regions. For non-stratified analyses, 
the Delta Region had higher rates of unknown subtype (RR=1.19; 95% CI=1.05-1.35) compared 
to the non-Delta Region after accounting for age and race/ethnicity groupings and contextual 
factors. There were no significant Delta/non-Delta differences in rates of any kind after 
controlling for relevant factors for either age stratification, except for unknown subtype in 
women aged 50+ in the Delta Region (RR=1.17; 95% CI=1.03-1.34).  For all race/ethnic 
stratifications, there were no Delta/non-Delta Region differences, except for an elevated rate of 
unknown subtype in non-Hispanic whites in the Delta Region. Among rural populations, the 
Delta Region had lower rates of HR-/HER2+ (RR=0.80; 95% CI=0.69-0.93) and higher rates of 
unknown status (RR=1.26; 95% CI=1.08-1.47) compared to the non-Delta Region after 
accounting for confounders.  Among urban populations, the Delta Region had higher rates of 
triple-negative breast cancer (RR=1.10; 95% CI=1.01-1.20) after controlling for relevant factors. 
Among populations who live in counties with less than 20% of the population living in poverty, 
the Delta Region had a lower rate of HR+/HER2+ breast cancer (RR=0.91; 95% CI=0.86-0.96) 
and a higher rate of breast cancers of unknown status (RR=1.29; 95% CI=1.07-1.55) after 
accounting for confounders. There were no Delta/non-Delta Region differences across subtypes 
for the cases in counties with greater than 20% of the population in poverty.  
         Table 2.7 displays the findings of the multivariable, multilevel negative binomial 
regression modeling of Delta Region breast cancer cases for all cases combined, individual 
subtypes, and cancers of unknown subtype. Rates were higher among non-Hispanic blacks for all 
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breast cancers (RR=1.06; 95% CI=1.02-1.10). Hispanics had lower rates of HR+/HER2- cancers 
(RR=0.82; 95% CI=0.69-0.97) compared to non-Hispanic whites after accounting for age and 
contextual variables. Compared to urban populations, rural populations had higher rates of breast 
cancers of unknown subtypes (RR=1.42; 95% CI=1.14-1.76) after controlling for confounders.   
Discussion 
        Population-level cancer registry data were analyzed to examine breast cancer incidence rate 
differences between the Delta and non-Delta regions of seven LMDR states for breast cancer 
overall and stratified by subtype. Overall breast cancer incidence rates were higher in the non-
Delta Region. However, women in the Delta Region had higher incidence rates of triple-negative 
breast cancer compared to non-Delta Region women, which was also true among black women 
specifically, but not white women. Regardless of stratifications, Delta women had higher rates of 
unknown subtype. After accounting for confounding characteristics, the elevated rate of triple-
negative breast cancer in the Delta Region was attenuated to non-statistical significance.  
However, the elevated rate of triple-negative breast cancer in urban women in the Delta Region 
remained in the multivariable analysis. The elevated rate of unknown subtype in the Delta also 
remained after adjustment. Analyses of data from the Delta Region only indicated that black 
women in the region had higher rates of breast cancer overall than white women, but rates of 
HR+/HER2- were higher in the white women. Black women in the Delta Region had higher rates 
of both HR- subtypes, most prominently triple-negative breast cancer.  The elevated overall 
breast cancer incidence rate in black Delta women remained after adjustment.  
          Descriptively, this current study found that women in the Delta Region had lower 
incidence rates of invasive breast cancer overall and of the HR+/HER2- subtype than women in 
the Delta Region across most stratifications, although this was explained by factors like 
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mammography utilization, rural-urban status, and other variables included in multivariable 
analysis. Previous studies have shown that—generally speaking at a state level-- mammography 
utilization is associated with higher rates of breast cancer overall and HR+/HER2- specifically 
(7). Similarly, a pooled analysis by Akinyemiju and colleagues found higher rates of breast 
cancer in urban populations (22). Indeed, over the last twenty years, the Delta Region has 
consistently had lower rates of mammography utilization compared to the non-Delta part of the 
LMDR and the rest of the country (3,40). Further, the Delta Region is more rural the rest of the 
LMDR (3,41). The lower overall rates of breast cancer and HR+/HER2- cancers in the Delta 
Region corroborate previous studies and are explained by utilization of mammography and 
rurality of the Delta Region.  
 Triple-negative breast cancer incidence rates were higher in the Delta Region compared 
to the non-Delta Region overall and among non-Hispanic blacks and urban populations, 
specifically. The higher rates of triple-negative breast cancer in the Delta Region overall was 
explained by age, race, and contextual factors. However, it may help explain the higher breast 
cancer mortality rate that is seen in the Region (4), as triple-negative breast cancers have worse 
survival than other subtypes. Also, as multiple studies have shown higher rates of triple-negative 
breast cancer in the South and Midwest than other parts of the country(7,16), the findings of the 
present study indicate that elevated rates may be particularly high within specific areas (i.e. the 
Delta Region) within the Midwest and the South.  
 Urban women in the Delta Region had higher rates of triple-negative breast cancer, even 
after accounting for important risk factors like age and race. There are other risk factors like 
greater parity and lack of breastfeeding/short duration of breastfeeding among parous women, 
that were unable to be accounted for in the present study, that can increase one’s risk for triple-
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negative breast cancer (42).  Of metropolitan areas with greater than half a million residents, the 
Memphis metropolitan area—the largest city in the Delta Region-- has the highest birth rates in 
the country (43). Caution must be exercised not to fall prey to ecological fallacy, but the higher 
birth rate among urban women in the Delta Region may play a role in the higher rate of triple-
negative breast cancer compared to non-Delta urban areas. Additionally, breastfeeding has been 
shown to reduce a women’s risk for triple-negative breast cancer. Multiple studies have shown 
that parous women who do not breastfeed or who had short breastfeeding duration are at greater 
risk for triple-negative breast cancer (42,44). Additionally, a meta-analysis of 27 studies found 
reduced odds of triple-negative breast cancer among parous women who breastfeed (45). 
Breastfeeding is one of the few modifiable risk factors for triple-negative breast cancer. 
Interventions aimed at improving breastfeeding initiation and duration in urban areas of the Delta 
Region may help reduce the incidence of triple-negative breast cancer. While rates of 
breastfeeding initiation and duration are lower in southern states than in the rest of the country, 
there is a reason to be optimistic about the urban Delta Region (46).  For example, in recent 
years, attitudes towards breastfeeding have improved in urban areas of the Delta Region like 
Memphis (47). Additionally, in the most recent CDC Breastfeeding Report Cards, all Lower 
Mississippi Delta Region states have experienced increased breastfeeding initiation rates and/or 
improved Maternal Practice in Infant Nutrition and Care scores, which is an indicator of 
breastfeeding-promoting policies in maternal care facilities (48,49). Interventions to continue to 
improve attitudes, practices, and policies around breastfeeding has the potential to reduce future 
triple-negative breast cancer incidence rates in the Region. 
 In the Delta Region, higher incidence rates of breast cancer were observed in non-
Hispanic black women compared to non-Hispanic white women in both descriptive and 
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multivariable analyses. This finding corroborates a study by DeSantis and colleagues which 
found that breast cancer incidence rates in the Delta Region states of Alabama, Kentucky, 
Louisiana, Mississippi, and Tennessee were higher in black women than in white women (6). 
Previous studies have suggested that the convergence of breast cancer incidence rates in black 
and white populations is driven by increased mammography utilization and increased rates of 
HR+/HER2- or ER+ breast cancers among black women (6,50). In the Delta Region, however, 
the elevated rates of breast cancer among black women are driven by HR- cancers, as both HR-
/HER2+ and triple-negative breast cancer rates are higher among black women. The elevated 
incidence of breast cancer in black women, even after accounting for age and contextual factors, 
suggests that there may be other contextual factors or individual factors specific to black women 
in the region that may contribute to higher rates. Studies have found that perceived experiences 
of racial discrimination are associated with increased risk of breast cancer, especially among 
young black women, among whom HR- cancers are more common (51). Similarly, Geronimus 
and colleagues posit a “weathering hypothesis” that black women disproportionately experience 
a myriad of life stressors compared to white women that contribute to biological indicators of 
stress (i.e. shorter telomere length and increased allostatic load) subsequently putting them at 
greater risk for chronic diseases, potentially including HR- breast cancers (52-54).  A study by 
Krieger found that black women born in or living in states that once had discriminatory Jim 
Crow laws (which includes six of the seven states in the present study) had higher rates of 
estrogen receptor-negative cancers than those born in states that did not have Jim Crow laws 
(55). While the relationship between racial discrimination and increased cumulative stressors and 
their impacts on breast cancer is still a burgeoning field of study, the history and lasting effects 
of slavery, segregation, and marginalization in the Delta Region may indeed play a role in the 
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elevated risk of breast cancer among black women in the Region (56). There is a great 
opportunity for social epidemiologists and other researchers to further explicate the relationship 
between the historical and current social context of the Delta Region and its effect on breast 
cancer.  
 Although not central to the study, higher rates of unknown subtype in the Delta Region 
were found in both descriptive and multivariable analyses across many stratifications. The study 
inclusion/exclusion criteria aimed to maximize completeness of subtype data by excluding cases 
in women over the age of 85 or cases that were reported in death certificates, autopsy, nursing 
home, or hospice care. However, missing information on cancer cases is more common among 
blacks and in areas of low socioeconomic status (26,27,31). Race and county level poverty were 
included in multivariable analysis and rates of unknown subtype, yet higher rates of unknown 
status remained, especially in rural areas of the Delta Region. In addition to socioeconomic 
factors, the location of case ascertainment may play a role in data completeness (7,26). Breast 
cancer cases diagnosed among rural Delta Regions women may be more likely to be diagnosed 
in smaller hospitals in impoverished areas where data reporting may be incomplete. Further, 
there is a nationwide cancer registrar shortage, of which, like any healthcare profession, could be 
at an even greater shortage in the Delta Region (57). This may affect the abstraction of cancer 
information in the Region’s rural hospitals in particular. Additionally, the rate of unknown 
subtype subsequently has an effect on the other rates. For example, HER2+ is the more common 
HER2 status, but in order for a case to be defined by that status, a definitive HER2 status of 
positive must be reported. Thus, HER2+ cancers, in particular, may be underrepresented. While 
HR status has been required to be reported for many years, HER2 status has only been required 
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since 2010.  As healthcare professionals become more accustomed to reporting that information, 
data completeness should improve in the Delta Region and throughout the country.  
 The current study was not without limitations. First, Missouri did not provide active 
consent for their data to be included in this study. While Missouri includes less than seven 
percent of the Delta Region population and is the Delta Region state with the largest percentage 
of white population, its exclusion may affect the study findings (1). For example, Delta Region 
disparities were identified for triple-negative breast cancers in urban populations especially. The 
absence of data from non-Delta urban areas with a high proportion of black residents like St. 
Louis and Kansas City may attenuate the identified disparity if data were included. Additionally, 
the non-Delta Region also included areas of Kentucky, Tennessee, Mississippi and Alabama that 
are part of the impoverished, federally designated Appalachian Regional Commission. This may 
make Delta Region disparities more difficult to identify than if national comparisons were able to 
be made, as the comparison group experience notable economic disparities as well. Also, data on 
individual-level factors that affect the risk of different breast cancer subtype are not available, 
including breastfeeding, oral contraceptive use, parity, age a first live birth, age at first 
pregnancy, obesity, and physical activity. Additionally, a three-level model proved to be too 
complex for the less common subtypes of breast cancer, and thus state-to-state variability was 
unable to be accounted for. Further, county of residence at diagnosis was used to characterize the 
contextual effects the cancer patient experienced. However, it is unknown where a cancer patient 
lived throughout her life and how the social and physical context of her residence throughout her 
life course may have affected her risk for breast cancer.  
 The present study had several strengths as well. First, this study was one of the first to 
explore cancer incidence across the multi-state Delta Region, as well as one of the first to 
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explore differences in breast cancer subtype at a sub-state level.  Previous studies have explored 
cancer mortality and screening disparities in the Delta Region (3,4), but the present study is 
likely the first to explore cancer incidence disparities within this federally designated, 
underserved region. Second, it utilizes population-based data inclusive of all cancer cases 
diagnosed in the LMDR states. Third, it employed multilevel modeling to explore place-based 
effects on cancer, which is underutilized in rural cancer research in particular (58). Because 
multilevel models assume the nonindependence of group membership, they produce less biased 
standard errors, reducing the risk of Type I errors.  
Conclusions 
 The higher rate of triple-negative breast cancer in the Delta Region identified in the 
present study may help explain the breast cancer mortality disparity that exists in the Region. 
Both the elevated rates of triple-negative breast cancer in the urban Delta region and the overall 
elevated rate of breast cancer among black women in the Delta may be explained by individual-
level factors like parity and breastfeeding initiation or duration. Additionally, these elevated rates 
may be explained by more upstream, contextual factors like discrimination that affect the biology 
of cancer etiology in black, urban women. Future research should explore the effect of 
unmeasured individual and contextual factors that may contribute to the disparities experienced 
by women in the Delta Region.  
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Figures and Tables  
Figure 2.1: Conceptual Model for Elucidating Breast Cancer Disparities in the Delta Region 
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Figure 2.2: Diagram of Multilevel Regression Models  
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Table 2.1:  Distribution of Breast Cancer Cases in the Lower Mississippi Delta States by Region and Subtype 
 Delta 
(N=19, 334) 
Non-Delta 
(N=62,889) 
 HR+/ 
HER2+ 
N (%) 
HR+/ 
HER2- 
N (%) 
HR-
/HER2+ 
N (%) 
Triple 
Negative 
N (%) 
Unknown 
N (%) 
HR+/ 
HER2+ 
N (%) 
HR+/ 
HER2- 
N (%) 
HR-/ 
HER2+ 
N (%) 
Triple 
Negative 
N (%) 
Unknown 
N (%) 
All 1,991 
(9.9%) 
11,684 
(60.2%) 
872 
(4.5%) 
2,735 
(14.1%) 
2,132 
(11.0%) 
6,419 
(10.2%) 
41,311 
(65.6%) 
2,677 
(4.2%) 
7,344 
(11.7%) 
5,150 
(8.2%) 
Age 
<50 
 
50+ 
 
469 
(12.8%) 
1,442 
(9.2%) 
 
1,918 
(52.4%) 
9,766 
(62.3%) 
 
190 
(5.2%) 
682 
(4.4%) 
 
735 
(20.1%) 
2,000 
(12.8%) 
 
352 
(9.6%) 
1,780 
(11.4%) 
 
1,728 
(14.2%) 
5,052 
(10.0%) 
 
7,126 
(58.4%) 
34,281 
(67.6%) 
 
2,044 
(16.8%) 
2,011 
(4.0%) 
 
1,858 
(15.2%) 
5,476 
(10.8%) 
 
855 
(7.0%) 
4,295 
(8.5%) 
Race/ 
Ethnicity 
NH 
White 
NH 
Black 
Hispanic 
 
 
1,273 
(9.9%) 
591 
(9.7%) 
31 
(11.0%) 
 
 
8,285 
(64.8%) 
3,118 
(51.2%) 
184 
(65.2%) 
 
 
502 
(3.9%) 
348 
(5.7%) 
*** 
 
 
 
1,341 
(10.5%) 
1,340 
(22.0%) 
31 
(11.0%) 
 
 
1,394 
(10.9%) 
692 
(11.4%) 
28 
(9.9%) 
 
 
5,052 
(10.0%) 
911 
(10.4%) 
289 
(13.1%) 
 
 
34,281 
(67.8%) 
4,772 
(54.7%) 
1,383 
(62.5%) 
 
 
2,011 
(4.0%) 
461 
(5.3%) 
114 
(5.2%) 
 
 
5,176 
(10.2%) 
1,760 
(20.2%) 
269 
(12.2%) 
 
 
4,066 
(8.0%) 
824 
(9.4%) 
158 
(7.1%) 
Rural-
Urban 
Status 
Rural 
 
Urban 
 
 
 
 
711 
(10.0%) 
1,200 
(9.8%) 
 
 
 
4,155 
(58.4%) 
7,529 
(61.6%) 
 
 
 
287 
(4.0%) 
585 
(4.9%) 
 
 
 
932 
(13.1%) 
1,803 
(14.8%) 
 
 
 
1,027 
(14.4%) 
1,105 
(9.0%) 
 
 
 
1,337 
(10.2%) 
5,082 
(9.7%) 
 
 
 
8,129 
(62.2%) 
33,182 
(63.5%) 
 
 
 
606 
(4.6%) 
2,069 
(4.2%) 
 
 
 
1,629 
(12.5%) 
5,705 
(11.5%) 
 
 
 
1,371 
(10.5%) 
3,779 
(7.6%) 
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Table 2.1 (cont.) 
 
 Delta 
(N=19, 334) 
Non-Delta 
(N=62,889) 
 HR+/ 
HER2+ 
N (%) 
HR+/ 
HER2- 
N (%) 
HR-
/HER2+ 
N (%) 
Triple 
Negative 
N (%) 
Unknown 
N (%) 
HR+/ 
HER2+ 
N (%) 
HR+/ 
HER2- 
N (%) 
HR-/ 
HER2+ 
N (%) 
Triple 
Negative 
N (%) 
Unknown 
N (%) 
Poverty 
Level 
<20% 
 
20+% 
 
 
 
891 
(10.1%) 
1,020 
(9.6%) 
 
 
5,425 
(61.5%) 
6,259 
(58.9%) 
 
 
389 
(4.4%) 
483 
(4.5%) 
 
 
1,151 
(13.0%) 
1,584 
(14.9%) 
 
 
968 
(11.0%) 
1,164 
(11.0%) 
 
 
5,288 
(10.1%) 
1,131 
(10.6%) 
 
 
34,816 
(66.6%) 
6,495 
(61.1%) 
 
 
2,175 
(4.2%) 
500 
(4.7%) 
 
 
5,983 
(11.4%) 
1,351 
(12.7%) 
 
 
4,003 
(7.7%) 
1,147 
(10.7%) 
NH=Non-Hispanic; *** indicates suppressed data due to fewer than 16 cases 
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Table 2.2: Age-adjusted Incidence Rates of Invasive Breast Cancer and Hormone Receptor Positive Breast Cancers by Delta Region 
Status and Stratified by Age, Race/Ethnicity, Rural-Urban Status, and Poverty Level 
 All Cases HR+/HER2+ HR+/HER2- 
 Cases IR† RR 
(95%CI) 
Cases IR† RR 
(95%CI) 
Cases IR† RR 
(95%CI) 
All 
Delta  
Non-Delta 
19,334 
62,889 
116.2 
120.8 
0.96 (0.95-0.98) 
Ref 
1,911 
6,419 
11.8 
12.7 
0.93 (0.88-0.98) 
Ref 
11,684 
41,311 
69.4 
78.7 
0.88 (0.86-0.90) 
Ref 
<50 Years Old 
Delta  
Non-Delta 
3,664 
12,198 
42.1 
43.0 
0.98 (0.94-1.02) 
Ref 
469 
1,728 
5.4 
6.1 
0.88 (0.79-0.98) 
Ref 
1,918 
7,126 
22.0 
25.0 
0.88 (0.84-0.93) 
Ref 
50+ Years Old 
 Delta  
Non-Delta 
15,670 
50,691 
321.9 
336.6 
0.96 (0.94-0.97) 
Ref 
1,442 
4,691 
29.4 
30.8 
0.95 (0.90-1.01) 
Ref 
9,766 
34,185 
200.7 
227.6 
0.88 (0.86-0.90) 
Ref 
Non-Hispanic Whites 
Delta 
Non-Delta 
12,795 
50,586 
114.5 
123.9 
0.92 (0.91-0.94) 
Ref 
1,273 
5,052 
11.9 
13.0 
0.92 (0.86-0.98) 
Ref 
8,285 
34,281 
72.9 
82.9 
0.88 (0.86-0.90) 
Ref 
Non-Hispanic Blacks 
Delta 
Non-Delta 
6,089 
8,728 
122.9 
123.8 
0.99 (0.96-1.03) 
Ref 
591 
911 
11.9 
12.7 
0.94 (0.84-1.04) 
Ref 
3,118 
4,772 
63.3 
68.4 
0.93 (0.88-0.97) 
Ref 
Hispanics 
Delta   
Non-Delta 
282 
2,213 
89.1 
84.8 
1.05 (0.92-1.19) 
Ref 
31 
289 
8.8 
10.4 
0.84 (0.55-1.23) 
Ref 
184 
1,383 
59.4 
54.8 
1.09 (0.92-1.27) 
Ref 
Urban 
Delta 
Non-Delta 
12,222 
49,817 
119.7 
123.2 
0.97 (0.95-0.99) 
Ref 
1,200 
5,082 
11.9 
12.8 
0.93 (0.87-0.99) 
Ref 
7,529 
33,182 
73.2 
81.6 
0.90 (0.87-0.92) 
Ref 
Rural 
Delta 
Non-Delta 
7,112 
13,072 
110.8 
112.6 
0.98 (0.96-1.01) 
Ref 
711 
1,337 
11.4 
12.0 
0.95 (0.87-1.05) 
Ref 
4,155 
8,129 
63.4 
69.0 
0.92 (0.88-0.96) 
Ref 
< 20% Below Poverty 
Delta 
Non-Delta 
8,824 
52,265 
119.0 
122.9 
0.97 (0.95-0.99) 
Ref 
891 
5,288 
12.2 
12.7 
0.96 (0.89-1.03) 
Ref 
5,425 
34,816 
72.3 
81.3 
0.89 (0.86-0.92) 
Ref 
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Table 2.2 (cont.) 
 All Cases HR+/HER2+ HR+/HER2- 
 Cases IR† RR 
(95%CI) 
Cases IR† RR 
(95%CI) 
Cases IR† RR 
(95%CI) 
20+% Below Poverty 
Delta 
Non-Delta 
10,510 
10,624 
114.0 
111.3 
1.02 (1.00-1.05) 
Ref 
1,020 
1,131 
11.4 
12.2 
0.93 (0.85-1.02) 
Ref 
6,259 
6,495 
67.0 
67.2 
1.00 (0.96-1.03) 
Ref 
IR=Incidence Rate; RR=Rate Ratio; Ref=Reference Group; †Rates are expressed per 100,000 population 
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Table 2.3: Age-adjusted Incidence Rates of Hormone Receptor Negative Breast Cancers and Unknown Subtype by Delta Region 
Status by Age, Race/Ethnicity, Rural-Urban Status, and Poverty Level 
 HR-/HER2+ Triple Negative Unknown 
 
 
Cases IR RR 
(95%CI) 
Cases IR RR 
(95%CI) 
Cases IR RR 
(95%CI) 
All  
Delta  
Non-Delta 
872 
2,677 
5.3 
5.2 
1.03 (0.95-1.11) 
Ref 
2,735 
7,334 
17.0 
14.4 
1.18 (1.13-1.24) 
Ref 
2,132 
5,150 
12.7 
9.8 
1.30 (1.23-1.37) 
Ref 
<50 Years Old 
Delta  
Non-Delta 
190 
631 
2.2 
2.2 
0.98 (0.83-1.15) 
Ref 
735 
1,858 
8.4 
6.6 
1.29 (1.18-1.40) 
Ref 
352 
855 
4.0 
3.0 
1.34 (1.18-1.52) 
Ref 
50+ Years Old 
Delta  
Non-Delta 
682 
2,044 
14.0 
13.4 
1.05 (0.96-1.14) 
Ref 
2,000 
5,476 
40.9 
36.1 
1.13 (1.08-1.19) 
Ref 
1,780 
4,295 
36.9 
28.7 
1.28 (1.21-1.36) 
Ref 
Non-Hispanic Whites 
Delta  
Non-Delta 
502 
2,011 
4.6 
5.1 
0.91 (0.82-1.01) 
Ref 
1,341 
5,176 
12.8 
13.2 
0.97 (0.91-1.03) 
Ref 
1,394 
4,066 
12.3 
9.8 
1.26 (1.18-1.34) 
Ref 
Non-Hispanic Blacks 
Delta  
Non-Delta 
348 
461 
6.9 
6.3 
1.09  (0.94-1.26) 
Ref 
1,340 
1,760 
26.8 
24.6 
1.09 (1.01-1.17) 
Ref 
692 
824 
14.1 
11.8 
1.20 (1.08-1.33) 
Ref 
Hispanics 
Delta  
Non-Delta 
*** 
114 
*** 
3.8 
*** 
Ref 
31 
269 
10.1 
9.8 
1.03 (0.68-1.50) 
Ref 
28 
158 
8.5 
6.0 
1.41 (0.90-2.13) 
Ref 
Urban 
Delta  
Non-Delta 
585 
2,069 
5.8 
5.2 
1.13 (1.02-1.24) 
Ref 
1,803 
5,705 
18.0 
14.3 
1.26 (1.19-1.33) 
Ref 
1,105 
3,779 
10.7 
9.3 
1.16 (1.08-1.24) 
Ref 
Rural 
Delta  
Non-Delta 
287 
606 
4.5 
5.4 
0.84 (0.72-0.98) 
Ref 
932 
1,629 
15.6 
14.7 
1.06 (0.97-1.16) 
Ref 
1,027 
1,371 
15.9 
11.6 
1.37 (1.26-1.49) 
Ref 
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Table 2.3 (cont.) 
 HR-/HER2+ Triple Negative Unknown 
 Cases IR RR 
(95%CI) 
Cases IR RR 
(95%CI) 
Cases IR RR 
(95%CI) 
<20% Below Poverty 
Delta  
Non-Delta 
389 
2,175 
5.3 
5.1 
1.03 (0.92-1.15) 
Ref 
1,151 
5,983 
16.2 
14.3 
1.13 (1.06-1.20) 
Ref 
968 
4,003 
13.0 
9.4 
1.39 (1.29-1.49) 
Ref 
20+% in Poverty 
Delta  
Non-Delta 
483 
500 
5.3 
5.3 
1.00 (0.88-1.14) 
Ref 
1,584 
1,351 
17.8 
14.7 
1.21 (1.12-1.31) 
Ref 
1,164 
1,147 
12.5 
11.9 
1.06 (0.97-1.15) 
Ref 
IR=Incidence Rate; RR=Rate Ratio; Ref=Reference Group; †Rates are expressed per 100,000 population 
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Table 2.4: Age-adjusted Incidence Rates of All Breast Cancer Cases and Hormone Receptor Positive Breast Cancers by 
Race/Ethnicity, Rural-Urban Status, and Poverty Level in the Delta Region 
 All Cases HR+/HER2+ HR+/HER2- 
 Cases IR RR 
(95%CI) 
Cases IR RR 
(95%CI) 
Cases IR RR 
(95%CI) 
Race/Ethnicity 
Hispanic 
Non- Hispanic Black 
Non- Hispanic White 
282 
6,089 
12,795 
89.1 
122.9 
114.5 
0.78 (0.69-0.88) 
1.07 (1.04-1.11) 
Ref 
31 
591 
1,273 
8.8 
11.9 
11.9 
0.74(0.49-1.06) 
1.00(0.90-1.11) 
Ref 
184 
3,118 
8,285 
59.4 
63.3 
72.9 
0.82(0.70-0.95) 
0.87(0.83-0.91) 
Ref 
Rural-Urban Status 
Rural  
Urban 
7,112 
12,222 
110.8 
119.7 
0.93 (0.90-0.95) 
Ref 
711 
1,200 
11.4 
11.9 
0.96 (0.87-1.06) 
Ref 
4,155 
7,529 
63.4 
73.2 
0.87(0.83-0.90) 
Ref 
Poverty Level 
20+% poverty 
<20% poverty 
10,510 
8,824 
114.0 
119.0 
0.96 (0.93-0.99) 
Ref 
1,020 
891 
11.4 
12.2 
0.93 (0.85-1.02) 
Ref 
6,259 
5,425 
67.0 
72.3 
0.93 (0.89-0.96) 
Ref 
IR=Incidence Rate; RR=Rate Ratio; Ref=Reference Group; †Rates are expressed per 100,000 population 
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Table 2.5: Age-adjusted Incidence Rates of Hormone Receptor Negative Breast Cancers and Unknown Subtype in the Delta Region 
by Race/Ethnicity, Rural-Urban Status, and Poverty Level in the Delta Region 
 HR-/HER2+ Triple Negative Unknown 
 Cases IR RR 
(95%CI) 
Cases IR RR 
(95%CI) 
Cases IR RR 
(95%CI) 
Race/Ethnicity 
Hispanic 
Non- Hispanic Black 
Non- Hispanic White 
*** 
348 
502 
*** 
6.9 
4.6 
*** 
1.49 (1.28-1.71) 
Ref 
31 
1,340 
1,341 
10.1 
26.8 
12.8 
0.79 (0.53-1.13) 
2.10 (1.94-2.27) 
Ref 
28 
692 
1,394 
8.5 
14.1 
12.3 
0.69 (0.45-1.00) 
1.15 (1.04-1.26) 
Ref 
Rural-Urban Status 
Rural  
Urban 
287 
585 
4.5 
5.8 
0.79 (0.68-0.91) 
Ref 
932 
1,803 
15.6 
18.0 
0.86 (0.80-0.94) 
Ref 
1,027 
1,105 
15.9 
10.7 
1.48 (1.35-1.61) 
Ref 
Poverty Level 
20+% poverty 
< 20% poverty 
483 
389 
5.3 
5.3 
1.00 (0.87-1.15) 
Ref 
1,584 
1,151 
17.8 
16.2 
1.10 (1.01-1.19) 
Ref 
1,164 
968 
12.5 
13.0 
0.97 (0.88-1.05) 
Ref 
IR=Incidence Rate; RR=Rate Ratio; Ref=Reference Group; †Rates are expressed per 100,000 population; *** Rate ratio suppressed as it is based on fewer than 
16 cases 
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Table 2.6: Multilevel Negative Binomial Regression Modeling of Invasive Breast Cancers by Delta Region Status and Stratified by 
Age, Race/Ethnicity, Rural-Urban Status, and Poverty Level 
 All Breast 
Cancers 
RR (95%CI) 
HR+/HER2+ 
RR (95%CI) 
HR+/HER2- 
RR (95%CI) 
HR-/HER2+ 
RR (95% CI) 
Triple Negative 
RR  (95%CI) 
Unknown 
RR (95% CI) 
All Cases a 1.00 (0.97-1.02) 0.95 (0.89-1.01) 0.98 (0.94-1.02) 0.96 (0.87-1.05) 1.01 (0.95-1.08) 1.19 (1.05-1.35) 
Age b 
50+ Years Old 0.99 (0.97-1.02) 0.94 (0.87-1.02) 0.98 (0.94-1.02) 0.96 (0.87-1.07) 0.99 (0.93-1.06) 1.17 (1.03-1.34) 
<50 Years Old 1.01 (0.96-1.06) 0.96 (0.85-1.08) 0.98 (0.91-1.05) 0.93 (0.77-1.11) 1.09 (0.98-1.22) 1.22 (0.98-1.51) 
Race/Ethnicity c 
Non-Hispanic 
White  
0.98 (0.95-1.01) 0.95 (0.89-1.03) 0.96 (0.92-1.00) 0.92 (0.82-1.02) 1.00 (0.93-1.07) 1.18 (1.04-1.35) 
Non-Hispanic 
Black 
1.04 (0.98-1.09) 0.80 (0.70-0.90) 1.01 (0.94-1.09) 0.86 (0.69-1.06) 1.07 (0.96-1.18) 1.14 (0.90-1.44) 
Hispanic 1.02 (0.85-1.21) 0.92 (0.62-1.36) 1.08 (0.88-1.32) *** 1.02 (0.75-1.38) 1.02 (0.66-1.58) 
Rural-Urban Status d 
Rural 1.00 (0.97-1.03) 0.94 (0.85-1.03) 0.99 (0.94-1.04) 0.80 (0.69-0.93) 0.93 (0.85-1.02) 1.26 (1.08-1.47) 
Urban 0.99 (0.95-1.03) 0.95 (0.87-1.04) 0.95 (0.90-1.02) 1.07 (0.95-1.20) 1.10 (1.01-1.20) 1.06 (0.85-1.31) 
Poverty Level e 
<20% Below 
Poverty 
0.98 (0.94-1.01) 0.97 (0.89-1.06) 0.91 (0.86-0.96) 1.01 (0.89-1.15) 1.07 (0.98-1.17) 1.29 (1.07-1.55) 
20+% Below 
Poverty 
1.00 (0.97-1.04) 0.93 (0.85-1.01) 1.02 (0.97-1.08) 0.90 (0.78-1.04) 0.93 (0.84-1.01) 1.15 (0.97-1.37) 
Non-Delta Region is Reference Group; RR=Rate Ratio; a Adjusting for age, race/ethnicity, rural-urban status, poverty level, area mammography utilization, and 
race/rural-urban status interaction (if statistically significant) ;b Adjusting for race/ethnicity, rural-urban status,  area mammography utilization, and race/rural-
urban status interaction; c Adjusting for age, area mammography utilization, and poverty level; d Adjusting for age, race/ethnicity, area mammography utilization, 
and poverty level; e Adjusting for age, race/ethnicity, area mammography utilization, rural-urban status, and race/rural-urban status interaction. *** Rate ratio 
suppressed as it is based on fewer than 16 cases. 
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Table 2.7: Multilevel Negative Binomial Regression Modeling of Invasive Breast Cancer by Subtype in the Delta Region 
 All Breast 
Cancers 
RR (95%CI) 
HR+/HER2+ 
RR (95%CI) 
HR+/HER2- 
RR  (95%CI) 
HR-/HER2+ 
RR (95% CI) 
Triple 
Negative 
RR  (95%CI) 
Unknown 
RR (95% CI) 
Race/Ethnicity 
Non-Hispanic 
White  
Non-Hispanic 
Black 
Hispanic 
Ref 
 
1.06 (1.02-1.10) 
 
0.93 (0.84-1.03) 
Ref 
 
1.02 (0.89-1.16) 
 
0.96 (0.67-1.36) 
Ref 
 
0.98 (0.92-1.04) 
 
0.82 (0.69-0.97) 
Ref 
 
1.10 (0.93-1.29) 
 
*** 
Ref 
 
1.05(0.96- 1.15) 
 
0.97 (0.74-1.29) 
Ref 
 
0.99 (0.89-1.11) 
 
1.10 (0.81-1.49) 
Rural-Urban Status 
Urban 
Rural 
Ref 
0.99 (0.95-1.04) 
Ref 
0.97 (0.86-1.09) 
Ref 
0.98 (0.92-1.04) 
Ref 
0.86 (0.73-1.01) 
Ref 
0.97 (0.88-1.06) 
Ref 
1.42 (1.14-1.76) 
Poverty Level 
<20% Below 
Poverty 
20+% Below 
Poverty 
Ref 
 
0.96 (0.92-1.00) 
Ref 
 
0.94 (0.85-1.05) 
Ref 
 
0.99 (0.93-1.06) 
 
Ref 
 
0.98 (0.84-1.15) 
 
Ref 
 
0.89 (0.81-0.99) 
Ref 
 
0.97 (0.78-1.20) 
 
 RR=Rate Ratio; All models also adjusted for age group, mammography utilization, and race-rural-urban status interaction (if significant); *** Rate ratio 
suppressed as it is based on fewer than 16 cases. 
 
.
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CHAPTER 3: BREAST CANCER STAGING BY SUBTYPE IN THE LOWER 
MISSISSIPPI DELTA REGION STATES 
Introduction 
The federally designated Delta Regional Authority (Delta Region) includes nearly 10 
million people living in 252 counties and parishes in eight states along the Mississippi River 
(Alabama, Arkansas, Illinois, Kentucky, Louisiana, Mississippi, Missouri, and Tennessee; Lower 
Mississippi Delta Region-LMDR- states). Roughly one in three residents in the Delta Region are 
black, and more than 20% of the population live in poverty (1). Additionally, this region has 
lower population density and poorer access to healthcare services compared to other areas in the 
LMDR states and the country as a whole (1,2). These factors make the Delta Region vulnerable 
to a myriad of health disparities, including breast cancer disparities. Women in the Delta Region 
have higher rates of breast cancer mortality than women elsewhere in the country (3). Further, 
black women in the Delta Region have higher breast cancer mortality rates than white women in 
the Region and black women in other parts of the country (3).  Nine of the ten counties with the 
nation’s highest breast cancer mortality rates are in the Delta Region (4). Additionally, studies 
have shown that the Delta Region has historically lower rates of adherence to mammography 
screening--even among women covered by Medicare-- than women in other parts of the country 
(2,5). Identifying the contributing factors to these breast cancer mortality disparities and the 
effects of lower mammography utilization are imperative to improve the health of the region.  
Several studies have shown that race/ethnicity, rural-urban status, socioeconomic 
position, and access to health care services affect the stage at which breast cancer is diagnosed. 
Cancers diagnosed at a more advanced stage have fewer treatment options and poorer survival. 
Multiple studies have shown descriptively that a higher percentage of black women are 
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diagnosed with more advanced stages of breast cancer compared to white women (6,7). Odds of 
advanced stage breast cancer remain high in black women, even after considering potential 
confounders (8,9). Other studies have shown that rural women have higher odds of being 
diagnosed with a breast cancer at a more advanced stage (10). Additionally, regardless of race or 
ethnicity, lower socioeconomic status was associated with more advanced staging in multiple 
studies (11-13). Other social factors—such as residential segregation—have been explored for 
possible association with more advanced stage of breast cancer, with studies showing mixed 
results (14-16). Some studies have also shown that women who live further from healthcare 
services or where there is a dearth of physicians are diagnosed with breast cancer at a more 
advanced stage (17).  
Like breast cancer stage, the molecular subtype of breast cancer guides treatment options 
and is associated with differences in prognosis, due in part to the variation in stage at diagnosis 
by subtype. Hormone-receptor-negative breast cancers present at a more advanced stage than 
other breast cancer subtypes, have fewer treatment options, and are associated with poorer 
survival than hormone receptor-positive breast cancers (18,19). Studies indicate that women 
diagnosed with triple-negative breast cancer, in particular, have greater odds of more advanced 
stage at diagnosis (20,21).  Other factors affect this dynamic between subtype and stage. Black 
women have higher incidence rates of distant stage breast cancer across subtypes, with studies 
also showing that black women have greater odds of advanced stage diagnosis across subtypes, 
even after controlling for confounding factors (22,23). 
The sociodemographic composition of the Delta Region suggests that women in the 
Region may be at high risk for more advanced staging of breast cancer across subtypes, which 
may be due to poor screening adherence and may contribute to higher breast cancer mortality 
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rate. The objective of this present study was threefold. First, it sought to determine the 
differences in the distribution breast cancer stage by subtype between the Delta and non-Delta 
Regions of the LMDR states. Second, it sought to determine the difference in the distribution of 
breast cancer stage by subtype among white and black women in the Delta Region. Third, it 
explored how the differences in breast cancer stage by subtype may be explained by contributing 
individual level and contextual factors, like age and county-level poverty rates, respectively. 
Methods 
Conceptual Model 
A conceptual model, drawing from Warnecke’s Model for Analysis of Population Health 
and Health Disparities, was developed to identify individual and area-level factors that may be 
associated with breast cancer stage by subtype within the Delta Region (Figure 3.1) (24).  The 
Delta Region is a conceptualized as a supramacro, policy-relevant context that may affect the 
distribution of the incidence of breast cancer staging by subtype. Specifically included are 
individual-level factors (age and race/ethnicity) that have been shown in previous studies to 
affect one’s risk for any breast cancer, one’s risk for developing specific subtypes of breast 
cancer, or one’s risk for being diagnosed at an earlier or more advanced stage (18,22). Social and 
physical contextual factors that affect breast cancer incidence rates overall or by specific subtype 
and stage are also depicted in this model, including socioeconomic factors, racial composition 
(as a crude measure of residential segregation), rural-urban status, mammography utilization, and 
provider density(10,15,20,25-27). 
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Data 
The North American Association of Central Cancer Registries (NAACCR) Cancer in 
North America (CiNA) Deluxe File provided case data on all breast cancer cases diagnosed in 
LMDR states between 2012 and 2014(28). To be included in this dataset, data from central 
cancer registries must have 90+% case ascertainment, passing edits of 97% or better, and other 
quality indicators. These data are based on the NAACCR December 2016 data submission. 
Regulatory support for cancer registries is provided by the state, province or territory in which 
the registry is located while most funding is federal. In the U.S., registries also participate in the 
National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program or 
the Centers for Disease Control and Prevention's National Program of Cancer Registries 
(NPCR) or both. In Canada, all registries submit data to the Canadian Cancer Registry 
maintained by Statistics Canada. Seven of the eight LMDR states provided active consent for 
their data to be included in this analysis (Alabama, Arkansas, Illinois, Kentucky, Louisiana, 
Mississippi, and Tennessee).  Missouri data were not included as they did not consent for their 
data to be used.  
All invasive female breast cancers were included (International Classification of Disease 
for Oncology 3rd Edition (ICD-O-3) of C500-C509), except for those with histology codes of 
9050-9055 (mesothelioma), 9140 (Kaposi’s sarcoma), 9590-9992 (leukemia and lymphoma), 
following the exclusion criteria used in a similar study (22). Cases who were missing on 
race/ethnicity and county of residence were 85 years of age or older, and/or were reported to 
their respective central cancer registry by way of a death certificate, autopsy report, or by 
nursing home or hospice were also excluded.   
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Germane to the current study, NAACCR CiNA Deluxe data file included age (19 
groups), race/ethnicity, county of residence at diagnosis, collaborative staging site-specific 
factors, 1,2, and 15, which correspond to estrogen receptor (ER), progesterone receptor (PR), and 
Human epidermal growth factor 2 (HER2) statuses, respectively, and  Surveillance 
Epidemiology and End Result (SEER) summary stage.  County of residence at diagnosis was 
used to determine if a patient lived in the Delta or non-Delta Regions of these states. ER, and PR 
status were considered jointly and categorized a cancer case’s hormone receptor (HR) status. 
HR+ cases included those that were ER+ or PR+ or borderline. HR- included those cases that 
were both ER- and PR-. For HER2 status, HER2+ and HER2- were categorized accordingly. 
Cases that were unknown on HR status and/or those cases with borderline or unknown HER2 
status were considered to be of unknown subtype. Based upon these site-specific factors, 
molecular subtypes of breast cancer cases were approximated: 1) HR+/HER2-; 2) HR+/HER2+; 
3)HR-/HER2+; 4) HR-/HER2- (triple negative); 5) unknown (18).  Cases were also categorized 
by their SEER summary stage. As has been commonly used in similar studies, regional and 
distant cancers were categorized as late stage (29-31). Localized cancers were categorized as 
early stage.  In situ and unknown/unstaged cancers were excluded from this analysis. 
Age-adjusted Incidence Rates and Rate Ratio Calculations 
 Age-adjusted incidence rates (IR) and rate ratios (RR) with 95% confidence intervals for 
all early and late stage, respectively, invasive breast cancers combined and individually by 
molecular subtype and unknown subtype status to compare Delta and non-Delta Region rates. 
Analyses were also stratified by race/ethnicity, rural-urban status, and percent living in poverty. 
Early and late stage age-adjusted incidence rates and rate ratio calculations were performed to 
evaluate racial, rural-urban, and poverty level differences within the Delta Region specifically as 
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well.  Rates were expressed per 100,000 population and were age-adjusted using the 2000 US 
standard population. Tiwari modifications were used in all analyses performed using SEER*Stat 
8.4.3.  
Multilevel Regression Models 
 Proc GLIMMIX in SAS 9.4 was used to construct multilevel regression models to 
calculate adjusted rate ratios for all breast cancers, each subtype individually, and breast cancers 
of unknown subtype as a means of comparing the Delta Region to the non-Delta Region overall 
and stratified by race/ethnicity, rural-urban status, and poverty level for both early and late-stage 
cancers. Similar analyses were performed examining solely Delta Region cases to assess 
race/ethnic, rural-urban, and poverty level differences within the Region. 
  Because counts were overdispersed for both early and late-stage cancers of all 
categorizations--all cancers combined, HR+/HER2+, HR+/HER2-, HR-/HER2+, triple-negative 
and unknown subtypes--multilevel negative binomial regression models were constructed. A 
three-level model in which analysis cells were nested within counties and counties were nested 
by state was initially tested, but models did not converge for all subtype analyses (Figure 3.2). 
Therefore, for consistency, a two-level model in which analysis cells were nested by county was 
used for all analyses.  For these models, analyses cells were constructed containing the number 
of cases for each respective stage grouping in each county, which were divided by age (<50 
years of age and 50+ years of age) and race/ethnicity (Non-Hispanic White, Non-Hispanic Black, 
Hispanic/Non-Hispanic Other). Analysis groups were divided at age 50 as it is the age at which 
estrogen receptor negative cancer rates peak, making 50 a good demarcation for risk, and 
because 50 years of age is the recommended starting age for mammography for women of 
average risk (32,33). Further, dichotomizing age optimizes the counts of each analysis cell, 
 84 
 
especially for the rarer subtypes, compared to creating more groupings. County was included in 
the model as both a random and a fixed effect and analysis cells were considered in the model as 
fixed effects. Age and race/ethnicity-specific rates were calculated for the entire geographic area 
of our study to estimate the expected counts for each analysis cell. The natural log of these 
expected counts was included in each model as an offset variable.  
       Factors chosen for consideration in the regression model building process had been used in 
previous research as contextual factors that may affect breast cancer incidence and staging, as 
shown in Figure 3.1, and may explain any differences in incidence between the Delta and non-
Delta Regions within the seven LMDR states.  County-level data characterizing these social and 
physical contextual factors were pulled from the American Community Survey (ACS), National 
Cancer Institute (NCI) County Level Modeled Estimates of Mammography Utilization, United 
States Department of Agriculture (USDA), and the Area Health Resource File (34-36). The ACS 
is a continuous national survey that collects information on a myriad of factors, including 
county-level sociodemographic characteristics (34). 2010-2014 ACS county-level factors on % 
living in poverty, median household income, % with at least a high school education, and % of 
the population that identify as black were extracted. USDA’s Rural-Urban Continuum Codes, 
which consider a county’s population size and adjacency to a metropolitan area, were used to 
categorize counties as either urban or rural (36). A code of 1-3 was considered urban; a code of 
4-9 was considered rural. The National Cancer Institute’s State Cancer Profile provided county-
level modeled estimates of the percentage of women aged 40+ who had a mammogram in the 
past two years (35). The Area Health Resource File provided data on the number of primary care 
physicians in each county for the years 2011 to 2014, which were used determine the average 
number of primary care physicians per 100,000 (i.e. provider density) for each county(37). 
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Ultimately, only one sociodemographic variable was considered in the model, poverty level, as 
these variables were highly correlated.  Poverty level was chosen as it has been considered the 
most robust socioeconomic variable for measuring inequalities in cancer incidence (38). All 
other variables were considered in the analysis: rural-urban status, provider density, and 
mammography utilization. Provider density proved to non-significantly contribute to all models 
and caused poorer goodness of fit as measured by the Akaike Information Criterion, and 
therefore was excluded from inclusion in final models. Because of the important, but 
understudied, consideration of the interaction between race and rural context, particularly in the 
South (39), the cross-level interaction between rural-urban status and race were considered in all 
models and was retained if the interaction was statistically significant.  Exponentials of 
coefficients estimated rate ratios. 95% confidence intervals were used to determine whether there 
were statistically significant differences in cancer incidence for early and late stages, 
respectively, between the Delta Region and non-Delta Region after accounting for the 
aforementioned potential confounders.  
Results 
 Table 3.1 displays the age-adjusted IRs and RRs for the Delta and non-Delta Regions for 
all cancers, each individual subtype, and those of unknown subtype for all cases and for non-
Hispanic whites and blacks. The age-adjusted incidence rate for early-stage breast cancer was 
lower in the Delta Region than the non-Delta Region (IR=70.4 and 76.4, respectively, RR=0.92, 
95% CI=0.90-0.94). There was no statistically significant difference in late-stage rates. Rates 
among non-Hispanic whites and blacks followed a similar pattern, as both groups had lower 
early-stage rates in the Delta Region, but no differences in late-stage breast cancer. For 
HR+/HER2- cancers, the Delta Region had lower rates of both early and late stages. The 
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Delta/non-Delta Region difference was particularly stark for early-stage cancers (IR=44.6 and 
52.7, respectively, RR=0.85; 95% CI=0.82-0.87).  For the racial/ethnic stratification, only in 
non-Hispanic white women were there a Delta/non-Delta Region difference in late-stage 
HR+/HER2- (RR=0.92; 95% CI=0.87-0.96).  Rates of both early and late stage triple negative 
breast cancers were higher in the Delta Region. The rate of early stage triple negative breast 
cancer was 9.9 per 100,000 in the Delta Region, compared to 8.7 per 100,000 in the non-Delta 
Region (RR=1.14, 95% CI=1.07-1.21). The rate of late-stage triple negative breast cancer was 
higher in the Delta Region compared to the non-Delta Region (IR=7.0 and 5.6, respectively, 
RR=1.24; 95% CI=1.16-1.34). Also of note, black women in the Delta Region had higher rates 
of late-stage triple-negative breast cancer than non-Delta black women (RR=1.15; 95% CI=1.03-
1.29). Compared to women in the non-Delta Region, women in the Delta Region also had higher 
rates of both early and late-stage cancers of unknown subtype. 
 Table 3.2 displays the age-adjusted IRs and RRs stratified by rural and urban status in the 
Delta and non-Delta Regions for all cancers, each individual subtype, and those of unknown 
subtype for all cases. Both the rural and urban Delta Region had lower rates of early-stage breast 
cancer compared to their respective non-Delta Region counterparts. HR+/HER2- cancers showed 
a similar association, as both the rural and the urban Delta had lower rates of early-stage cancers 
than the non-Delta Region, but there was no difference in late-stage cancers. For HR-/HER2+ 
breast cancers, there was no difference in the rural Delta and non-Delta Regions for either early 
or late stage cancer. The urban Delta Region had higher rates of early-stage HR-/HER2+ breast 
cancer compared to non-Delta urban women (RR=1.18; 95% CI=1.03-1.35). There were no 
regional rural differences for late-stage triple-negative cancers. The urban Delta Region had 
higher rates of both early and late stage triple-negative breast cancer than non-Delta women. The 
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rate of early-stage triple-negative breast cancer in the urban Delta Region was 10.5 per 100,000 
compared to 8.7 per 100,000 in the non-Delta Region. For late-stage triple-negative breast 
cancers, the rates in the Delta and non-Delta Regions were 7.3 and 5.6 per 100,000, respectively 
(RR=1.31; 95% CI=1.20-1.43). Both rural and urban Delta Regions had higher rates of both 
early and late stage breast cancer of unknown subtype compared to the non-Delta Region. 
  Table 3.3 displays the age-adjusted IRs and RRs stratified by poverty level in the Delta 
and non-Delta Regions. Women in the Delta Region who lived in counties with 20+% of the 
population living in poverty (i.e. high poverty) had higher rates of late-stage breast cancer 
compared to women in high poverty areas of the non-Delta (IR=43.9 and 41.0 per 100,000, 
respectively, RR=1.07; 95% CI=1.02-1.12). For HR+/HER2- breast cancer, women in high 
poverty counties in the Delta Region had higher rates of late-stage breast cancer than those in 
high poverty counties in the non-Delta Region (RR=1.07; 95% CI=1.01-1.14). For women in 
counties with less than 20% of the population in poverty, the Delta Region had lower rates of 
both early and late stage HR+/HER2- cancers. The Delta Region had higher rates of both early 
and late stage triple-negative breast cancers for both poverty stratifications compared to their 
non-Delta counterparts. Of particular note is the Delta/non-Delta Region difference in late-stage 
triple-negative breast cancers in high poverty counties (RR=1.26, 95% CI=1.12-1.42). Rates of 
both early and late stage breast cancers of unknown subtype are higher in the Delta Region than 
the non-Delta Region in counties with less than 20% of the population in poverty.  
 Table 3.4 displays the age-adjusted IRs and RRs for early and late stage breast cancers by 
subtype within the Delta Region stratified by race, rural-urban status, and poverty level. Black 
women in the Delta Region had lower rates of early stage breast cancer (RR=0.91; 95% CI=0.87-
0.95) but higher rates of late-stage breast cancer (RR=1.34; 95% CI=1.28-1.41) compared to 
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white women. A similar relationship was seen for HR+/HER2- cancers, as black women had 
lower rates of early-stage cancer (RR=0.75; 95% CI=0.71-0.79), but higher rates of late-stage 
cancer (RR=1.10; 95% CI=1.03-1.18).  For HR-/HER2+ cancers, black women had higher early 
(RR=1.33; 95% CI=1.08-1.64) and late stage cancer rates (RR=1.65; 95% CI=1.34-2.02) 
compared to white women in the Region. For triple-negative breast cancers, black women had 
higher rates of both early (RR=1.79; 95% CI=1.61-1.98) and late stage (RR=2.62; 95% CI=2.31-
2.98) cancers as well. Rural women in the Delta Region had lower rates of early-stage breast 
cancer for all breast cancer cases combined (RR=0.89; 95% CI=0.85-0.92) and for each 
individual subtype, except HR+/HER2+ cases, compared to urban Delta residents. The rural 
Delta Region had lower rates of late-stage breast cancers of all subtypes combined (RR=0.94; 
95% CI=0.85-0.92) and both HR+/HER2- and triple-negative cancers. Rural women had higher 
rates of both early and late stage breast cancer of unknown subtype. Women who live in higher 
poverty counties in the Delta Region have lower rates of early-stage breast cancer than less 
impoverished women for all breast cancers combined and for all subtypes individually except 
both HR- subtypes where there was no difference.  Women in higher poverty Delta counties had 
higher rates of late-stage triple negative breast cancer (RR=1.20; 95% CI=1.06-1.36).  
Table 3.5 displays the results of multivariable, multilevel negative binomial regression 
modeling for early and late stages of all breast cancer cases, individual subtypes, and cases of 
unknown subtype for all cases and stratification by race/ethnicity, rural-urban status, and poverty 
level. There is no difference between the Delta and non-Delta Regions in early or late stage 
cancers for all subtypes combined or any individual subtype across most stratifications when 
accounting for relevant first level and contextual confounders. Urban women in the Delta Region 
have higher rates of early stage triple negative breast cancer than non-Delta women after 
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adjusting for relevant factors (RR=1.10; 95% CI=1.01-1.21).  Women in the Delta Region who 
lived in counties with less than 20% of the population in poverty had lower rates of HR+/HER2- 
cancers than non-Delta women after adjusting for relevant factors (RR=0.91; 95% CI=0.85-
0.97). Unknown subtype rates were higher in the Delta vs. the non-Delta for the following 
groupings/stratifications: early and late stages of all breast cancers, early stage in white women, 
late stage in black women, early and late stage in rural women, early and late stage in women 
who lived in “low poverty” counties.  
Table 3.6 displays the results of multivariable, multilevel negative binomial regression 
modeling for early and late stages of all breast cancer cases, individual subtypes, and cases of 
unknown subtype for all cases and stratification by race/ethnicity, rural-urban status, and poverty 
level within the Delta Region. Lower rates of early-stage cancers persisted in rural women for all 
subtypes combined, as well as HR+/HER2- and HR-/HER2+ cancers.  Black women in the Delta 
Region had higher rates of all late-stage breast cancers (RR=1.10; 95% CI=1.04-1.15) and higher 
rates of triple-negative breast cancer (RR=1.17, 95% CI=1.00-1.33) compared to white women 
in the Region, even after accounting for age and relevant contextual factors. Higher rates of late-
stage unknown subtypes persisted in the rural Delta after controlling for other factors. 
Discussion 
This present study utilized population-level cancer registry data to examine early and 
late-stage breast cancer incidence rate differences between the Delta and non-Delta regions of 
seven LMDR states for all breast cancers combined and stratified by subtype. There were no 
early and late stage incidence differences between the Delta and non-Delta Regions for all breast 
cancers combined. For both stage groupings, the Delta Region had lower rates of HR+/HER2- 
than non-Delta Region women but had higher rates of both early and late stage triple negative 
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breast cancers. Compared to their respective non-Delta women, rural Delta women had lower 
rates of early-stage HR+/HER2- breast cancer while urban Delta women had higher early and 
late stage triple negative breast cancers. Higher rates of unknown breast cancers of both staging 
groups tended to be higher in the Delta Region across most demographic stratifications. After 
adjusting for first and second level variables, any rate differences by stage were attenuated, 
except for some unknown subtype stratifications. In analyses of the Delta Region alone, black 
women had lower rates of early-stage breast cancer, but higher rates of late-stage breast cancer 
compared to white women. Black women also had higher rates of early and late stage HR- 
cancers. Rural Delta women had lower rates of both early and late stage breast cancers than their 
urban counterparts, an association that remained even after adjustment.  
 The overall rate of early-stage breast cancer was lower in the Delta Region than the non-
Delta Region as were both early and late stage HR+/HER2- breast cancers. These lower rates 
across stages may be explained by the historically low levels of mammography utilization by 
women in the Delta Region (2,5).  Ecological studies have shown that increased mammography 
utilization is correlated with high overall and HR+/HER2- breast cancer rates (22). Indeed, in the 
multivariable analysis of this study, the statistically significantly lower rates of overall and 
HR+/HER2- cancers for early and late stage were attenuated to statistical non-significance after 
accounting for factors like mammography utilization. HR+/HER2- is the subtype with the best 
prognosis, but it is also the most common subtype. Further, studies suggest that high rates of 
early-stage HR+/HER2- breast cancers may be indicative of overdiagnosis, which may occur in 
nearly one out of every three breast cancer diagnoses (22, 40). It is unclear how much the higher 
rates of early-stage HR+/HER2- breast cancers in the non-Delta Region are driven by 
overdiagnosis compared to a true excess of incident cases.   
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The lower rates of late-stage breast cancers and HR+/HER2- cancers may suggest that the 
higher mortality rates in the Delta Region may be driven by the less common, but more 
aggressive molecular subtypes (i.e. triple-negative),  and/or by lower quality breast cancer 
treatment in the region. A study of breast cancer patients in Appalachia, a similarly 
socioeconomically disparate region with breast cancer mortality disparities, found that less than 
half of women who were eligible for post-surgical targeted therapy based upon subtype and 
staging actually did receive it, an indicator of poor treatment quality (41). However, there is a 
dearth of literature on cancer treatment quality in the Delta Region as a potential factor in the 
mortality disparity. This paucity of research provides an opportunity to further explicate the 
breast cancer mortality disparity in the Delta Region.  
 In the analysis of the Delta Region alone, black women had lower rates of early-stage 
breast cancer, but higher rates of late-stage breast cancer compared to white women for both all 
subtypes combined and for each individual subtype specifically, except the HR+/HER2+ 
subtype. Elevated rates of late-stage breast cancers among black women in the Delta Region 
remained for all subtypes combined and for the HR+/HER2- subtype specifically after 
accounting for age and contextual factors. These findings corroborate previous studies indicating 
higher rates of advanced stage breast cancer in black women compared to white women (8-10). 
Further, it underscores the importance of culturally component, tailored interventions to improve 
cancer screening rates and subsequently reduce the rate of late-stage cancers in black women in 
the Region. Several studies have shown that utilizing lay health advisors/community health 
advisors and/or faith-based settings can increase breast cancer screening among black women in 
Delta Region communities or other communities in the Deep South (42-45). One of these 
interventions includes Erwin’s “Witness Project”, which was developed and tested in the 
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Arkansas Delta and utilizes lay health advisors who are cancer survivors to educate black women 
on cancer screening in a faith-based setting (42,43). The Witness Project model has been 
identified as one of the NCI’s Research-Tested Intervention Programs, a collection of effective, 
evidence-based programs that can be implemented targeted population groups or communities 
(46). Additionally, the American Cancer Society has successfully piloted a community health 
advisor program to improve cancer screening rates in black communities in the Deep South, 
which has some geographic overlap with the Delta Region (45). Scaling up these successful 
interventions and implementing them across the black communities within the Delta Region may 
help reduce the racial disparity in breast cancer staging through early detection. Because elevated 
rates of late-stage breast cancer were experienced among black women for all subtypes, it is 
important to note that different screening modalities will be more effective to detect each 
subtype. While typical X-Ray mammography may be effective for identifying HR+/HER2- 
breast cancers, ultrasound or MRI mammography are more effective for detecting triple-negative 
breast cancers (47-49). In fact, some organizations, such as the American Cancer Society and the 
National Comprehensive Cancer Network recommend breast MRI for women at particularly 
high risk (50-51). Interventions should also emphasize the effectiveness of different modalities to 
detect different subtypes, especially as triple-negative breast cancers are more common in black 
women.  
 The current study was not without limitations. First, data from one LMDR state, 
Missouri, were not included as they did not consent for their data to be used. While Missouri 
includes less than seven percent of the Delta Region population and is the Delta Region state 
with the largest percentage of white population, its omission may affect the study findings (1). 
For example, Delta Region disparities were identified for triple-negative breast cancers in urban 
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populations especially. The absence of data from non-Delta urban areas with a high proportion of 
black residents like St. Louis and Kansas City may alter the identified disparity. Finally, a three-
level model proved to be too complex for the less common subtypes of breast cancer, especially 
with stratifications by stage. Thus state-to-state variability was unable to be accounted for.  
However, this study had several strengths. First, it utilized population-based cancer registry data, 
which includes all cancer cases that were diagnosed in the LMDR states during the study period. 
Second, it employed multilevel modeling to explore place-based effects on cancer staging, a 
method that has been underutilized in rural cancer research (52). Multilevel models assume the 
nonindependence of group membership (i.e. counties) and thus, produce less biased standard 
errors and reduce the risk of Type I errors. This study was the first to explore cancer staging 
differences across the multi-state Delta Region. Additionally, it was one of the first to explore 
staging differences in breast cancers stratified by the four molecular subtypes, rather than 
adjusting for subtype when assessing differences in stage.  
Conclusions 
 Late stage breast cancer disparities between the Delta and non-Delta-Region were largely 
non-existent. This suggests that the higher rates of triple-negative breast cancer in the region and 
potential treatment disparities may be the key contributors to the Delta Region’s breast cancer 
mortality disparities. Within the Delta Region, black women had higher rates of late-stage breast 
cancer across most subtypes. The Delta Region is rife with successful examples of community-
based, culturally competent interventions to increase breast cancer screening uptake in black 
women. Scaling up these interventions throughout the Delta Region may help improve screening 
rates in black women and increase early detection. Further, it is important to ensure that 
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appropriate screening modalities be utilized to detect different breast cancer subtypes at an 
earlier, more treatable stage.  
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Figures and Tables 
Figure 3.1: Conceptual Model for Elucidating Breast Cancer Disparities in the Delta Region 
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Figure 3.2: Diagram of Multilevel Regression Models  
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Table 3.1: Age-Adjusted Incidence Rate and Rate Ratios by Subtype and Stage and Race in the Delta and non-Delta Regions of the 
Lower Mississippi Delta Region States 
 All Non-Hispanic Black Non-Hispanic White 
 Non-Delta Delta Non-Delta Delta Non-Delta Delta 
 Count IR† Count IR†  RR 
(95% 
CI) 
Count IR† Count IR  RR 
(95% 
CI) 
Count IR† Count  IR† RR 
(95% 
CI) 
All Subtypes       
    
Early 
    
Late 
 
40,184 
 
21,726 
 
76.4 
 
42.5 
 
11,853 
 
7,088 
 
70.4 
 
43.4 
0.92 
(0.90-
0.94) 
1.02 
(0.99-
1.05) 
 
4,973 
 
3,609 
 
70.7 
 
51.1 
 
3,304 
 
2,627 
 
66.5 
 
53.0 
0.94 
(0.90-
0.98) 
1.04 
(0.98-
1.09) 
 
33,092 
 
16,715 
 
79.9 
 
42.1 
 
8,294 
 
4,274 
 
73.1 
 
39.4 
0.91 
(0.89-
0.94) 
0.94 
(0.90-
0.97) 
HR+/HER2- 
 
Early 
 
Late 
 
27,941 
 
13,160 
 
52.7 
 
25.6 
 
7,583 
 
4,025 
 
44.6 
 
24.3 
0.85 
(0.82-
0.87) 
0.95 
(0.92-
0.99) 
 
2,866 
 
1,889 
 
41.1 
 
26.1 
 
1,801 
 
1,291 
 
36.5 
 
27.0 
0.89 
(0.84-
0.94) 
0.97 
(0.90-
1.04) 
 
23,691 
 
10,411 
 
56.5 
 
26.0 
 
5,610 
 
2,626 
 
48.7 
 
23.8 
0.86 
(0.84-
0.89) 
0.92 
(0.87-
0.96) 
HR+/HER2+ 
 
Early 
 
Late    
 
3,526 
 
2,864 
 
6.9 
 
5.7 
 
1,035 
 
857 
 
6.2 
 
5.4 
0.90 
(0.84-
0.97) 
0.95 
(0.88-
1.03) 
 
461 
 
445 
 
6.4 
 
6.3 
 
292 
 
292 
 
5.8 
 
6.0 
0.91 
(0.78-
1.05) 
0.95 
(0.81-
1.11) 
 
2,813 
 
2,218 
 
7.1 
 
5.8 
 
721 
 
540 
 
6.5 
 
5.3 
0.92 
(0.84-
1.00) 
0.91 
(0.82-
1.00) 
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Table 3.1 (cont.) 
 All Non-Hispanic Black Non-Hispanic White 
 Non-Delta Delta Non-Delta Delta Non-Delta Delta 
HR-/HER2+ 
 
Early 
  
Late 
 
1,311 
 
1,360 
 
2.5 
 
2.6 
 
440 
 
425 
 
2.7 
 
2.6 
1.06 
(0.95-
1.19) 
0.99 
(0.88-
1.11) 
 
206 
 
253 
 
2.8 
 
3.5 
 
162 
 
183 
 
3.2 
 
3.6 
1.15 
(0.93-
1.43) 
1.03 
(0.84-
1.25) 
 
1,011 
 
991 
 
2.5 
 
2.5 
 
264 
 
234 
 
2.4 
 
2.2 
0.96 
(0.83-
1.10) 
0.86 
(0.74-
1.01) 
Triple Negative           
 
Early 
 
Late 
 
4,448 
 
2,836 
 
8.7 
 
5.6 
 
1,606 
 
1,107 
 
9.9 
 
7.0 
1.14 
(1.07-
1.21) 
1.24 
(1.16-
1.34) 
 
997 
 
754 
 
13.9 
 
10.6 
 
724 
 
605 
 
14.4 
 
12.2 
1.03 
(0.93-
1.14) 
1.15 
(1.03-
1.29) 
 
3,217 
 
1,920 
 
8.1 
 
5.0 
 
856 
 
476 
 
8.0 
 
4.6 
0.99 
(0.91-
1.07) 
0.94 
(0.84-
1.04) 
Unknown           
 
Early 
 
Late 
 
2,958 
 
1,516 
 
5.6 
 
2.9 
 
1,189 
 
674 
 
7.1 
 
4.0 
1.26 
(1.17-
1.35) 
1.38 
(1.26-
1.52) 
 
443 
 
268 
 
6.4 
 
3.8 
 
 
 
325 
 
256 
 
 
6.5 
 
5.1 
1.02 
(0.88-
1.19) 
1.36 
(1.13-
1.62) 
 
2,360 
 
1,175 
  
 
5.6 
 
2.8 
 
843 
 
398 
 
7.4 
 
3.5 
1.31 
(1.21-
1.43) 
1.25 
(1.11-
1.41) 
Non-Delta Region is Reference Group; IR=Incidence Rate; RR=Rate Ratio; †Rates are expressed per 100,000 population 
 
 
 
 
 99 
 
Table 3.2: Age-Adjusted Incidence Rates and Rate Ratios by Subtype and Rural-Urban Status in the Delta and non-Delta Regions of 
the Lower Mississippi Delta Region States 
 Rural Urban 
 Non-Delta Delta Non-Delta Delta 
 Count IR Count IR  RR (95% CI) Count IR Count IR  RR (95% CI) 
All Subtypes  
Early 
Late 
8,132 
4,679 
69.1 
41.3 
4,277 
2,617 
65.4 
41.9 
0.95 (0.91-0.98) 
1.01 (0.96-1.07) 
32,231 
17,134 
79.0 
43.0 
7,606 
4,488 
73.7 
44.6 
0.93 (0.91-0.96) 
1.04 (1.00-1.07) 
HR+/HER2- 
Early 
Late 
5,407 
2,671 
45.1 
23.5 
2,679 
1,446 
40.3 
22.6 
0.89 (0.85-0.94) 
0.96 (0.90-1.03) 
22,652 
10,537 
55.3 
26.3 
4,915 
2,585 
47.4 
25.5 
0.86 (0.83-0.88) 
0.97 (0.93-1.01) 
HR+/HER2+      
Early 
Late    
703 
631 
6.3 
5.7 
383 
323 
6.0 
5.4 
0.95 (0.83-1.08) 
0.95 (0.83-1.10) 
2,841 
2,250 
7.1 
5.8 
657 
535 
6.4 
5.4 
0.90 (0.82-0.98) 
0.94 (0.86-1.04) 
HR-/HER2+      
Early 
Late 
285 
315 
2.5 
2.8 
137 
147 
2.1 
2.4 
0.82 (0.66-1.02) 
0.85 (0.69-1.05) 
1,303 
1,039 
2.5 
2.6 
303 
278 
3.0 
2.7 
1.18 (1.03-1.35) 
1.06 (0.92-1.21) 
Triple Negative      
Early 
Late 
977 
648 
8.8 
5.9 
543 
385 
8.9 
6.6 
1.02 (0.91-1.13) 
1.12 (0.98-1.29) 
3,485 
2,198 
8.7 
5.6 
1,064 
726 
10.5 
7.3 
1.21 (1.13-1.30) 
1.31 (1.20-1.43) 
Unknown      
Early 
Late 
760 
414 
6.5 
3.5 
535 
316 
8.2 
4.9 
1.27 (1.13-1.42) 
1.41 (1.21-1.65) 
2,220 
1,110 
5.4 
3.5 
667 
364 
6.4 
2.7 
1.19 (1.09-1.30) 
1.29 (1.14-1.45) 
Non-Delta Region is Reference Group; IR=Incidence Rate; RR=Rate Ratio; †Rates are expressed per 100,000 population 
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Table 3.3: Age-Adjusted Incidence Rate and Rate Ratios by Stage, Subtype, and Poverty Level in the Delta and non-Delta Regions of 
the Lower Mississippi Delta Region States 
 20+% in Poverty <20% in Poverty 
 Non-Delta Delta Non-Delta Delta 
 Count IR Count IR  IR Count IR Count IR IRR 
All Subtypes 
Early 
Late 
6,485 
3,838 
67.2 
41.0 
6,279 
3,976 
67.1 
43.9 
1.00 (0.96-1.04) 
1.07 (1.02-1.12) 
33,699 
17,888 
78.5 
42.8 
5,574 
3,112 
74.4 
42.7 
0.95 (0.92-0.98) 
1.00 (0.96-1.04) 
HR+/HER2- 
Early 
Late 
4,271 
2,143 
43.6 
22.8 
3,975 
2,235 
42.1 
24.4 
0.96 (0.92-1.01) 
1.07 (1.01-1.14) 
23,670 
11,017 
54.8 
26.2 
3,608 
1,790 
47.7 
24.3 
0.87 (0.84-0.90) 
0.93 (0.88-0.97) 
HR+/HER2+ 
Early 
Late 
590 
526 
6.4 
5.6 
538 
472 
5.8 
5.4 
0.90 (0.80-1.02) 
0.97 (0.85-1.10) 
2,936 
2,338 
7.0 
5.7 
497 
385 
6.7 
5.4 
0.96 (0.86-1.05) 
0.95 (0.85-1.06) 
HR-/HER2+ 
Early 
Late 
229 
265 
2.4 
2.9 
244 
233 
2.7 
2.6 
1.14 (0.94-1.38) 
0.88 (0.73-1.06) 
1,082 
1,085 
2.5 
2.6 
196 
192 
2.6 
2.7 
1.03 (0.88-1.21) 
1.03 (0.87-1.21) 
Triple Negative 
Early 
Late 
777 
551 
8.4 
6.0 
905 
665 
10.0 
7.6 
1.19 (1.07-1.31) 
1.26 (1.12-1.42) 
3,671 
2,285 
8.7 
5.6 
701 
442 
9.7 
6.3 
1.11 (1.02-1.21) 
1.14 (1.02-1.26) 
Unknown 
Early 
Late 
618 
353 
6.4 
3.6 
617 
371 
6.6 
4.0 
1.03 (0.92-1.16) 
1.10 (0.94-1.28) 
2,340 
1,163 
5.4 
2.7 
572 
303 
7.7 
4.0 
1.41 (1.28-1.55) 
1.48 (1.30-1.69) 
Non-Delta Region is Reference Group; IR=Incidence Rate; RR=Rate Ratio; †Rates are expressed per 100,000 population 
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Table 3.4: Age-Adjusted Incidence Rates in the Delta Region by Race, Rural-Urban Status, and County Poverty Level 
 Race Rural-Urban Poverty Level 
 White† Black Urban† Rural Under 20%† 20+%  
 Count IR‡ Count IR 
‡ 
RR 
(95% 
CI) 
Count IR‡ Count IR  RR 
(95% 
CI) 
Count IR‡ Count IR‡ RR 
(95% 
CI) 
All Subtypes       
Early 
 
   
Late 
8,294 
 
 
4,274 
73.1 
 
 
39.4 
3,304 
 
 
2,627 
66.5 
 
 
53.0 
0.91 
(0.87-
0.95) 
1.34 
(1.28-
1.41) 
7,606 
 
 
4,488 
73.7 
 
 
44.6 
4,277 
 
 
2,617 
65.4 
 
 
41.9 
0.89 
(0.85-
0.92) 
0.94 
(0.89-
0.99) 
5,574 
 
 
3,112 
74.4 
 
 
42.7 
6,279 
 
 
3,976 
67.1 
 
 
43.9 
0.90 
(0.87-
0.94) 
1.03 
(0.98-
1.08) 
HR+/HER2- 
Early 
 
 
Late 
5,610 
 
 
2,626 
48.7 
 
 
23.8 
1,801 
 
 
1,291 
36.5 
 
 
26.1 
0.75 
(0.71-
0.79) 
1.10 
(1.03-
1.18) 
4,915 
 
 
2,585 
47.4 
 
 
25.5 
2,679 
 
 
1,446 
40.3 
 
 
22.6 
0.85 
(0.81-
0.89) 
0.89 
(0.83-
0.95) 
3,608 
 
 
1,790 
47.7 
 
 
24.3 
3,975 
 
 
2,235 
42.1 
 
 
24.4 
0.88 
(0.84-
0.92) 
1.01 
(0.94-
1.07) 
HR+/HER2+ 
Early 
 
 
Late    
721 
 
 
540 
6.5 
 
 
5.3 
292 
 
 
292 
5.8 
 
 
6.0 
0.89 
(0.77-
1.03) 
1.13 
(0.97-
1.32) 
657 
 
 
535 
6.4 
 
 
5.4 
383 
 
 
323 
6.0 
 
 
5.4 
0.93 
(0.81-
1.06) 
0.99 
(0.86-
1.15) 
497 
 
 
385 
6.7 
 
 
5.4 
538 
 
 
472 
5.8 
 
 
5.4 
0.87 
(0.77-
0.99) 
1.00 
(0.87-
1.15) 
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Table 3.4 (cont.) 
 Race Rural-Urban Poverty Level 
 White† Black Urban† Rural Under 20%† 20+%  
 Count IR‡ Count IR 
‡ 
RR 
(95% 
CI) 
Count IR‡ Count IR  RR 
(95% 
CI) 
Count IR‡ Count IR‡ RR 
(95% 
CI) 
HR-/HER2+ 
Early 
  
 
 
 Late 
264 
 
 
 
234 
2.4 
 
 
 
2.2 
162 
 
 
 
163 
3.2 
 
 
 
3.6 
1.33 
(1.08-
1.64) 
1.65 
(1.34-
2.02) 
303 
 
 
 
278 
3.0 
 
 
 
2.7 
137 
 
 
 
147 
2.1 
 
 
 
2.4 
0.70 
(0.56-
0.86) 
0.87 
(0.70-
1.07) 
196 
 
 
 
192 
2.6 
 
 
 
2.7 
244 
 
 
 
233 
2.7 
 
 
 
2.6 
1.02 
(0.84-
1.25) 
0.96 
(0.79-
1.18) 
Triple Negative      
Early 
 
 
Late 
856 
 
 
476 
8.0 
 
 
4.6 
724 
 
 
12.2 
14.4 
 
 
12.2 
1.79 
(1.61-
1.98) 
2.62 
(2.31-
2.98) 
1,064 
 
 
726 
10.5 
 
 
7.3 
543 
 
 
385 
8.9 
 
 
6.6 
0.85 
(0.76-
0.94) 
0.90 
(0.79-
1.02) 
701 
 
 
442 
9.7 
 
 
6.3 
905 
 
 
665 
10.0 
 
 
7.6 
1.03 
(0.93-
1.14) 
1.20 
(1.06-
1.36) 
Unknown 
Early 
 
 
Late 
843 
 
 
398 
7.4 
 
 
3.5 
325 
 
 
256 
6.5 
 
 
5.1 
0.88 
(0.77-
1.01) 
1.44 
(1.22-
1.70) 
663 
 
 
361 
6.4 
 
 
3.5 
526 
 
 
313 
 
8.1 
 
 
4.8 
1.26 
(1.12-
1.42) 
1.38 
(1.18-
1.62) 
572 
 
 
303 
7.7 
 
 
4.0 
617 
 
 
371 
6.6 
 
 
4.0 
0.86 
(0.76-
0.96) 
0.98  
(0.84-
1.15) 
IR=Incidence Rate; RR=Rate Ratio; †Reference Group; ‡Rates are expressed per 100,000 population 
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Table 3.5: Multilevel Negative Binomial Regression Modeling of Early and Late Stage Invasive Breast Cancers by Delta Region 
Status and Stratified by Race/Ethnicity, Rural-Urban Status, and Poverty Level  
Delta vs. non-Delta Region (Reference Group) 
 All Breast 
Cancers 
IDR (95% CI) 
HR+/HER2+ 
IDR (95% CI) 
HR+/HER2- 
IDR (95% CI) 
HR-/HER2+ 
IDR (95% CI) 
Triple Negative 
IDR (95% CI) 
Unknown 
IDR (95% CI) 
All Casesa 
Early 
Late 
0.99 (0.95-1.02) 
1.00 (0.96-1.04) 
0.96 (0.88-1.04) 
0.92 (0.84-1.01) 
0.95 (0.91-1.00) 
1.00 (0.95-1.05) 
1.00 (0.87-1.14) 
0.91 (0.80-1.04) 
1.03 (0.96-1.11) 
0.99 (0.90-1.09) 
1.21 (1.05-1.38) 
1.24 (1.06-1.44) 
Non-Hispanic Whitesb 
Early 
Late 
0.98 (0.94-1.02) 
0.97 (0.93-1.01) 
0.98 (0.90-1.08) 
0.91 (0.81-1.01) 
0.94 (0.89-0.99) 
0.98 (0.92-1.03) 
0.98 (0.85-1.14) 
0.87 (0.74-1.02) 
1.00 (0.92-1.10) 
0.92 (0.82-1.04) 
1.25 (1.08-1.44) 
1.18 (0.99-1.39) 
Non-Hispanic Blacksb 
Early 
Late 
1.01 (0.94-1.09) 
1.02 (0.95-1.09) 
0.80 (0.63-1.01) 
0.81 (0.65-0.99) 
1.09 (0.89-1.07) 
1.02 (0.92-1.14) 
0.86 (0.67-1.11) 
0.88 (0.68-1.15) 
1.11 (0.98-1.25) 
1.00 (0.86-1.15) 
1.09 (0.82-1.45) 
1.49 (1.14-1.94) 
Ruralc 
Early 
Late 
0.98 (0.94-1.03) 
0.96 (0.91-1.01) 
0.95( 0.83-1.09) 
0.91 (0.78-1.06) 
0.95 (0.89-1.01) 
0.96 (0.89-1.04) 
0.87 (0.69-1.09) 
0.72 (0.58-0.90) 
0.92 (0.81-1.04) 
0.87 (0.75-1.01) 
1.26 (1.05-1.50) 
1.30 (1.07-1.56) 
Urbanc  
Early 
Late 
0.99 (0.94-1.04) 
1.04 (0.99-1.09) 
0.93 (0.84-1.04) 
0.92 (0.82-1.04) 
0.95 (0.88-1.01) 
1.03 (0.95-1.11) 
1.10 (0.94-1.29) 
1.05 (0.89-1.25) 
1.10 (1.01-1.21) 
1.09 (0.96-1.24) 
1.11 (0.89-1.38) 
1.14 (0.88-1.48) 
20+% in Povertyd 
Early 
Late 
1.00 (0.95-1.05) 
0.97 (0.92-1.03) 
0.89 (0.78-1.01) 
0.89 (0.77-1.02) 
0.99 (0.93-1.05) 
1.00 (0.99-1.01) 
1.02 (0.84-1.26) 
0.75 (0.59-0.93) 
0.95 (0.84-1.07) 
0.91 (0.78-1.06) 
1.10 (0.92-1.32) 
1.11 (0.90-1.37) 
<20% in Povertyd 
Early 
Late 
0.97 (0.92-1.02) 
1.01 (0.96-1.06) 
0.98 (0.88-1.10) 
0.93 (0.82-1.06) 
0.91(0.85-0.97) 
0.96 (0.89-1.03) 
1.02 (0.85-1.21) 
1.06 (0.88-1.27) 
1.05 (0.96-1.15) 
1.03 (0.91-1.18) 
1.32 (1.09-1.61) 
1.39 (1.11-1.72) 
Non-Delta Region is Reference Group; RR=Rate Ratio; a Adjusting for age, race/ethnicity, rural-urban status, poverty level, area mammography utilization, and 
race/rural-urban status interaction (if statistically significant);b Adjusting for race/ethnicity, rural-urban status, area mammography utilization, and race/rural-
urban status interaction; c Adjusting for age, area mammography utilization, and poverty level; d Adjusting for age, race/ethnicity, racial composition, area 
mammography utilization, and poverty level; e Adjusting for age, race/ethnicity,  area mammography utilization, rural-urban status, and race/rural-urban status 
interaction 
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Table 3.6: Multilevel Negative Binomial Regression Modeling of Early and Late Stage Invasive Breast Cancers in the Delta Region 
and Stratified by Age, Race/Ethnicity, Rural-Urban Status and Poverty Level  
 All Breast 
Cancers 
RR (95% CI) 
HR+/HER2+ 
RR (95% CI) 
HR+/HER2- 
RR (95% CI) 
HR-/HER2+ 
RR (95% CI) 
Triple Negative 
RR (95% CI) 
Unknown 
RR (95% CI) 
Early Stage 
Race/Ethnicity 
Non-Hispanic 
White  
Non-Hispanic 
Black 
Ref 
 
1.04 (0.99-1.10) 
Ref 
 
1.12 (0.77-1.64) 
Ref 
 
1.02 (0.96-1.09) 
Ref 
 
1.06 (0.85-1.32) 
 
Ref 
 
1.03 (0.92-1.14) 
Ref 
 
0.87 (0.75-1.00) 
Rural-Urban Status 
Urban 
Rural 
Ref 
0.94 (0.89-0.99) 
Ref 
0.99 (0.77-1.26) 
Ref 
0.91 (0.84-0.98) 
Ref 
0.74 (0.59-0.92) 
Ref 
0.92 (0.81-1.04) 
Ref 
1.26 (0.99-1.59) 
Poverty Level 
<20% Below 
Poverty 
20+% Below 
Poverty 
Ref 
 
0.94 (0.89-1.00) 
 
Ref 
 
0.85 (0.72-0.99) 
Ref 
 
0.97 (0.90-1.05) 
Ref 
 
1.01 (0.82-1.26) 
Ref 
 
0.90 (0.80-1.03) 
Ref 
 
0.86 (0.68-1.08) 
Late Stage 
Race/Ethnicity 
Non-Hispanic 
White  
Non-Hispanic 
Black 
Ref 
 
1.10 (1.04-1.15) 
Ref 
 
1.06 (0.91-1.25) 
Ref 
 
1.05 (0.96-1.15) 
 
Ref 
 
1.13 (0.87-1.47) 
Ref 
 
1.16 (1.00-1.33) 
Ref 
 
1.14 (0.96-1.36) 
Rural-Urban Status 
Urban 
Rural 
Ref 
0.99 (0.94-1.04) 
Ref 
1.02 (0.87-1.19) 
Ref 
0.90 (0.82-0.98) 
Ref 
0.86 (0.64-1.16) 
Ref 
0.97 (0.82-1.15) 
Ref 
1.36 (1.16-1.80) 
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Table 3.6 (cont) 
 All Breast 
Cancers 
RR (95% CI) 
HR+/HER2+ 
RR (95% CI) 
HR+/HER2- 
RR (95% CI) 
HR-/HER2+ 
RR (95% CI) 
Triple Negative 
RR (95% CI) 
Unknown 
RR (95% CI) 
Poverty Level 
<20% Below 
Poverty 
20+% Below 
Poverty 
Ref 
 
0.97 (0.92-1.02) 
 
Ref 
 
0.97 (0.83-1.13) 
 
Ref 
 
0.96 (0.89-1.04) 
 
Ref 
 
0.86 (0.68-1.10) 
 
Ref 
 
0.94 (0.79-1.12) 
 
Ref 
 
0.89 (0.71-1.10) 
 
RR=Rate Ratio; All models also adjusted for age group, mammography utilization, and race-rural-urban status interaction (if significant) 
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CHAPTER 4: SPATIAL ACCESSIBILITY TO MAMMOGRAPHY SERVICES IN THE 
LOWER MISSISSIPPI DELTA REGION STATES 
Introduction 
The Delta Region Authority (Delta Region) is a region along the Mississippi River that 
has been federally designated to improve economic opportunity (1). It comprises 252 counties 
and parishes in the eight Lower Mississippi Delta (LMDR) states, which include Alabama, 
Arkansas, Illinois, Kentucky, Louisiana, Mississippi, Missouri, and Tennessee, and contains 
nearly 10 million residents. The Delta Region is characterized by high poverty, high proportions 
of black residents, geographic isolation, and limited access to care (1,2). Further, it has higher 
rates of breast cancer mortality than both the rest of the country and the rest of the LMDR (3). 
Nine of the ten counties in the nation with the highest breast cancer mortality rates are in the 
Delta Region (4). Historically, women in the region have lower rates of mammography 
utilization than the rest of the country (2,5).  Breast cancer disparities are even more striking 
among black women in the Delta Region (3). The interplay between spatial access to care and 
racial composition has been postulated as a contributing factor to breast cancer disparities (6,7). 
There are also fewer primary care physicians relative to the population (2). However, inequalities 
in spatial access to mammography services within the LMDR and between LMDR and non-
LMDR areas of the Delta Region states have not been studied. Spatial accessibility considers the 
number of facilities that are accessible within a given distance or travel time (8). Determining 
and evaluating geographic variation in spatial access to mammography in the Delta Region may 
help explain why women in the Region have poorer rates of mammography utilization and 
higher breast cancer mortality rates.  
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 There are numerous methods to assess spatial access to healthcare services such as 
mammography services (8-10). For example, the 2 Step Floating Catchment Area (2SFCA) 
method is a commonly used geographic information system (GIS) approach to evaluate the 
potential spatial accessibility of health care services (e.g. mammography facilities) by 
considering the supply of healthcare services relative to the population within a certain 
catchment area (11). Potential spatial access considers the “probable entry” into the health care 
system, not utilization itself, and takes into account distance or travel time to the healthcare 
service of interest.  The 2SFCA method has multiple strengths. First, while it considers the 
distance to care, it does not assume that people utilize care at the location that is geographically 
closest. Rather, it assumes they seek care within a given travel time or distance (i.e. catchment 
area), and as such, may access multiple locations within the catchment area. However, it does not 
take into account distance decay, meaning, for example, it assumes that a resident who lives 29 
minutes from a facility in a 30-minute catchment area has the same level of access as someone 
who lives 1 minute from a facility (i.e. it overestimates spatial access for those with long travel 
times).  In order to mitigate that limitation, Luo and Qi developed an enhanced two-step floating 
catchment area (E2SFCA) method which applies weights to multiple zones within a catchment 
area that take into account distance decay (12). Both the 2SFCA and the E2SFCA methods have 
been used to characterize spatial access to mammography facilities in multiple studies in 
multiple geographic extents, including individual cities, states, and regions like the U.S. South 
and Appalachia (7,13-17).  
Although 2SFCA and E2SFCA methods have been used to describe access to 
mammography in areas like Appalachia, they have not yet been used to characterize spatial 
access to mammography in other federally designated areas with significant health disparities 
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such as the Delta Region. Therefore, the objective of the present study is to use the E2SFCA 
method to evaluate spatial access to mammography in the eight Delta Region states to achieve 
the following aims:  
1) To compare spatial accessibility to mammography services for women living in the 
Delta Region compared to those living in the non-Delta region of the LMDR states  
2) To identify areas of low and high spatial access to mammography services in the 
Delta Region 
3) To evaluate the relationship between racial composition and spatial access to 
mammography in the Delta Region 
Methods 
 Spatial techniques were used to quantify spatial accessibility to mammography services 
in the LMDR states. Census tracts within the LMDR states were categorized as Delta Region or 
non-Delta Region based upon their location inside or outside the federally designated Delta 
Regional Authority (1).  Spatial statistics were then used to assess whether or not spatial 
accessibility was clustered within the Delta Region and to identify areas of low and high spatial 
accessibility. Further, univariate analyses were performed to compare how accessibility varied 
between the Delta and non-Delta Regions and between rural and urban areas. Additionally, 
bivariate statistical and spatial analyses were used to assess the relationship between spatial 
access and racial composition.    
Data Sources 
To represent “supply” of mammography facilities, the FDA mammography facilities file 
was utilized. This file is a publicly available source of addresses of all facilities in the United 
States that have been approved by FDA-accredited entities to have a radiation emitting device 
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(i.e. mammography machines) in accordance with the Mammography Quality Standards Act 
(18). Data were obtained for the 8 LMDR states and all facilities in adjacent states that were 
within 60 minutes’ drive time of an LMDR state. Facilities not accessible to the general public, 
including facilities affiliated with the Veterans’ Administration, military bases, correctional 
facilities, and the Indian Health Service, were excluded. All addresses were geocoded using the 
U.S. Census Bureau’s geocoder or GoogleMaps if the U.S. Census Bureau’s geocoder was 
unable to generate a valid geocode.  
To represent demand for mammography screening services, 2010-2014 data from the 
American Community Survey (ACS) were used. The ACS is an ongoing national survey 
performed by the U.S. Census Bureau that collects information on a variety of factors including 
data on census tract level population counts by age and gender (19).  Data from the ACS on the 
number of women between the ages of 45-74 in the LMDR states were extracted. This age 
grouping was used as it includes the age categories available from the ACS that are most congruent 
with the ages recommended by the United States Preventive Services Task Force to receive regular 
mammograms (20).   
United States Department of Agriculture (USDA) and ACS data characterized the rural-
urban status designation and racial composition of each census tract. The USDA primary Rural-
Urban Commuting Area (RUCA) codes were used to categorize census tracts in the MDR states 
as rural or urban. RUCA codes catalog census tracts according to their population density, 
urbanization, and daily commuting patterns (21). RUCA designations include 10 codes with 1 
being the most metropolitan and 10 being the most rural. Codes 1-3 indicate a metropolitan area; 
codes 4-6 a micropolitan area; codes 7-10 small town or rural areas. These codes were collapsed 
into two groups: urban (Codes 1-3) and rural (4-10).  ACS data were also used to determine the 
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racial composition of women in the LMDR by calculating the percent of women of 
recommended screening age who identified as black in each census tract (19).  
Measuring Spatial Accessibility 
The E2SFCA method was used to calculate a spatial accessibility score for every census 
tract in the eight LMDR states for all women aged 45-74. This method considers both the supply 
of and demand for healthcare services within a given catchment area. In keeping with similar 
studies assessing spatial access to mammography in large, mostly rural regions in the United 
States, a 60 minute drive time catchment area was used (13,15).  The first step of this method 
creates a facility (Sj)-population (Pk) ratio (Rj) within a given catchment area taking into account 
distance decay in four smaller zones (i.e. a weight-Wr- for each zone-r) within the catchment 
area:  
Step 1:    𝑅𝑗 =
𝑆𝑗
∑ ∑ 𝑃𝑘𝑊𝑟𝑘∈(𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 (𝑘,𝑗)<𝑑0
4
𝑟=1
 
The network analyst tool in ARCGIS was used to construct the four zones-- 0-10 minutes, 10-19 
minutes, 20-29 minutes, 30-60 minutes’ drive time—with the catchment area. A facility-
population ratio was calculated within each zone considering slow and fast distance decay 
functions as proposed by McGrail and colleagues and applied for assessing access to care in 
large regions that include both rural and urban areas (22). 
 Fast decay weights: 1, 0.60, 0.25, 0.05 
 Slow decay weights: 1, 0.80, 0.55, 0.15 
The population of any census tract whose centroid fell within a respective zone was included in 
the ratio.  The decay function represents the fact that spatial access to mammography declines as 
travel time to the facility increases, thus facility-population ratios in zones further away from the 
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facility carry successively less weight (i.e. populations further away from a facility are less likely 
to use this facility).  Because results can be sensitive to the choice of decay function weights and 
the appropriate weights for mammography services in the LMDR are unknown, two sets of 
weights, designated as “fast” and “slow” were used.  Compared to slow functions, fast decay 
functions apply smaller weights to each travel time zone, reflecting a steeper decline in 
mammography access as travel time increases.   Facility-to-population ratios were computed 
using each set of weights, as noted in Table 4.1.   
The second step of the E2SFCA method involves constructing similar travel time zones 
around the centroid of each individual census tract (k) and summing the facility-population ratios 
(Rj) by applying the appropriate weights. The sum represents the spatial accessibility score (𝐴𝑖
𝑓) 
for each census tract.  
Step 2:   𝐴𝑖
𝐹 = ∑ ∑ 𝑅𝑗𝑗 ∈(𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒(𝑖,𝑗)≤𝑑0 𝑊𝑟
4
𝑟=1  
Rural-urban designations, racial composition, and fast and slow decay spatial 
accessibility scores in the Delta Region were mapped using ARCGIS 10.4.1. These maps 
displayed racial composition and spatial accessibility scores in five groups using natural jenks 
classification, which identifies natural breaks in score values to maximize variance between 
groups and minimize variance within groups.  Global and Local Moran’s I statistics were 
calculated in ARCGIS 10.4.1 for both spatial accessibility scores to determine if these scores 
were spatially clustered and where clusters of low and high spatial accessibility scores exist. To 
quantify spatial relationships among census tracts, a 100-kilometer distance and a minimum of 2 
neighbors were used, following previous studies that have analyzed spatial clusters over a large 
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geographic area (23). These statistics were calculated for both the slow and fast decay 
accessibility scores.  
The Local Moran’s I identified local spatial clusters of census tracts according to four 
pattern types: low access clusters, high access clusters, low-high spatial outliers, high-low spatial 
outliers (24). Low-access clusters are concentrated geographic areas of low accessibility scores; 
high-access clusters are concentrated geographic areas of high accessibility scores. Low-high 
spatial outliers are areas where tracts with low accessibility scores are surrounded by tracts with 
high accessibility scores; high-low spatial outliers identify tracts with high spatial access that are 
surrounded by tracts with low accessibility scores. Census tracts that do not fall into any of these 
four categories represent areas where there is no statistically significant spatial clustering of 
accessibility scores. 
Correlation analysis was used to assess the association between racial population 
composition and spatial accessibility scores.  Because racial composition and spatial accessibility 
scores are not normally distributed, Spearman’s rank coefficients were used.  These values were 
calculated for the entire Delta Region and separately for each state as well by rural-urban status.  
Bivariate Local Moran’s I analysis using GeoDa was performed to identify areas where census 
tracts with high black population percentages are surrounded by tracts with high (or low) spatial 
access to mammography. Similar to the univariate Local Moran’s I, this analysis identifies four 
spatial patterns: low access-high black population proportion; high access-high black population 
proportion; low access-low black population proportion; and high access-low black population 
proportion. Of greatest interest is identifying areas with low access and high black population 
proportions.  
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Descriptive, Univariate, and Bivariate Statistical Analysis 
Summary statistics (mean, standard deviation, median) were calculated for accessibility 
scores for both weights for the Delta Region compared to the non-Delta Region in the 8 LMDR 
states combined and for each state individually. Because accessibility scores were overdispersed, 
Wilcoxon Two-Sample Tests were performed to determine if Delta/non-Delta Region spatial 
accessibility scores differed significantly. Additionally, accessibility scores were compared by 
rural-urban status. In sum, the following comparisons were made for both sets of distance decay 
weights: urban vs. rural Delta Region; rural Delta Region vs. rural non-Delta Region; and urban 
Delta Region vs. urban non-Delta Region.  
Results 
Choropleth Maps of Rural-Urban Status and Racial Composition 
Figure 4.1A displays the rural-urban distribution of census tracts within the Delta Region. 
Most of the Delta Region was rural with the exception of large urban centers in Memphis, 
Tennessee; Little Rock, Arkansas; and New Orleans, Louisiana and smaller urban centers 
scattered throughout the Region. Figure 4.1B shows the percentage of women aged 45-75 within 
each census tract who are black. Generally speaking, there was a north-south gradient, with 
higher proportions of black women of recommended screening age in Mississippi, Alabama, and 
southern Arkansas.  
Choropleth Maps and Spatial Analysis of Spatial Accessibility Scores 
  Choropleth maps of both the fast and slow weighted spatial accessibility scores in the 
Delta Region show that spatial access to mammography varies considerably, with areas of high 
spatial access generally concentrated in the northern and Alabama portions of the Delta region 
(Figure 4.2). Global Moran’s I statistics for both fast and slow decay weights indicate moderate 
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clustering of spatial accessibility scores in the Delta Region, Moran’s I of 0.35 and 0.43, 
respectively (Table 4.1).  Local Moran’s I analysis for both weights shows large clusters of high 
accessibility scores in the Illinois and Kentucky portions of the Delta Region with smaller 
clusters of high accessibility scattered throughout the rest of the Region. Large clusters of low 
accessibility scores are found in the Missouri, Arkansas, and Tennessee portions of the Region, 
with particular clustering immediately surrounding Memphis, Tennessee.  
Univariate Analysis of Spatial Accessibility Scores 
  Based on a Wilcoxon test, there was no statistically significant difference in fast decay 
spatial accessibility score by Delta Region designation, with median scores of 0.000175 and 
0.000161 in the Delta Region and non-Delta designations, respectively (p=0.40) (Table 4.3). 
Median fast decay scores in the Delta Region ranged from 0.000138 in Arkansas to 0.000243 in 
Illinois. Illinois and Louisiana were the only states with statistically significant differences in 
median fast decay spatial accessibility scores between Delta and non-Delta regions.  The median 
spatial accessibility score was higher in the Illinois Delta Region compared to the non-Delta 
Region part of the state (0.000243 and 0.000156, respectively, p<0.001). The median spatial 
accessibility score in the Louisiana Delta Region was lower than in the non-Delta part of the 
state (0.000178 vs. 0.000203; p<0.001).  
Findings for the slow decay spatial accessibility scores were somewhat similar to the fast 
decay scores. Overall, there were no differences in median spatial accessibility scores between 
the Delta and non-Delta Regions (0.000181 and 0.000166, respectively; p=0.50). There were no 
statistically significant differences in Delta and non-Delta Region slow decay spatial 
accessibility scores by state, except for Illinois, Kentucky, and Louisiana. In Illinois, the median 
slow accessibility score is higher in the Delta compared to the non-Delta region (0.000244 and 
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0.000159, respectively; p<0.0001). Similarly, the Delta Region of Kentucky had a higher median 
slow decay spatial accessibility score than the non-Delta Region part of the state (0.000220 and 
0.000214, respectively; p=0.01). However, the Delta Region part of Louisiana had lower median 
slow decay spatial accessibility score than the non-Delta part of the state (0.000178 and 
0.000237, p<0.001).  
Spatial accessibility scores also did not differ significantly between the rural and urban 
Delta and between the urban Delta and non-Delta designations for fast decay scores (Table 4.3). 
However, median spatial access was slightly higher in the rural DRA vs. the non-DRA 
(0.000171 vs. 0.000170, p=0.02). For the slow decay score, however, census tracts in the rural 
Delta Region had a lower median slow decay spatial accessibility score (0.00171) than the urban 
Delta Region (0.000186) (p=0.0006).  Rural census tracts in the Delta Region had a higher 
median slow decay spatial accessibility score than rural census tracts in the non-Delta Region 
(0.000171 and 0.000168, respectively; p=0.04). Urban census tracts in the Delta Region also had 
a higher median slow decay spatial accessibility score than the non-Delta urban census tracts 
(0.000186 and 0.000165, respectively; p=0.0007). 
Bivariate Analysis of the Relationship between Spatial Accessibility Scores and Racial 
Composition 
   For both the fast and slow decay scores, racial composition and accessibility showed a 
weak, but statistically significant, positive correlation for the Delta Region as a whole 
(Spearman’s rho=0.107 and 0.0856; p<0.001, respectively) (Table 4.4).  In Alabama, the slow 
decay score showed a moderate, negative correlation between racial composition and spatial 
accessibility (Spearman’s rho=-0.237; p<0.01). In Arkansas and Missouri, both fast and slow 
decay scores were moderately correlated with racial composition while in Louisiana, Mississippi, 
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and Tennessee, there was weak, positive correlation between racial composition and both fast 
and slow decay spatial accessibility scores. There was no statistically significant correlation 
between racial composition and spatial accessibility in Illinois, nor when stratifying the Delta 
Region by rural and urban status.  
Bivariate Moran’s I analysis showed low spatial clustering of racial composition and fast 
decay spatial accessibility scores (Moran’s I=0.036).  In total, 86 census tracts scattered 
throughout Alabama, Arkansas, Tennessee, Mississippi, and Louisiana had a high proportion of 
black women of screening age and low spatial accessibility scores in nearby census tracts (Figure 
4.3A). The Bivariate Moran’s I analysis showed similar low spatial clustering of racial 
composition and slow spatial accessibility scores (Moran’s I=0.049). The spatial pattern is very 
similar to that for the fast accessibility scores, with 90 census tracts scattered throughout 
Alabama, Arkansas, Tennessee, Mississippi, and Louisiana showing a high proportion of black 
women of screening age and low spatial accessibility scores in neighboring census tracts (Figure 
4.3B).  
Discussion 
This study found no difference in tract-level spatial accessibility to mammography 
facilities between the Delta and non-Delta Regions overall considering both decay weights. 
However, when scores were stratified by state, access was higher in the Delta Region of Illinois 
compared to the non-Delta area of the state while the Delta Region part of Louisiana had lower 
spatial accessibility than the non-Delta part of the state. The Kentucky Delta Region had higher 
spatial accessibility scores than the non-Delta part for slow accessibility weights.  Global 
Moran’s I showed moderate clustering for both decay speeds. Local Moran’s I showed clusters 
of high spatial accessibility in the Delta Region of Illinois and the westernmost part of the 
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Kentucky Delta. Low spatial access was clustered in much of the Arkansas Delta and parts of 
Tennessee and Mississippi (i.e. a cluster of low spatial access around Memphis). Smaller clusters 
of low spatial access were seen in southern Louisiana as well. These findings reveal uneven 
patterns of spatial access to mammography within the Delta Region and notable areas of low 
spatial access in central and southern areas where mammography facilities are underdeveloped. 
There was weak to moderate positive correlation between racial composition (% of 
screening aged women in the census tract who are black) and spatial accessibility scores for the 
Delta Region as a whole and within most individual states. These positive correlations indicate 
that in some states, mammography facilities are more spatially accessible to tracts where black 
women make up a larger proportion of the local population.  However, the slow decay score in 
the Alabama Delta Region was weakly, negatively correlated with racial composition. For both 
decay scores, there were census tracts scattered throughout the southern part of the Delta Region 
with high black racial composition and low neighboring spatial accessibility scores.  
These findings suggest that there is little difference in spatial access to mammography in the 
Delta Region compared to the non-Delta Region within the LMDR states. However, there was 
intrastate variability by Delta Region designation in Illinois, Kentucky, and Louisiana, with 
Louisiana being the only state with lower spatial access in the Delta Region. Further, median 
spatial accessibility scores varied by state within the Delta Region with the lowest scores in 
Arkansas and the highest scores in Illinois. This geographic variation points to inequalities in 
spatial access despite the overall availability of mammography services at levels comparable to 
non-Delta regions of the LMDR states. 
In sum, these findings have two key public health implications. First, the overall lack of 
spatial accessibility differences in the Delta vs. non-Delta Region suggests that lower utilization 
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of mammography screening and higher breast cancer mortality in the region may not be due to 
disparities in spatial access to care. Instead, low mammography utilization may be due to aspatial 
factors such as financial, knowledge, and psychosocial barriers to screening services. Continued 
interventions are needed to address these nonspatial barriers to mammography utilization in the 
Delta Region (25,26).  Additional research is needed to elucidate the factors associated with the 
breast cancer mortality disparity in this region, such as breast cancer staging and subtype. Recent 
studies have shown higher rates of the most aggressive breast cancer subtypes (i.e. triple-
negative) in several LMDR states, but it is unknown if the Delta Region specifically has higher 
rates (27,28). Second, identified state-to-state variability in spatial access may provide guidance 
for resource allocation of federal funds targeted for the Delta Regional Authority, such as the 
USDA’s Delta Health Services Grant, to those areas with particular disparities compared to the 
non-designated part of the state or compared to other areas within the Delta Region.  
In addition to the findings of the univariate statistics, the findings of the spatial analysis 
help identify clusters of low access to mammography services which may help guide resource 
allocation and interventions. Clusters of low spatial access were identified in large parts of 
Arkansas and Missouri as well as smaller clusters in Tennessee, Mississippi, and Louisiana for 
both decay speeds. Arkansas also had the lowest spatial accessibility with the Delta Region of all 
states.  These findings add to the growing body of literature suggesting that using spatial 
methods to assess access to screening services may guide the allocation of resources and identify 
service shortage areas (13,17). These methods can be extended in two ways. First, GIS-based 
measures can be applied to the evaluation of other providers of cancer screening services (e.g. 
gastroenterologists who perform colonoscopies or lung cancer screening locations). Second, they 
can be used in combination with spatial methods that identify clusters of high late-stage cancers 
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or cancer mortality. Many studies have suggested that using spatial methods to visually display 
and/or identify clusters of low screening rates, late-stage cancers or cancer deaths may guide 
screening interventions (23,29,30). However, there is limited research that simultaneously 
considers the geographic clustering of areas with both low access to services and high rates of 
late-stage cancers or mortality or low screening rates. Evaluating the clustering of both low 
access and high risk or low utilization may more effectively target interventions to areas most in 
need of screening services.  
In addition to simultaneously evaluating access and risk, it is also important to consider 
the relationship between access and area level demographic characteristics that may play a role 
in cancer disparities, like racial composition (6,7). Racial composition (i.e. the percentage of the 
female population of screening age who were black) proved to be positively, but only weakly 
correlated with spatial access. There was slight variation at the state level, as the slow decay 
score in Alabama was negatively and weakly associated with racial composition; however spatial 
accessibility scores were positively, and moderately correlated for most other states.  The 
bivariate LISA analysis revealed scattered small clusters of tracts containing high proportions of 
black populations surrounded by tracts with low spatial access to mammography. These tracts 
are home to large concentrations of black women who are at higher risk for late breast cancer 
diagnosis and mortality, yet mammography screening facilities are in short supply in nearby 
areas.  Such places may be good sites to target screening interventions to those who might be at 
high risk for poor cancer outcomes in the Delta Region. Other studies have suggested similar 
approaches In Toronto, Canada, Lofters and colleagues considered clustering of primary care 
physicians and racial/ethnic groups to help target cancer screening interventions (29). Similarly, 
Towne and colleagues assessed access to screening services among American Native and Alaska 
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Natives (31). However, neither of these studies used bivariate Local Moran’s I analysis as the 
present study did. This method may be effective to identify areas with dual risk factors for poor 
cancer outcomes: sociodemographic composition and access to screening services.  
All analyses were performed using both fast and slow decay weights. For the most part, 
fast and slow decay scores yielded fairly similar results in univariate and bivariate analysis and 
in spatial analyses, which is consistent with other studies that test different sets of weights 
applied to the E2SFCA method to evaluate spatial access to health care services (11,17,22). 
However, the slow decay was more sensitive in identifying rural-urban differences within the 
Delta Region states and in the Delta Region, respectively. This is consistent with McGrail’s 
findings which indicate that implementing a decay function of any sort, even with additional 
rules, affects rural and urban accessibility scores differently (22). While the choice of decay 
score is arbitrary, Luo suggests that a faster decay score be utilized for more common health care 
services like pharmacies, while a slower decay score be used for scarcer services like cancer care 
services (11). Mammography services are less available than pharmacies but more available than 
cancer treatment facilities, making it unclear which decay function would be more appropriate. 
Additional research should explore what decay weights, proposed by Luo or others, may be most 
accurate to determine spatial access based upon the ubiquity of a given service, especially when 
applied to geographically large regions that are largely rural, but also have some urban centers. 
Alternatively, a continuous or variable decay function could be further assessed for its utility in 
assessing spatial access to services as the rural-urban gradient (15,22,32).  
Limitations and Strengths 
This study has certain limitations—both in characterizing supply and demand for 
mammography services. To characterize supply of mammography, only facility locations were 
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considered, not the number of machines at each facility, as that information was not publicly 
available. This may mean that spatial accessibility is underestimated.  To characterize demand 
for services, ACS population estimates were used. ACS data are meant to describe, not estimate, 
populations. Unlike the census which theoretically accounts for the entire U.S. populations, the 
ACS is a sample, and therefore subject to both sampling and nonsampling errors.  Further, 
population estimates were for women aged 45-74, the age category available in ACS that is most 
congruent with recommended screening ages. However, many women who utilizing screening 
are younger or older than recommended screening age (33). Thus, the population estimates used 
are representative of theoretical demand, not practical demand.  
Despite these limitations, this study has many strengths. First, the E2SFCA method was used, 
which, compared to other methods, more appropriately considers accessibility relative to 
distance traveled. Further, an understudied region that experiences significant health and access 
to care disparities was examined. This study was one of the first to use a variation of the 2SFCA 
method to consider how access to care may vary by racial composition.  The findings identify 
gaps in spatial access to mammography that should be targeted in creating new facilities, 
including mobile and fixed site services, and in planning educational and informational 
programs. 
Conclusions 
  The E2SFCA method was used to evaluate access to mammography services in the Delta 
Region. Access to services did not vary between the Delta and non-Delta Region within the eight 
states of interest. There was state-level variation in access, and spatial statistics found that there 
were clusters of low access in especially in Arkansas, Mississippi, and Louisiana. The 
relationship between racial composition and spatial access was explored but found no notable 
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relationship between a high proportion of black residents and low spatial access was identified. 
Relevant to the Delta Region, the identified areas of low access may be targets for resource 
allocation and public health interventions. Relevant to health services research, broadly speaking, 
the approaches used in this study could be applied to other screening services, and research could 
explore the overlapping relationship between sociodemographic characteristics and access to 
care.  
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Figures and Tables 
Figure 4.1: Rural-Urban Designation (A) and Racial Composition (B) in the Delta Region 
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Figure 4.2: Spatial Accessibility Scores, Fast (A) and Slow (B) Decay 
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Figure 4.3: Local Moran's I for the Delta Region, Fast Decay (A) and Slow Decay (B) 
 
 
 
 130 
 
Figure 4.4: Bivariate Local Moran’s I; Racial Composition and Spatial Accessibility  
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Table 4.1: Global Moran’s I Results 
 Decay Speed Moran’s I Z Score P Value 
Delta Region Fast 0.35 102.82 <0.001 
Slow 0.43 125.8 <0.001 
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Table 4.2: Spatial Accessibility to Mammography in the Lower Mississippi Delta by State and 
Delta Designation 
 Delta Non-Delta  
 Mean (SD) Median Mean (SD) Median P-value† 
Fast Decay 
All 0.000181 
(0.000101) 
0.000175 0.000207 
(0.000251) 
0.000161 0.40 
Alabama 0.000213 
(0.000173) 
0.000168 0.000195 
(0.000287) 
0.000136 0.07 
Arkansas 0.000146 
(0.000091) 
0.000138 0.000189 
(0.000202) 
0.000136 0.26 
Illinois 0.000248 
(0.000085) 
0.000243 0.000194 
(0.000214) 
0.000156 <0.001 
Kentucky 0.000254 
(0.000150) 
0.000222 0.000232 
(0.000170) 
0.000202 0.06 
Louisiana 0.000174 
(0.000168) 
0.000168 0.000282 
(0.000203) 
0.000203 <0.001 
Missouri 0.000178 
(0.000105) 
0.000188 0.000235 
(0.000298) 
0.000164 0.24 
Mississippi 0.000184 
(0.000112) 
0.000166 0.000191 
(0.000094) 
0.000183 0.14 
Tennessee 0.000179 
(0.000067) 
0.000186 0.000204 
(0.000341) 
0.000160 0.16 
Slow Decay 
All 0.000181 
(0.00008) 
0.000181 0.000209 
(0.000241) 
0.000166 0.50 
Alabama 0.000197 
(0.000131) 
0.000162 0.000198 
(0.000278) 
0.000157 0.66 
Arkansas 0.000147 
(0.000065) 
0.000144 0.000187 
(0.000188) 
0.000135 0.91 
Illinois 0.000244 
(0.000057) 
0.000244 0.000195 
(0.000244) 
0.000159 <0.001 
Kentucky 0.000252 
(0.000119) 
0.000220 0.000233 
(0.000151) 
0.000214 0.01 
Louisiana 0.000176 
(0.000063) 
0.000178 0.000274 
(0.000199) 
0.000237 <0.001 
Missouri 0.000173 
(0.000078) 
0.000181 0.000237 
(0.000290) 
0.000169 0.16 
Mississippi 0.000187 
(0.000086) 
0.000184 0.000187 
(0.000072) 
0.000185 0.97 
Tennessee 0.000178 
(0.000049) 
0.000190 0.000204 
(0.000331) 
0.000167 0.25 
SD=standard deviation; † Wilcoxon Two-Sample Test 
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Table 4.3: Spatial Accessibility Scores by Rural-Urban Status 
 Rural Urban  
Fast Decay 
 Mean (SD) Median Mean (SD) Median P-value† 
Delta Region 0.000183 
(0.000111) 
0.000171 0.000180 
(0.000094) 
0.000175 0.61 
 Delta Non-Delta  
Rural 0.000183 
(0.000111) 
0.000171 0.000243 
(0.000363) 
0.000170 0.02 
Urban 0.000180 
(0.000094) 
0.000175 0.000198 
(0.000206) 
0.000160 0.47 
Slow Decay 
Delta Region 0.000175 
(0.000082) 
0.000171 0.000185 
(0.000076) 
0.000186 0.0006 
 Delta Non-Delta  
Rural 0.000175 
(0.000082) 
0.000171 0.000238 
(0.000347) 
0.000168 0.04 
Urban 0.000185 
(0.000076) 
0.000186 0.000199 
(0.000195) 
0.000164 0.0007 
SD=standard deviation; † Wilcoxon Rank Two-Sample Test 
Table 4.4:  Correlation between Spatial Accessibility and Racial Composition in the Delta 
Region 
 Fast Decay Spatial 
Accessibility Score 
Slow Decay Spatial 
Accessibility Score 
All 0.107020† 0.08565† 
Alabama -0.13783 -0.23700‡ 
Arkansas 0.25786† 0.26536† 
Illinois -0.14645 -0.19792 
Kentucky 0.22022* 0.05157 
Louisiana 0.19113† 0.17955† 
Missouri 0.39701† 0.42192† 
Mississippi 0.19640† 0.20512† 
Tennessee 0.16037† 0.17629† 
Rural Delta Region -0.00760 -0.05282 
Urban Delta Region 0.21253 0.18202 
†p<0.0001;‡p<0.01;*p<0.05 
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CHAPTER 5: DISCUSSION AND CONCLUSIONS 
 The Delta Regional Authority is a federal-state partnership aiming to improve 
socioeconomic conditions in 252 counties and parishes in the eight-state region along the 
Mississippi River and in the Alabama Black Belt. The Delta Region’s sociodemographic 
composition put it at a three-pronged risk for health disparities. First, it has a high proportion 
(32.4%) of black residents (1). Second, more than one in five residents live in poverty, and more 
than forty percent of the counties are persistent poverty counties (1). Third, although there are 
some metropolitan areas like Memphis, Little Rock, and New Orleans, the Region is largely 
rural. Because of these risks, the Delta Region experience cancer and access to care disparities. 
Compared to the nation as a whole, residents in the region have higher rates of all causes of 
death, cancer mortality, and breast cancer mortality (2-4). Breast cancer mortality rates are also 
higher among black women in the region compared to white women (2). Residents of the Delta 
Region have limited access to primary care physicians and federally qualified health centers (5, 
6). Additionally, a lower proportion of women in the Delta Region utilize mammography (5, 7). 
Both of these factors may be indicative of less access to mammography services and increased 
risk of late-stage breast cancer. Some of the risk factors for the triple-negative breast cancer 
subtype—which is the most aggressive and least treatable subtype-- and more advanced cancer 
staging are more prevalent in this region, including a higher proportion of blacks, geographic 
location in the South/Midwest, rurality, and low income (1,8-9). However, there is limited 
research on what specific cancer factors—subtype, staging, and access to mammography—may 
exist in this region that contribute to these higher breast cancer mortality rates. This dissertation 
explored differences in subtype, staging, and access to mammography to help explain the 
mortality disparities in the Delta Region. This chapter briefly summarizes the findings of this 
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dissertation and how these findings might the guide development of preventive interventions, 
regional policies, resource allocation, and future research efforts.  
 Chapter 2 of this dissertation addressed breast cancer subtype differences and identified 
higher rates of triple-negative breast cancer in the Delta Region compared to the non-Delta 
Region. Although this elevated rate of triple-negative breast cancer in the Delta Region was 
attenuated in multivariable analyses, the elevated rate was maintained in urban areas. Black 
residents in the Delta Region had higher rates of hormone receptor negative cancers than white 
women in the Region. Chapter 3 of this dissertation examined the difference in breast cancer 
staging by subtype and found that no particularly notable differences in late-stage between the 
Delta and non-Delta Regions. However, black women in the Delta Region had lower rates of 
early-stage breast cancer, but higher rates of late-stage breast cancers than their white 
counterparts. Chapter 4 examined spatial access to mammography in the Lower Mississippi 
Delta Region states and found that, for the most part, women in the Delta Region had similar 
access to mammography services as non-Delta Region women. However, clusters of low spatial 
access in areas within the Delta Region were identified. 
 Broadly speaking, the findings of this dissertation have public health implications for 
community-based intervention, state-level policy change, and regional resource allocation. 
Additionally, these findings provide the foundation for further research to continue to explore 
breast cancer disparities in the Region, to examine regional disparities for other cancer types, and 
to promote collaborative academic partnerships across the Delta Region. 
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Public Health Implications 
This dissertation identified regional and racial disparities in the breast cancer subtype and 
staging. The Delta Region, particularly black women and those living in urban areas, had higher 
rates of triple-negative breast cancer. There are few modifiable risk factors for triple negative 
breast cancers, but increasing breastfeeding initiation and duration among black, Delta Region 
women may be one way to reduce triple-negative breast cancer rates (10). Additionally, within 
the Delta Region, black women had lower rates of early stage breast cancer and higher rates of 
late-stage breast cancer, indicating that mammography utilization rates may be lower among 
black women in the region.  Successful, community-based efforts in pockets of the Delta Region 
could be scaled up and broadly disseminated to continue to educate black women on screening 
and increase screening rates. Further, there are state-level policy changes that may be helpful to 
improve breast cancer disparities.  Finally, Delta Region-specific resources from the Health 
Resource and Service Administration (HRSA), the United States Department of Agriculture 
(USDA), and general federal appropriations for the Delta Region may be allocated to improve 
breast cancer prevention efforts and to make mammography services more available for 
underserved residents. 
 To decrease triple-negative breast cancer rates, interventions to increase breastfeeding 
initiation and duration, particularly among multiparous black women in urban areas of the Delta 
Region, may prove to be effective. A 2005 study found that the East South Central Region, 
which includes several Delta Region states, were least likely to identify the health benefits of 
breastfeeding and were less likely to have a positive opinion about breastfeeding in public (11). 
However, there is reason to be optimistic about efforts reduce women’s risk for triple-negative 
breast cancer in the Delta Region.  For example, Memphis, Tennessee, which may be particularly 
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at risk for high rates of triple-negative breast cancer due to its racial composition, high birthrates, 
and low breastfeeding rates, has made particular strides in attitudes and efforts related to 
breastfeeding (11). There are groups like the Shelby County Breastfeeding Coalition that aim to 
promote breastfeeding in the County (12). Further, a 2015 study by Nouer and colleagues found 
that attitudes toward breastfeeding and understanding of its health benefits have improved in 
women of all races in Memphis (13). Continued coalition-building efforts, increased knowledge, 
and improved attitudes toward breastfeeding may have long-term effects on the diagnosis of 
triple-negative breast cancer.  
 Additionally, to reduce late-stage breast cancer diagnoses in black women in the Delta 
Region, there is an opportunity to scale up and disseminate effective, community-based 
education interventions throughout the Region to increase screening rates and improve early 
detection. Indeed, while previous studies have shown that Delta Region women are less likely to 
be up-to-date with screening recommendations, this dissertation found that women in the Delta 
Region had similar spatial access to mammography services as those outside of the Region. This 
suggests that aspatial barriers to mammography (e.g. psychosocial and/or financial barriers) may 
play a role. Interventions utilizing lay health advisors/community health advisors have been 
shown to effectively increase breast cancer screening among black women Delta Region 
communities or other communities in the Deep South (14-17). Erwin’s “Witness Project” was 
developed and tested in the Arkansas Delta and utilized lay health advisors who are cancer 
survivors to educate black women on cancer screening in a faith-based setting (15-16). This 
program has been identified as one of the National Cancer Institute’s (NCI) Research-Tested 
Intervention Programs (18). Additionally, the American Cancer Society has successfully piloted 
a community health advisor program to improve cancer screening rates in black communities in 
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the Deep South, which has some geographic overlap with the Delta Region (17). In the 
Mississippi Delta of the state of Mississippi is a particularly stellar example of community-based 
work is the work spearheaded by Freddie White-Johnson through the Fannie Lou Hamer Cancer 
Foundation (FLHCF) and the University of Southern Mississippi’s Mississippi Network for 
Cancer Prevention & Control (19). The work led by Ms. White-Johnson in her role at the 
University of Southern Mississippi uses community health advisors to educate community 
members in nine counties in western Mississippi.  Her work funded by the FLHCF included 
cancer education, outreach, and advocacy in the Region. For these efforts, the FLHCF and Ms. 
White Johnson received the Eugene Washington PCORI Engagement Award. The wealth of 
effective efforts can provide models for other communities in the Delta desiring to educate 
women on breast cancer screening and improve breast cancer mortality rates.  
 In addition to community-based interventions, there are policy-based efforts that may be 
helpful in improving breast cancer outcomes in the Delta Region. First, during this dissertation’s 
study period (2012-2014), only three of the eight Delta Region states (Arkansas, Illinois, and 
Kentucky) had expanded Medicaid, a provision of the Affordable Care Act that broadened the 
eligibility criteria for Medicaid coverage (20). While this has since increased to four states, as 
Louisiana has expanded coverage, further expansion in Alabama, Missouri, and Mississippi 
would help provide coverage for the most vulnerable populations to receive coverage for 
mammography and cancer treatments, which would indeed help the prognosis for cancer 
patients. Studies have shown that cancer screening rates among low-income individuals were 
higher in states that expanded Medicaid compared to those that did not, and states that did not 
expand Medicaid, especially in the South, had higher breast cancer mortality-incidence ratios and 
lower screening rates (21-22). Because the Affordable Care Act’s Medicaid expansion criteria 
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broaden the income level for which people are eligible, expansion may be particularly beneficial 
for people in the Delta Region, who experience significant economic challenges. Additionally, it 
is important to ensure that Breast and Cervical Cancer Screening programs are appropriately 
funded. These programs provide cancer screening to low-income women who are uninsured or 
underinsured. However, according to the American Cancer Society’s Cancer Action Network, 
only two Delta Region states (Arkansas and Illinois) have state appropriations at or above 100% 
of the CDC-funding levels (23). Three states are below 33% of the CDC-funding levels 
(Alabama, Kentucky, and Missouri), and three states are between 33% and 99% of the CDC-
funding levels (Louisiana, Mississippi, and Tennessee). Much like Medicaid expansion, 
adequately funding programs for early detection, navigation services, and connections to needed 
treatment are vital to reducing disparities.  
 There are several Delta Region-specific grant mechanisms and programs that may be 
utilized to improve access to mammography services in the Delta Region. The USDA 
disseminates funds through the Delta Health Services Grant mechanism that aims to address 
“unmet health needs” in the region in the form of healthcare services, health education programs, 
healthcare job training, or expansion of healthcare infrastructure (24). Past grant awards have 
gone to telemedicine expansion or simulation training and equipment (25-26). Findings from this 
dissertation provide the evidence for potential grant applicants who may be interested in address 
breast cancer disparities to develop applications for increasing mobile mammography efforts, 
building infrastructure for free-standing mammography centers, and training cancer registrars. 
All of these potential applications could provide and/or facilitate healthcare services in the region 
while improving occupational and economic opportunities in the Delta Region.   
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Future Research Directions 
 The findings of this dissertation help explain why women in the Delta Region have 
higher breast cancer mortality rates than women in the non-Delta Region. Additionally, these 
findings help explicate why black women in the Region have higher rates white women in the 
Region and black women outside of the Region. There are three areas particularly important 
research avenues to consider to better understand the cancer disparities in the Delta Region. One, 
there is a need to continue to explicate the Delta Region’s breast cancer disparities, both in 
etiology and treatment. Second, there are additional areas of cancer disparities in the Region that 
are also understudied that need to be explored. Third, there is an opportunity to develop 
partnerships across the Region to synergize research efforts and reduce disparities.  
Continued Elucidation of Delta Region Cancer Disparities 
 While the current study helped to identify higher rates of triple-negative breast cancer 
rates as a contributing factor to the high breast cancer mortality rates in the Delta Region, these 
higher rates do not fully explain these mortality disparities. In addition to the higher triple-
negative breast cancer rates in the Delta Region, this dissertation found that black women in the 
Delta Region had higher overall breast cancer incidence rates than white Delta Region women. It 
is important to understand the contributing factors to breast cancer among black women. A 
current cohort study, the Southern Community Cohort Study (SCCS), has the potential to be an 
important data source to further explore the cause of breast cancer in the black women in the 
Delta Region if appropriate geographic data are available for research purposes (26-27). The 
NCI-funded SCCS began in 2001 and enrolled roughly 85,000 participants in twelve southern 
states, six of which are Delta Region states. Recruitment stopped in 2009, and participants are 
being followed prospectively. More than a two-thirds of participants are black. The baseline 
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questionnaire for this study asks extensive questions about demographics, personal health 
history, family health history, health care utilization, nutrition and physical activity habits, 
occupational history, and other topical areas. Participants also provided a blood or buccal swab 
sample. The rich data from this study may provide insight into factors put black women at 
greater risk for breast cancer in this region. Future research should utilize these data to explore 
additional factors that may help explicate additional factors that may explain the breast cancer 
disparities in this region.  
 In addition to exploring disparities risk factors, it is important to understand how 
disparities in breast cancer treatment may contribute to the mortality disparities in the Delta 
Region. A study utilizing Surveillance Epidemiology and End Results (SEER) data found that 
black women were less likely to receive guideline-concordant treatment across most subtypes 
(28). A study in the Delta Region city of Memphis found that black breast cancer patients were 
less likely to receive surgery, radiation, chemotherapy, and endocrine therapy than white women, 
but the study did not stratify or control for subtype (29). With the appropriate dataset with 
appropriate geographic coverage (e.g. Medicare data), research could explore certain aspects of 
treatment within the Delta Region population. Additionally, healthcare systems data from 
systems in the Delta Region, like data used in the Vidal study, may be a good source of data to 
explore treatment disparities in smaller geographic areas of the Delta Region. 
 Breast cancer is not the only area of cancer disparities in the Delta Region. Studies have 
indicated notable mortality disparities in colorectal, cervical, lung, and prostate cancers (2,30-
32). These cancers, in particular, are important because they are the greatest contributors to the 
overall cancer mortality rate (e.g. lung and colorectal cancers) and/or there is significant 
opportunity to intervene with preventive and screening interventions (e.g. colorectal and cervical 
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cancers). Indeed, there have been studies that have explored these disparities, such as human 
papillomavirus vaccination uptake (which can prevent cervical cancer), at a regional level (33). 
There have also been community-based interventions to address colorectal cancer screening 
within pockets of the Delta Region (34). Continued regional epidemiological studies and 
community-based interventions should be undertaken to further elucidate and reduce regional 
disparities.  
 To be sure, there are challenges to addressing disparities across a multi-state region. A 
2008 report from the University of Tennessee Health Science Center and the Mississippi State 
Department of Health Data identified the state-to-state variability in demographic, 
socioeconomic, health behavior, and health outcomes data as a particular challenge to address 
the region’s disparities (35). However, there are some national level avenues for data acquisition 
that may be fruitful. For example, this dissertation utilized cancer surveillance data from the 
North American Association of Central Cancer Registries (NAACCR) Cancer in North America 
Deluxe File. NAACCR members may request multi-state cancer data that includes the county of 
residence which would allow for identification of Delta Region counties. This data source 
includes population-based, individual-level information on the demographic, tumor, treatment, 
and survival characteristics of all cancer cases within the requested geographic area, contingent 
upon state consent. Federal data sources on demographics, healthcare workforce, and health 
behaviors and outcomes include the American Community Survey, the Area Health Resource 
File, and the CDC’s WONDER data. These data sources provide information at a county level, 
or smaller in the case of the American Community Survey, but there are limitations in the type of 
analyses that can be performed. For the most part, utilization of these data sources will limit 
researchers to ecological analyses. However, these sources are still important and effective 
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resources. Administrative data from Medicare is another source of data to assess cancer 
disparities within the Delta Region. A strength of this data source is that it includes individual-
level data, but a weakness is that it is primarily limited to individuals 65 years of age and older.  
Regional Collaborations to Reduce Disparities  
There is an enormous opportunity to develop collaborative academic research 
opportunities throughout the Delta Region to capitalize on resources and expertise that exist at 
academic institutions who serve the Delta Region. Work that is being done in the context of the 
similarly designated Appalachian Regional Commission can be a model for the more recently 
designated Delta Regional Authority. Several academic institutions are currently doing health 
disparities in pockets of the Delta Region. Coordinating and/or collaborating on efforts across 
academic institutions can help leverage the expertise and resources of each institution.  
  Appalachia was federally designated in 1965, 35 years before the Delta Region received 
its designation. With this history, the Appalachian region has been able to develop networks to 
address cancer disparities within its region. One example is the Appalachian Community Cancer 
Network, which is one of NCI’s Community Network Program Centers (36). The Network is 
headquartered at the University of Kentucky but includes additional regional offices at Ohio 
State University, Pennsylvania State University, Virginia Tech University, and West Virginia 
University. Additionally, this Network has active community advisory boards in Kentucky, 
Ohio, Pennsylvania, Virginia, and West Virginia. This network was built upon nearly a decade of 
work from a previous NCI-funded Appalachian Leadership on Cancer which mobilized 1,800 
community leaders who built coalitions in 71 counties in the Region (37). The work done in 
Appalachia provides a successful framework for the Delta Region to model. While developing a 
multi-state, regional network to facilitate cancer disparity efforts would indeed take a decade, 
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there already are single state networks, innumerable coalitions, and multiple academic 
institutions are actively engaged in research throughout the region. 
 Some of the active community-based work led by academic institutions in Arkansas and 
Mississippi has already been discussed in this chapter. However, Illinois provides a multi-faceted 
example of the collaborative work that is being done within the Delta Region of the state. In 
2008, the Healthy Southern Illinois Delta Network was formed (38). This Network brought 
together Southern Illinois University’s Center for Rural Health and Social Service Development, 
Southern Illinois Healthcare, and several coalitions from local health departments in the Region. 
The formation of this Network enabled local health departments and other organizations to join 
forces on grant applications and initiatives.  Additionally, there are currently at least three 
academic institutions working with healthcare systems and public health departments in the 
Delta Region of Illinois on cancer disparity efforts. Southern Illinois University School of 
Medicine and Washington University School of Medicine in St. Louis have funding from an NCI 
grant to address rural cancer disparities in both central and southern Illinois (39). Much of this 
work is being done in the Delta Region of southern Illinois. Additionally, the University of 
Illinois-Chicago is working with one of the local health departments in the Delta Region to 
address cancer disparities through community-engaged research (40).  Indeed, this is just a 
snapshot of the work being done in a single state. There are similar Networks and academic 
research being done to address cancer disparities throughout the Delta Region. 
 In April 2015, the Delta Research Consortium was launched at a summit meeting at 
Arkansas State University (41). This meeting brought together representatives from many of the 
46 institutions of higher education in the Delta Region. Although the meeting was not specific to 
health research, one of the emerging interest groups at the event centered on “biomedical/public 
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health” research. Although the next steps of this consortium remain unclear, re-visiting the 
efforts of this meeting may provide the foundation for develop of collaborative research efforts 
in the Delta Region. This chapter introduces only a fraction of the collaborations and research 
efforts of communities and academic institutions in the Delta Region. In order to reduce and 
eliminate the disparities in the Region, it will take all of these coalitions and institutions working 
together.  
Conclusions 
 This dissertation identified disparities in breast cancer subtype, staging, and access to 
mammography services in the Delta Region. In particular, women in the Delta Region had higher 
rates of triple-negative breast cancer than non-Delta women. Rates of triple-negative breast 
cancer remained higher in urban Delta women, even after accounting for age, race, and 
contextual factors. Further, black women had higher rates of breast cancer in the Delta region 
than white women. While disparities in breast cancer staging in the Region were minimal, black 
women in the Delta Region had higher rates of late-stage breast cancer compared to their white 
counterparts. There were few differences in spatial access to mammography services in the Delta 
Region compared to the non-Delta Region. However, clusters of low access were identified 
throughout the Region. To address these disparities, several recommendations are summarized: 
  interventions to increase breastfeeding uptake and mammography utilization  
 state-level policy improvements to increase access to screening services 
 dissemination of Delta Region-specific federal funding to increase access to screening 
services 
 continued breast cancer disparities research to elucidate the etiology of breast cancer and 
to understand treatment disparities in the Delta Region 
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 new avenues of epidemiological and health services research to explore disparities in 
other cancer types in the Delta Region 
 development of a region-wide research network, similar to Appalachia, for academic 
institutions and other partners to address the Delta Region’s cancer disparities 
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